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1. Introduction  
 
1.1 Proteases 
 
Proteases or peptidases are enzymes that catalyze the breakdown of peptide 
bonds (proteolysis) in a protein molecule. Some proteases are very specific and produce 
a limited proteolysis while others degrade proteins (quaternary and tertiary structure) 
completely into single amino acid residues. They are either secreted by cells into the 
surrounding tissues to cause destruction of proteins in extracellular material or they may 
be secreted into an area for the breakdown of a particular protein. On the basis of their 
catalytic mechanism, proteases are further divided into five catalytic classes: aspartic, 
cysteine, metalloproteinase, serine, and unclassified. Of the five, metalloproteinases and 
serine proteases comprise the largest classes. Examples for metalloproteinases include 
MMPs (thermolysin), while serine proteases include thrombin, trypsin and 
chymotrypsin to name a few.  
The proteases act not only as simple degradative enzymes but their highly 
specific mode of action (hydrolysis) can regulate a wide variety of biological processes 
(Yan and Blomme, 2003). The proteolytic processing involving highly specific and 
limited substrate cleavage controls the intracellular and extracellular localisation of 
several proteins and their activation. By virtue of their catalytic activity, proteases 
regulate almost all biological processes, like cell proliferation, differentiation, 
migration, apoptosis, wound healing and angiogenesis. Thus, dysregulation of their 
expression and functional pattern can result in various pathologic conditions, such as 
neurodegenerative and cardiovascular diseases and cancer (Yan and Blomme, 2003). 
Therefore, it is of utmost importance to identify and functionally characterise the 
substrates through which proteases act and manifest their action, since these substrates 
can be potential therapeutic targets for treatment of pathologic conditions (Yan and 
Blomme, 2003).  
 
1.2 Protease-activated receptors (PARs) 
 
Serine proteases like thrombin and trypsin not only participate in degradation of 
extracellular proteins but can also act as a signaling molecule that regulate multiple 
cellular functions by activating specific cell surface receptors, the Protease-Activated 
Receptors (PARs). PARs are G-protein-coupled receptor that utilize a unique 
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mechanism to convert an extracellular proteolytic cleavage event into a transmembrane 
signal (Coughlin, 2000). PARs belong to family 1 group b of the superfamily of GPCRs 
and consist of typical 7-transmembrane helics connected by 3 extracellular and 3 
intracellular loops together with an extracellular N-terminal and intracellular C-terminal 
domains (Bockaert and Pin, 1999) (Figure 1.1).  
The interesting mechanism of receptor activation involves cleavage of the 
receptor at a specific site within the extracellular amino terminus, thus unmasking a new 
N-terminus tethered ligand, which binds intramolecularly to the receptor and activates 
transmembrane signaling. Six or more specific amino acid residues within the newly 
exposed tethered ligand interact with extracellular loop 2 (Lerner et al., 1996) and 
transmembrane domains of the cleaved receptor (Dery et al., 1998; Coughlin, 2000). 
Thus, PARs are peptide receptors carrying their own ligands, which remain cryptic until 
unmasked by receptor cleavage due to binding of agonist to extracellular N-terminal 
domain (Coughlin, 2000). Synthetic peptides that mimic the tethered ligand of receptor 
can activate the receptor irrespective of agonist and receptor cleavage (Coughlin, 2000). 
Ultimately, activated receptor interacts with heterotrimeric G proteins in the plasma 
membrane via intracellular loop 3 (Chen et al., 2001), which transduce the signal.   
 
Figure 1.1. Activation Mechanism of PARs (Wang and Reiser, 2003a). 
Following irreversible proteolytic cleavage of PAR by thrombin, trypsin or tryptase 
(depending on the receptor subtype), a new N-terminus is unmasked acting as tethered 
ligand (boxed segment). This tethered ligand can interact with extracellular loop-2 of 
the receptor (dashed). A synthetic peptide derived from the N-terminal sequence of 
PAR (PAR-AP) is able to activate the receptor in the absence of protease-mediated 
cleavage. Other proteases may also act on the extracellular N-terminus, either exposing 
the tethered ligand to activate PAR or disabling the tethered ligand to inactivate PARs 
by cleaving at a site downstream of the tethered ligand sequence (Renesto et al., 1997). 
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The intracellular loops 2 and 3 have been proposed to play a role in G protein coupling 
for PAR-1 (Hollenberg and Compton, 2002). 
 
1.3 Irreversible activation and trafficking of PARs 
 
Since the cleavage of the receptor is irreversible, the cleaved receptor cannot be 
reactivated. Once activated, the receptor rapidly uncouples from the transmembrane 
signalling and internalised by phosphorylation-dependent mechanism (Coughlin, 2000). 
The internalised receptor is either targeted to lysosomes  or few molecules recycle back 
to cell surface but remain inactive. PARs are also maintained in large intracellular pools 
in the Golgi apparatus and in vesicles. Resensitization of the receptor involves 
mobilization of the intracellular pools (Dery et al., 1998; Coughlin, 1999, 2000).  
 
1.4 Classification and cloning of PARs 
 
Four subtypes of PARs are known: PAR-1-4. PAR-1 and PAR-3 are activated by 
thrombin (Vu et al., 1991a; Ishihara et al., 1997), PAR-4 is activated by both thrombin 
and trypsin (Xu et al., 1998), while PAR-2 is activated by trypsin and mast cell tryptase 
(Nystedt et al., 1994). PAR-1-3 genes co-localise to the same region of the human 
genome at chromosome 5q13 unlike PAR-4 which is located on chromosome 19p12 
(Kahn et al., 1998a; Cupit et al., 1999). Genetic mapping study in human vascular 
endothelial cells show the presence of PAR-1-3 gene cluster within 110 to 220 kb 
distance on chromosome 5q13 (Schmidt et al., 1998; Cupit et al., 1999). In case of 
mouse, PAR-1-3 are located on chromosome 13d2 and PAR-4 on 8b3 (Kahn et al., 
1998a). Genetic analysis of the PAR family shows that PAR-1 and PAR-2 arose from a 
gene duplication event and indeed all 4 subtypes share high homology between them 
and conserved across species (human and mouse) (Kahn et al., 1998b). The four 
subtypes have identical gene structure comprising 2 exons, each separated by a very 
long single intron of 4-22 kb in case of PAR-1-3 and only 274 bp long for PAR-4 (Kahn 
et al., 1998a; Cupit et al., 1999). In all 4 cases a short first exon encodes the 5’-
untranslated sequence, start codon, and signal peptide, and the second, larger exon 
encodes the receptor protein and 3’-untranslated sequence (Kahn et al., 1998a). 
The cDNA has been cloned from human, mice and rat for all 4 receptor 
subtypes, PAR-1 (Vu et al., 1991a; Coughlin et al., 1992b; Zhong et al., 1992), PAR-2 
(Bohm et al., 1996; Nystedt et al., 1994; Nystedt et al., 1995; Saifeddine et al., 1996), 
PAR-3 (Ishihara et al., 1997; Cupit et al., 1999) and PAR-4 (Xu et al., 1998) (Kahn et 
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al., 1998b) (Hoogerwerf et al., 2002). PAR-1 was the first receptor of this family to be 
cloned. It is also referred to as thrombin receptor and represents the prototype of this 
receptor family since most of the activation paradigm, signalling mechanism and 
physiological studies elucidating the role of PARs were identified using PAR-1 
(Coughlin et al., 1992a; Coughlin, 1994; Cunningham and Donovan, 1997; Ubl and 
Reiser, 1997; Dery et al., 1998; Coughlin, 2000; Wang et al., 2002b).  
cDNA encoding a functional human thrombin receptor (PAR-1) was cloned by 
direct expression cloning in Xenopus oocytes (Vu et al., 1991a). mRNA from cells 
highly responsive to thrombin were injected into Xenopus oocytes and the resulting 
transcript encoding the receptor was purified and tested for calcium release. In oocytes 
expressing the receptor, thrombin was found to be an extremely potent agonist 
compared with less effective trypsin. The response to thrombin was found to be blocked 
by thrombin agonist hirudin indicating the specific nature of thrombin receptor (Vu et 
al., 1991a). Subsequently thrombin receptor was also cloned from hamster lung 
fibroblasts (Rasmussen et al., 1991), mouse (Coughlin et al., 1992b) and rat (Zhong et 
al., 1992). PAR-2 was first cloned in mouse (Nystedt et al., 1994). A cosmid clone 
containing a 3.7 kb Pst-1 fragment with an ORF encoding a putative 395 amino acid 
protein similar to human PAR-1 was identified from mouse genomic library under 
moderate stringency conditions. This clone had 30% identity with human PAR-1 and 
28% with mouse PAR-1 (Nystedt et al., 1994). Human PAR-2 was cloned using PCR 
based approach from human kidney cDNA (Bohm et al., 1996). Cells transfected with 
human PAR-2 were found to be activated by trypsin and both human and mouse 
activating peptide and hTRAP, thus confirming the presence of functionally and 
physiologically active PAR-2 (Nystedt et al., 1995). PAR-3 as a second thrombin 
receptor was identified when platelets from mice whose thrombin receptor gene was 
disrupted were still found to be responding to thrombin (Connolly et al., 1996). Human 
PAR-3 was identified using a PCR- based strategy (Ishihara et al., 1997). Human PAR-
3 cDNA was found to have 27% amino acid homology with human PAR-1 and 28% 
with human PAR-2. PAR-4 the last known member of this family was cloned by 
identification of PAR-like sequences in Expressed Sequence TAG (EST) libraries 
(Kahn et al., 1998b; Xu et al., 1998).  
A comparison between thrombin receptors (PAR-1,-3 and –4) reveals certain 
structural differences which determine their ability in responding to agonist. PAR-1 and 
PAR-3 in their N-terminal exodomain have thrombin-interacting sequences at both N- 
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and C-terminal to the thrombin cleavage site (Coughlin, 2000). The C-terminal 
sequence resembles the C-terminal tail of leech anticoagulant hirudin, and similar to 
hirudin can bind to thrombin fibrinogen-binding exosite. The binding of thrombin to 
this site on PAR-1 and PAR-3 is important for receptor cleavage at low agonist 
concentration (Coughlin, 2000). PAR-4 lacks the hirudin-like sequence and hence high 
thrombin concentration is required for PAR-4 activation (Coughlin, 2000). 
 
1.5 Agonists of PARs     
 
The main agonist of PAR-1, -3 and –4 is thrombin, a multifunctional serine 
protease. Thrombin is the principal component of the blood coagulation cascade, and 
also involved in nervous system growth and maintenance. Thrombin is generated from 
its precursor molecule, prothrombin, which is cleaved by factor Xa, in association with 
factor Va, calcium and phospholipids (Festoff et al., 1996). Apart from plasma, 
prothrombin mRNA and protein are also known to be expressed in CNS (Dihanich et 
al., 1991). Thrombin is a 39 kDa molecule compared to its precursor prothrombin which 
is 71.6 kDa. During coagulation cascade thrombin mediates cleavage of soluble 
fibrinogen into insoluble fibrin which forms clot. Thrombin is involved in neurite 
retraction and this catalytic activity of thrombin is very specific and is known to be 
reversed on thrombin removal from the tissue culture medium (Festoff et al., 1996), loss 
of stellate morphology by astrocytes (Cavanaugh et al., 1990), release of endothelin-1 
by astrocytes (Ehrenreich et al., 1993). Low thrombin concentration can induce glial 
cell mitosis (Cavanaugh et al., 1990); expression of c-fos and c-jun mRNA in astrocytic 
cell line (Trejo et al., 1992). Thrombin can stimulate aggregation of platelets (Berndt 
and Phillips, 1981), macrophages (Bar-Shavit et al., 1983) and fibroblast (Glenn et al., 
1980) which plays important role in protecting the body following injury. Thrombin 
also play an important role in Alzheimer’s disease. It attenuates β-amyloid induced 
degeneration (Pike et al., 1996).    
Thrombin is cleaved to its active form at the site of injury (Friedmann et al., 
1999; Friedmann et al., 2001a). Thrombin can induce either apoptosis-
neurodegeneration (Donovan et al., 1997; Smirnova et al., 1998; Turgeon et al., 1998) 
or neuroprotection (Donovan and Cunningham, 1998) in astrocytes and neurons in 
cultures as well as in vivo. Its concentration-dependent action is well documented with 
regard to tissue repair and wound healing as reported in the case of several injury 
models, like OGD in hippocampal organotypic slices (Striggow et al., 2000), optic 
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nerve crush in rat, a mild trauma model of CNS (Friedmann et al., 1999; Friedmann et 
al., 2001a) and brain injury (Vaughan et al., 1995; Cunningham and Donovan, 1997).  
Most of the effects of thrombin are mediated by its main receptor PAR-1 
(Chambers et al., 1998; Weinstein et al., 1998; Cheung et al., 1999), but a recent study 
(Vergnolle et al., 2002) has highlighted the role of PAR-4 receptor activation in pro-
inflammatory properties of thrombin. It cleaves between Arg42-Ser43 of the extracellular 
N-terminal domain of the receptor, in the second extracellular loop of the domain 
(Suttnar et al., 2000). Thrombin cleavage site on the receptor is followed by a sequence 
of charged residues which interact with an anion binding site on thrombin, inducing 
conformational changes in the receptor and thus promoting efficient receptor hydrolysis. 
The charged domain of the receptor resemble the hirudin domain, which inhibits the 
thrombin action by binding to its anion site (Vu et al., 1991b). Thrombin cleaves PAR-3 
at Lys38-Thr39 which also contains a hirudin-like site that interacts with thrombin 
(Ishihara et al., 1997). PAR-4 can be activated by both thrombin and trypsin. It is 
cleaved at Arg47-Gly48 in the N-terminal sequence. γ-thrombin, which lacks a 
fibrinogen-binding exosite is as effective in activating PAR-4 as α-thrombin, unlike 
PAR-1 and PAR-3 where γ-thrombin is much less potent than α-thrombin. This 
difference is due to the presence of thrombin-binding site within the amino terminal 
region of PAR-1 and PAR-3 (Xu et al., 1998). 
Another protease which acts as agonist of PARs is trypsin. Trypsin is basically 
known as a digestive enzyme and occurs in gastro-intestinal tract as an inactive 
zymogen, trypsinogen. Trypsin is activated to its active form by enterokinase. Trypsin 
cleaves PAR-2 at Arg34-Ser35 residues. Trypsin interacts with PAR-2 only at the 
cleavage site (Nystedt et al., 1994). Apart  from PAR-2, trypsin can also activate PAR-1 
(Ubl et al., 1998) and PAR-4 (Xu et al., 1998). 
Because of the unique activating mechanism of PARs resulting in exposure of 
the tethered ligand which subsequently binds to the receptor and activates it, it is 
possible to directly use the synthetic peptides (Activating peptides: AP) mimicking the 
tethered ligand sequence to activate the receptor without the need for proteolytic 
cleavage. SFLLR-NH2, PAR-1 AP derived from human PAR-1 sequence can be used to 
activate both PAR-1 and PAR-2 (Hollenberg et al., 1997). Now a more specific PAR-1 
AP, TRag is also known (Kawabata et al., 1999; Wang et al., 2002a). PAR-2 AP both 
human and mouse are capable of activating PAR-2 and elicit responses similar to 
trypsin, but they cannot activate PAR-1 (Hollenberg et al., 1993). Recent studies from 
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our laboratory have shown that PAR-3 AP (TFRGAP) is capable of inducing Ca2+ 
signalling in astrocytes, albeit to a very modest degree (Wang et al., 2002a). PAR-4 
activating peptides are capable of activating the receptor only at a high concentration of 
the AP, and a longer incubation period leads to toxic effect in astrocytes (Wang et al., 
2002a). 
Apart from thrombin and trypsin, other serine proteases are also capable of 
activating PARs but not so strongly. Granzyme A released on cytotoxic T lymphocytes 
stimulation is capable of activating PAR-1 in neurons and astrocytes (Suidan et al., 
1994). Since trypsin is not present in brain, studies were conducted to find PAR-2 
agonists in brain or areas where trypsin has no access. Tryptase which is released by 
mast cells was found to activate PAR-2 with similar efficiency as PAR-2 activating 
peptides (Molino et al., 1997). Serine proteases not only activate PARs but some of 
them also inactivate them. Prominent among them are cathepsin G (Molino et al., 1995), 
elastase and proteinase 3 (Renesto et al., 1997), and plasmin (Parry et al., 1996). 
Metalloproteinase, like thermolysin (Chen et al., 1996) can inactivate PARs.  
     
1.6 Distribution of PARs in tissues and cell types 
 
Of the four subtype of PARs, PAR-1 is the most intensely and thoroughly 
studied receptor of this family. Its expression has been reported in embryonic and 
postnatal brain (Weinstein et al., 1995; Niclou et al., 1998). PAR-1 mRNA is found in 
variety of cell types like endothelial cells, fibroblasts, monocytes, platelets, osteoblasts, 
smooth muscle cells, uterine stromal cells, epithelial cells, neurons and glia in brain and 
cell lines like human embryonic kidney (HEK), glioma cells (NG108) (Vu et al., 1991a; 
Howells et al., 1993; Jenkins et al., 1993; Arena et al., 1996; Ubl et al., 1998; Striggow 
et al., 2001; Wang et al., 2002a).  
Widespread PAR-2 immunoreactivity has been reported in the developing 
central and peripheral nervous system (Jenkins et al., 2000). PAR-2 expression has been 
described in several tissues and cell types like in endothelial and epithelial cells, skin, 
eye and bone cells, brain, peripheral nerves, in the majority of gastrointestinal tissues, 
lung, cardiac muscle, blood vessels, kidney, ovary, testis, in CNS during 
embryogenesis, neurons, astrocytes, glioma cell line, smooth muscle cells, neutrophils 
(Abraham et al., 2000; D'Andrea et al., 1998; Jenkins et al., 2000; Bohm et al., 1996; 
Steinhoff et al., 1999; Striggow et al., 2001; Ubl et al., 1998; Wang et al., 2002a; al-Ani 
et al., 1995; Howells et al., 1997; Corvera et al., 1999).  
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Studies on PAR-3 and PAR-4 are confined mainly to tissues of hematopoietic 
origin like platelets, megakaryocytes, bone marrow and spleen (Ishihara et al., 1997) but 
their expression has also been detected in lung, heart, thyroid, liver, pancreas, small 
intestine, placenta and testis (Ishihara et al., 1997; Ishihara et al., 1998; Kahn et al., 
1998b; Xu et al., 1998; Hoogerwerf et al., 2002; Vergnolle et al., 2002). Human 
platelets lack PAR-3 but express PAR-1 and PAR-4 (Xu et al., 1998; Kahn et al., 1999), 
unlike mouse platelet which express both PAR-3 and PAR-4 (Kahn et al., 1998b). In a 
recent study the presence of all 4 PAR subtypes has been described in cultured rat 
astrocytes (Wang et al., 2002a). Also, the expression pattern of the 4 receptor subtype 
was characterized in brain (Striggow et al., 2001). These authors have shown the 
presence of PARs in different brain areas, particularly in neuronal structures of cortex, 
hippocampus, amygdala, and hypothalamus.  
In mouse platelets, the expression of PAR-3 was found to be necessary for full 
activation of thrombin since PAR-3 deficient mouse platelets expressing only PAR-4 
show delayed and weak thrombin response compared with normal mice platelets (Kahn 
et al., 1998b). Mouse PAR-3 by itself does not result in any signalling cascade on 
thrombin stimulation but facilitates thrombin stimulation of PAR-4 by functioning as a 
tethering protein for the protease (Nakanishi-Matsui et al., 2000). Mice lacking PAR-2 
have been shown to have an enhanced response to PAR-1, suggesting possibility of 
direct PAR-PAR interaction (Damiano et al., 1999b). 
 
1.7 Mechanism of PAR signal transduction 
 
Receptor activation by agonist binding results in conformational change that 
leads to interaction of receptor with heterotrimeric G proteins. This further leads to 
catalytic exchange of GTP for GDP on the α-subunit of the G-protein. The α− subunit 
and  βγ heterodimer can activate different effector enzymes or ion channels until GTP is 
hydrolysed and G proteins return to their inactive state (Simon et al., 1991). Of all 
PARs, signalling mechanism for PAR-1 is most studied and well understood. The 
signalling mechanism for PAR-1 either proceeds via inhibition of cAMP through 
interaction with inhibitory G proteins (Kanthou et al., 1996) or via stimulation of 
phospholipase C-catalysed hydrolysis of phosphoinositides, resulting in formation of 
InsP3, mobilization of intracellular Ca2+, and generation of diacylglycerol, the 
endogenous activator of protein kinase C (Hung et al., 1992). Extensive studies from 
our laboratory have highlighted the role of thrombin (PAR-1)- induced proliferation via 
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MAPK pathway in astrocytes  resulting in ERK 1/2 phosphorylation (Wang et al., 
2002b). Thrombin-stimulated ERK1/2 activation is mainly mediated by PAR-1 via two 
branches: the PTX-sensitive G protein/(βγ-subunits)-phosphatidylinositol 3-kinase 
branch, and the Gq-PLC-(InsP3 receptor)/ Ca 2+ -PKC pathway. Thrombin- or PAR-1-
AP-induced ERK activation is partially blocked by a selective EGF receptor inhibitor. 
Nevertheless, transphosphorylation of EGF receptor is unlikely for ERK1/2 activation 
and is certainly not involved in PAR-1-induced proliferation (Wang et al., 2002b; Wang 
and Reiser, 2003b). Studies using C-tail of PAR-1 to identify molecules involved in 
downstream signalling (Mahajan et al., 2000; Pai et al., 2001) have shown that not only 
PAR-1 transmits intracellular signal via G-proteins bound to its 3rd intracellular loop 
(Chen et al., 2001), but C-tail interaction also results in PAR-1 mediated morphological 
changes in astrocytes (Mahajan et al., 2000; Pai et al., 2001). 
Compared with a large number of studies done to explore PAR-1 signalling 
pathway, little is known about mechanism of PAR-2 intracellular signalling. Trypsin 
and PAR-2 AP activation via heterotrimeric G proteins can stimulate IP3 formation and 
Ca2+ in numerous cell types (Schultheiss et al., 1997). PAR-2 signalling via PTX 
sensitive pathway has been shown to be associated with tyrosine phosphorylation of 
SHP-2 (Yu et al., 1997). In enterocytes PAR-2 agonists can stimulate arachidonic acid  
release and rapid generation of prostaglandins, suggesting activation of phospholipase 
A2 and cyclooxygenase-1 (Kong et al., 1997). PAR-2 has also been shown to be linked 
to SAP kinases, JNK and p38MAP kinase (Sabri et al., 2000). 
 
1.8 PAR expression in tissue injury 
 
Several recent studies on PARs have focused on their potential role in regulation 
of inflammation and response to injury. PAR-1 expression was found to be upregulated 
as a consequence of spinal cord injury (Citron et al., 2000), and sciatic nerve injury 
(Niclou et al., 1998), while it is downregulated after facial nerve transection (Niclou et 
al., 1998). Also cell surface expression of PAR-1 has been investigated under 
hypoglycemic and hypoxic conditions both in the presence and absence of thrombin 
(Weinstein et al., 1998). Altered PAR-1 expression also contributes to sclerotic and 
inflammatory processes in human vasculature (Nelken et al., 1992). PAR-1 expression 
also increases in rheumatoid and osteoarthritis contributing to inflammatory process 
(Morris et al., 1996). Thrombin stimulation of PAR-1 leads to platelet aggregation, 
vasodilation and vasoconstriction, increased vascular permeability and cellular adhesion 
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and infiltration by chemotaxis (Hung et al., 1992). Out of the 4 receptor subtypes of the 
PAR family, the role of PAR-2 in the regulation of inflammation is most widely 
documented. PAR-2 expression was found upregulated after carotid artery injury 
(Cheung et al., 1999) and in respiratory epithelium of asthmatic patients (Knight et al., 
2001). Agonists of PAR-2 are involved in protease-induced neurogenic inflammation 
(Steinhoff et al., 2000) and cutaneous inflammation (Shpacovitch et al., 2002) via 
receptor activation. PAR-2 also plays a major role in pathophysiology of vascular and 
gastric smooth muscle contractility (al-Ani et al., 1995). Besides its pro-inflammatory 
role, PAR-2 activation has been shown to exert a protective effect in myocardial 
ischemic-reperfusion injury (Cirino et al., 2000). PAR-1, PAR-2 and PAR-4 are known 
to modulate cytokine and prostaglandin production in primary human bronchial 
epithelial cells activation during lung inflammation (Asokananthan et al., 2002). PAR-2 
and PAR-4 are upregulated in human coronary artery as a result of inflammatory stimuli 
(Hamilton et al., 2001), and PAR-1, PAR-2 and PAR-3 are transiently upregulated after 
experimentally induced ischemia in organotypic hippocampal slice cultures (Striggow et 
al., 2001). Our recent work has shown that mRNA expression of PAR-1 to -3 was not 
affected by transient global ischemia (Riek-Burchardt et al., 2002). Taken together, 
these studies highlight the growing importance of the PAR family in patho-
physiological situations of neurodegeneration. 
 
1.9 The yeast-two hybrid assay 
 
The two-hybrid system addresses one of life’s fundamental questions: How does 
one find a meaningful partner? If a protein has a known function, new proteins that bind 
to it bring additional components into play, ultimately contributing to the understanding 
of the process under study. Alternatively, a protein’s function may be obscure but the 
protein may be of obvious relevance; for example, its gene may be mutated in human 
disease. In this case, partners with known roles may turn up and provide essential clues. 
Thus, the method is a tractable and rapid form of genetics for organisms, such as 
mammals, that cannot be readily manipulated (MacDonald Paul N., 2001).  
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1.9.1 Principle of the two-hybrid assay 
 
 
 
 
Figure 1.2. The two hybrid principle (Matchmaker Library construction and screening 
manual, Clontech, Heidelberg, Germany). GAL4-based two-hybrid system provides a 
sensitive transcriptional assay for detecting protein interactions in vivo in yeast. The 
DNA-BD is amino acids 1-147 of the yeast GAL4 protein, which binds to the GAL 
UAS upstream of the reporter genes. The AD is amino acids 768-881 of the GAL4 
protein and functions as a transcriptional activator. 
 
 
Transcription-based two-hybrid systems require three tools: one plasmid 
encoding a protein domain with promoter-specific DNA-binding activity, a second 
plasmid encoding a protein domain that serves as a transcription activator, and a yeast 
strain containing transcription-activated reporter genes. The gene encoding a protein of 
interest (the ‘bait’) is cloned as an in-frame fusion to the DNA-binding domain (DNA-
BD), and genes encoding additional proteins of interest, or a library of proteins (the 
‘target’), are cloned as in-frame fusions to the transcription activation domain (AD). 
Both plasmids are then transformed into an appropriate yeast strain. The bait protein is 
expressed as a fusion to the DNA-BD and is thus localised to the promoter of a reporter 
gene in the yeast nucleus. The target protein (or library of proteins) is expressed as a 
fusion to the transcription AD. Interaction between the bait and target results in the co-
localisation of the transcription AD to the DNA of the host strain, activating 
transcription of the adjacent reporter gene and generating a phenotypic signal.  
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To date, the yeast two-hybrid system has enabled the discovery of many novel 
proteins that play important roles in diverse biological processes. For example: the use 
of the two-hybrid system to analyse cell surface receptor and ligand interactions, 
analysis of protein–protein interactions mediating the yeast pheromone response 
pathway, and the discovery of new regulators of the cell cycle. Studies on interactions 
between cell surface ligand–receptor demonstrates that even though the yeast two-
hybrid interaction takes place in the nucleus of the yeast cell, it is still applicable to 
analysing ligand–receptor interactions that normally take place on the cell surface 
(MacDonald Paul N., 2001). 
 
1.10 Working model and the aims of the thesis project 
 
The main focus of the present project was to study the effect of different forms 
of brain injury on a family of cell surface receptors known to be involved in tissue 
repair and modulating brain injury processes (Xi et al., 2003), and further elucidate the 
role of protein-protein interaction of one of the receptor subtypes in intracellular 
signalling.  
For this purpose the optic nerve crush (ONC) model of rat was used as a 
prototype of traumatic axonal injury in the central nervous system (Gennarelli et al., 
1989; Sautter and Sabel, 1993; Sabel et al., 1997). Axonal damage has now been 
identified as a major primary response of brain tissue to mechanical insult (Gennarelli et 
al., 1989). Studying human and experimental animal brains for events surrounding 
trauma to axons presents several limitations, keeping in mind the complexity of the 
whole brain (Gennarelli et al., 1989). In such situations a model of axonal damage is 
required where the lesion is highly specific, graded and reproducible, and lesion 
severity can be correlated with functional outcome and recovery of function can be 
followed within a defined time course (Sautter and Sabel, 1993).  
For these diverse several reasons ONC injury model provides an ideal substitute 
for studying pathophysiology of induced trauma which resembled diffuse axonal 
damage in human as a result of closed head injury (Gennarelli et al., 1989; Sautter and 
Sabel, 1993). The injury-induced changes in retinal ganglion cell (RGC) axons and 
response of RGCs such as- transient shrinkage of cells, loss of retrograde transport, cell 
death and cytoplasmic atrophy have been well described in ONC model (Misantone et 
al., 1984; Barron et al., 1986). RGCs are a specialized type of nerve cells (neurons) that 
collect signals from other neurons in the eye and convey this information to the brain. 
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The nerve fibers, or axons, of RGCs form the optic nerve. The optic nerve is structurally 
and functionally well separated, unlike fibre tracts in brain or spinal cord, thus allowing 
specific and precise lesions and clear identification of injury–induced changes. 
Following ONC, significant spontaneous recovery to near prelesion performance levels 
occurs in 2-3 weeks (Sautter and Sabel, 1993).  
Injury to the optic nerve, either crush or axotomy, have been used previously to 
study tissue repair mechanism in non-regenerating central nervous system (Tesser et al., 
1986; Herdegen et al., 1993; McKerracher et al., 1993a, b; Isenmann and Bahr, 1997; 
Isenmann et al., 1997; Dieterich et al., 2002). Studies in our laboratory using the ONC 
model have shown a loss of almost 70-80% RGCs as a result of an early necrosis and 
subsequent apoptosis within 2 weeks after injury (Sautter and Sabel, 1993; Kreutz et al., 
1997; Bien et al., 1999). Using in vivo confocal neuroimaging technique (ICON) it has 
been shown in our laboratory that following the time course of morphological changes 
of RGCs after ONC in living rats can help to predict their fate in terms of neuronal 
survival or death (Rousseau et al., 1999). Increased thrombin levels at the injury site 
have also been reported in the ONC model of rat  (Friedmann et al., 1999; Friedmann et 
al., 2001a). In this study an increase in thrombin levels as early as 6 h after crush was 
observed with maximal levels at 1 day after injury (Friedmann et al., 2001a; Friedmann 
et al., 1999), The observation of such early thrombin up-regulation after crush indicates 
that thrombin might be involved in pathophysiology of ONC as it is known that 
thrombin at a higher concentration in brain has a detrimental effect (Striggow et al., 
2000).  
Aim 1: Since thrombin is an endogenous ligand of protease-activated 
receptors (PAR-1, -3 and –4), we decided to study the effect of ONC on PAR 
mRNA expression in retina.  
Considering that thrombin is a serine protease whose levels are known to 
increase even when blood-brain barrier is intact as a result of several types of brain 
injuries (Xi et al., 2003), we decided to investigate the effect of another type of brain 
injury i.e., ischemic stroke on PAR mRNA expression. It is known that prothrombin 
mRNA is expressed in CNS (Dihanich et al., 1991) and that it is up-regulated in brain 
following cerebral ischemia (Riek-Burchardt et al., 2002) and spinal cord injury (Citron 
et al., 2000).  
Focal ischemia results in inflammatory reaction, including macrophage 
infiltration, microglia activation, edema formation, upregulation of cytokines and 
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adhesion molecules, microvascular impairment and blood-brain barrier disruption (Liao 
et al., 2001; Danton and Dietrich, 2003). The differential response of all the elements 
involved in inflammation can either be detrimental, leading to secondary brain damage, 
or beneficial, resulting in neuronal regeneration after injury (Liao et al., 2001; Danton 
and Dietrich, 2003). Thrombin is known to be produced as a result of an inflammatory 
reaction at the site of injury (Cirino et al., 2000; Cocks and Moffatt, 2000).  
Earlier studies from our laboratory have shown that thrombin receptor-activating 
peptide mimicked the effects of low concentration of thrombin (50 pM) in reducing 
ischemic neuronal injury in vitro (Striggow et al., 2000); and transient up-regulation of 
receptors PAR-1 to -3 as a result of OGD in organotypic hippocampal slice cultures 
(Striggow et al., 2001).  
Aim 2: The data on the role of thrombin in brain ischemia including our 
own previous work prompted us to look at the mRNA expression pattern of PARs 
after transient focal ischemia in the present study. For this we induced transient 
focal ischemia by occlusion of the Middle Cerebral Artery (MCA) in rat which is a 
prototypical and well-established model for studying the outcome of stroke. Occlusion 
of the MCA was done by microinjection of endothelin-1 near the MCA (Sharkey et al., 
1994; Reid et al., 1995). This animal model for studying stroke has the advantage of 
reduced reperfusion damage. Additionally, the slow onset of reperfusion more closely 
reflects the clinical situation of stroke. 
Receptor activation on the extracellular surface of the cell results in transmission 
of the response via intracellular signalling that finally culminates in the nucleus 
resulting in gene activation. Intracellular signalling requires a series of proteins to 
transfer information from one moiety to another in a sequential manner and in the 
process of amplifying the signal. Each moiety involved in signalling can interact with 
several other moieties depending on the preceding signal. Anomalies in the signalling 
cascade can lead to deleterious effects with major pathological implications. Hence it is 
important to understand the signalling mechanism in order to unravel its intricacies. 
Involvement of PARs in inflammation, tissue injury and neuronal signalling 
(Vergnolle et al., 2001a) makes them an interesting candidate for studying their 
intracellular signalling network. Work done in our laboratory has already elucidated the 
PAR-1 signalling mechanism in astrocytes (Wang et al., 2002b). In previous reports 
novel protein-protein interactions using the carboxy tail of PAR-1 were found by the 
classical yeast-two hybrid screen (Mahajan et al., 2000; Pai et al., 2001). These studies 
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highlighted the role of PAR-1 interacting proteins in signalling to cytoskeleton 
(Mahajan et al., 2000; Pai et al., 2001).  
 Aim 3: Since PAR-2 is the most extensively studied and implicated 
receptor subtype in brain injury such as ONC and ischemia (Napoli et al., 2000; 
Vergnolle et al., 2001b; Rohatgi et al., 2003), we decided to use this receptor 
subtype in a yeast-two hybrid screen to find novel interacting protein(s). Then their 
role in PAR-2 signalling pathway should be identified either under normal or 
pathophysiological conditions.  
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       1.11 Yeast-two hybrid library construction and screening protocol 
Generation of cDNA library
100 ng of total RNA or 25 ng of poly A+ RNA
Synthesise of first-strand cDNA
Amplification of ds cDNA by LD-PCR
Purification (size selection) of ds cDNA
Construction of DNA-BD fusion
Cloning of bait gene into DNA-BD vector, pGBKT7
Transformation of AH109 and Y187 with bait fusion
protein and testing for autonomous reporter gene
activation and cell toxicity
 bait fusion protein inactive and nontoxic
•Construction of an AD fusion library
•Screening by Sequential transformation
Library Construction (two-steps)
•transformation of AH109 with bait protein
•bait containing AH109 transformed with:
     -ds cDNA
     -Sma I-linear pGADT7-Rec 
                Two- hybrid Screening
Selection of transformants expressing interacting proteins
                       Analysis
  Verification of positive interactions
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2. Materials and Methods 
 
2.1 Materials 
 
2.1.1 Animals 
 
a) Hsdcpb:WU rats: Pups and adult (12 weeks old) male. 
b) Male Sprague Dawley rats 
 
2.1.2 Cell lines 
 
a) Human embryonic kidney (HEK 293-epithelial) 
b) Rat N2A (neuronal) 
c) NG108 (mouse neuroblastoma x rat glioma hybrid) 
d) Retinal ganglion cell (RGC-neuronal) 
 
2.1.3 Bacterial and yeast strains 
 
 Strain Genotype Reference 
Bacteria: E coli XL1-Blue supE44, hsdR17, 
recA1, endA1, 
gyrA46, thi, relA1, 
lac, [F’ proAB, lacIq, 
Z∆M15, Tn10(tetr)]  
Sambrook 
et al., 
1989 
Yeast:Saccharomyces 
cerevisiae 
AH109  MATa, trp1-901, 
leu2-3, 112, ura3-52, 
his3-200, gal∆4, 
gal80∆, LYS2 : : 
GAL1UAS-
GAL1TATA-HIS3, 
GAL2UAS -
GAL2TATA-ADE2,  
URA3 : : MEL1UAS-
MEL1TATA-lacZ, 
MEL1 
 
James et 
al., 1996; 
Clontech  
Yeast:Saccharomyces 
cerevisiae 
Y187 MATα, ura3- 52, 
his3- 200, ade2- 101, 
trp1- 901, leu2- 3, 
112, gal4∆, met–, 
gal80∆, 
Harper et 
al., 1993 
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URA3 : : GAL1UAS -
GAL1TATA -lacZ, 
MEL1 
 
 
 
 
2.1.4 Plasmid vectors 
 
Name Size(Kb) Antibiotic 
resistance 
Yeast 
nutritional 
selection 
marker 
Manufacturer 
pGBKT7 7.3 kanamycin tryptophan Clontech, 
Heidelberg,  
Germany 
pGADT7-
Rec 
8.0 ampicillin leucine  
pCMV-HA 3.8 ampicillin -  
pEGFP-N1 4.7 kanamycin/ 
neomycin 
-  
pEGFP-C2 4.7 kanamycin/ 
neomycin 
-  
pDsRed2-
N1 
4.7 kanamycin/ 
neomycin 
-  
pcDNA3.1/
Myc-His 
(B) 
5.5 ampicillin/ 
neomycin 
- Invitrogen, 
Karlsruhe, 
Germany 
 
 
 
 
 
2.1.5 RNA 
 
Rat retina poly A+ RNA                                           Clontech, Heidelberg, Germany 
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2.1.6 Enzymes  
 
Enzymes and buffer Manufacturer 
Shrimp Alkaline Phosphatase  Boeringer, Mannheim, Germany 
Sal I Gibco BRL (Life Technologies), 
Karlsruhe, Germany 
T4 DNA Ligase  
Bam HI MBI Fermentas, St. Leon-Rot, Germany
Eco RI  
Eco RV  
Hind III  
Xho I  
Y/Tango+ (10X) buffer  
Sfi I New England Biolabs, Beverly, MA, 
USA 
RNasin-Ribonuclease inhibitor Promega, Mannheim, Germany 
 
 
2.1.7 Kits 
 
Type of kit             Usage Manufacturer 
BigDye Terminator 
Cycle Sequencing            
Ready Reaction kit  
 
DNA sequencing Applied Biosystems, 
Warrington, UK 
ECL+Plus  detection of western 
blot  
Amersham Pharmacia 
Biotech, 
Buckinghamshire, UK 
MatchMaker Library 
Construction & 
Screening kit 
cDNA library 
construction and 
screening in yeast 
Clontech, Heidelberg, 
Germany 
Concert Rapid PCR 
Purification system 
Cleaning of PCR, 
restriction digestion 
product 
Gibco BRL (Life 
Technologies), 
Karlsruhe, Germany 
 20
Concert Rapid Gel 
Extraction system 
Cleaning of PCR 
product from gel 
 
Invisorb Spin Plasmid 
Mini kit 
Plasmid isolation Invitek, Berlin, 
Germany 
HiSpeed Plasmid Midi 
kit 
Plasmid isolation Qiagen, Hilden, 
Germany 
Hotstar Taq Master Mix 
kit  
PCR  
Omniscript Reverse 
Transcription kit 
Making of cDNA    
Qiashredder  Homogenisation of 
Animal tissue for RNA 
isolation 
 
RNase-Free DNase Set Removal of genomic 
DNA during RNA 
isolation 
 
RNeasy Maxi, Midi and 
Mini kit (Isolation of 
RNA) 
Isolation of RNA  
Supersignal West Pico 
kit 
Detection of western 
blot 
Pierce, Rockford, IL, 
USA 
 
 
 
2.1.8 Laboratory instruments  
 
Instrument Manufacturer 
ABI PRISMTM 310 Genetic Analyzer Applied Biosystems Division, Foster 
City, CA, USA 
ProBlott membrane (PVDF membrane)  
Mighty Small II (for western blotting 
electrophoresis) 
Amersham Pharmacia Biotech 
Buckinghamshire, UK 
 
T3 Thermocycler Biometra, Göttingen, Germany 
Electrophoresis power supply Bio-Rad Laboratories, München, 
Germany 
Gel electrophoresis system  
Semi-dry Transfer Cell  
Mini PROTEAN II (Tankblot)  
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GS-800 Calibrated Densitometer  
LSM510 laser scanning confocal 
microscope Axiovert 135 fluorescence 
microscope  
Carl Zeiss, Jena, Germany 
Sorvall RC-5B Refrigerated Superspeed 
Centrifuge 
Dupont Instruments, Hamburg, 
Germany 
pH Meter (pH526) WTW 
Eagle Eye Still video system Stratagene, Heidelberg, Germany 
Thermomixer comfort Eppendof 
Biofuge A, 13 R, 3.2 RS (centrifuge) Heraeus, Hamburg, Germany 
LaminAir (clean bench)  
Cell culture incubator  
Microplate reader Molecular Devices 
Innova 4230 Refrigerated incubator 
shaker 
New Brunswick Scientific, Nürtingen, 
Germany 
UV/visible Spectrophotometer Pharmacia Biotech 
Gel-blotting-papers Schleicher & Schuell, Dassel, Germany 
Protran BA83 Cellulosenitrat (E) (0.2 
µm) 
 
Protran BA79 nitrocellulose transfer 
membrane (0.1 µm) 
 
 
                                                                                  
 
 
 
2.1.9 Chemicals and Reagents 
 
Chemicals Manufacturer 
Protein A Amersham Pharmacia Biotech, 
Buckinghamshire, UK 
 
Template Suppression Reagent (TSR) Applied Biosystems Division, Foster 
City, CA, USA 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Biochrom, Berlin, Germany 
DMEM + HAM’S F12 (1:1)  
Fetal calf serum (FCS)  
Penicillin and Streptomycin  
HBSS (w/o Ca2+ and Mg2+)  
Ampicillin  
Kanamycin sulphate  
Bio-Rad protein assay dye reagent 
concentrate 
Bio-Rad Laboratories, München, 
Germany 
Bacto Agar BD Bioscience (Clontech), Heidelberg, 
Germany 
Bacto Tryptone  
Bacto Yeast extract  
Yeast Nitrogen base w/o amino acids  
Amino acid dropout media (DO)  
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Ponceau S solution (0.2% in acetic acid) Boehringer, Mannheim, Germany 
G418 Sulphate Calbiochem, La Jolla, CA, USA 
ImmersolTM 518N (Immersion oil for 
microscopy) 
Carl Zeiss, Oberkochen, Germany 
HAT supplement GIBCO BRL, Karlsruhe, Germany 
NuPAGE Novex 10% Bis-Tris Pre-Cast 
Gel 
Invitrogen, Groningen, Netherland 
NuPAGE Antioxidant  
NuPAGE Transfer Buffer (20x)  
NuPAGE  LDS Sample Buffer (4x)  
NuPAGE  MOPS SDS Running Buffer 
(20x) 
 
X-gal (5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside) 
 
Accutase PAA 
DOTAP Roche Diagnostic, Mannheim, Germany
Blotto, non-fat dry milk Santa Cruz Biotechnology, Heidelberg, 
Germany 
TEMED SERVA, Heidelberg, Germany 
Triton-X-100  
Tween 20 SIGMA, Deisenhofen, Germany 
MES (2-[N-Morpholino]ethanesulfonic 
acid) Hydrate 
 
Glass Beads, 425-600 microns 
(unwashed) 
 
Dimethyl sulfoxide (DMSO)  
DMF (N,N-dimethylformamide)  
β-mercaptoethanol  
Adenine hemisulphate  
Igepal CA630  
Chloral hydrate  
 
 
 
 
2.1.10 Antibodies 
 
Antibody Manufacturer 
mouse monoclonal antibody against 
glial fibrillary acidic protein (GFAP) 
Boehringer, Mannheim, Germany 
rabbit polyclonal antibody against α-
crystallin A 
Biomol, Hamburg, Germany 
rabbit polyclonal IgG against HA-tag Clontech, Heidelberg, Germany 
peroxidase-conjugated anti-mouse and 
anti-rabbit IgG  
 
Dianova, Hamburg, Germany 
mouse monoclonal antibody against 
Myc 
Invitrogen, Groningen, Netherland 
rabbit polyclonal anti-GFP  
Alexa555 anti-mouse IgG and Alexa488 Molecular Probes, Eugene, OR, USA 
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anti-rabbit IgG  
mouse monoclonal anti-PAR-2 (SAM-
11) 
Santa Cruz Biotechnology, Heidelberg, 
Germany 
rabbit polyclonal affinity purified 
antibody against HA-tag 
SIGMA, Deisenhofen, Germany 
mouse monoclonal antibody against 
synaptotagmin 1 (cytoplasmic tail) 
SYSY-Synaptic Systems, Goettingen, 
Germany 
                                           
 
2.1.11 Buffers and solvents 
 
2.1.11.1 Cell culture medium and solutions 
 
HEK-293 cells- DMEM/HAM’S F12 (1:1) with 2mM Glutamine, 10% FCS, 100U/ml 
Penicillin, 100 µg/ml Streptomycin  
 
N2A cells- DMEM: 3.7 g/L NaHCO3, 4.5 g/L D-glucose, 1.028 g/L N-Acetyl L-alanyl-
L-glutamine, 10% FCS, 100U/ml Penicillin, 100 µg/ml Streptomycin 
 
NG-108 cells- DMEM: 3.7 g/L NaHCO3, 4.5 g/L D-glucose, 1.028 g/L N-Acetyl L-
alanyl-L-glutamine, 10% FCS, 100 U/ml Penicillin, 100 µg/ml Streptomycin, HAT 
supplement (50X) – 200 µl/ 10 cm dish 
 
RGC-5 cells- DMEM: 3.7 g/L NaHCO3, 1.0 g/L D-glucose, 1.028 g/L N-Acetyl L-
alanyl-L-glutamine, 10% FCS, 100U/ml Penicillin, 100 µg/ml Streptomycin 
 
HBSS (Hanck’s balanced salt solution) without Ca2+ and Mg2+ 
 
Accutase 
 
G418 Sulphate- stock: 500 mg/ml, working  concentration: 500 µg/ ml 
 
2.1.11.2 Buffer and solutions 
 
• DEPC (Diethyl pyrocarbonate) water: 0.1%= 1ml/ 1lt water  
 
• 1x PBS: 137 mM NaCl, 2.6 mM KCl, 8.1 mM Na2PHO4, 1.4 mM KH2PO4, pH 7.4 
 
• 1xTBE: 89 mM Tris, 89 mM Boric acid, 2 mM EDTA, pH 8.0 
 
• 1xTE: 10 mM Tris/HCl, pH 7.4, 1 mM EDTA, pH 8.0 
 
 24
• 10X MOPS: 0,2 M MOPS, 10 mM Na2-EDTA, 50 mM Na-Acetate, pH 7.0 
 
• Ethidium bromide solution: 10 mg/ml 
 
• TCM: 10 mM Tris/HCl, pH 7.5, 10 mM CaCl2, 10 mM MgCl2 
 
• 4% PFA (Paraformaldehyde) solution: 4% PFA, 120 mM sodium phosphate, pH 7.4, 
4% Saccharose  
 
• FTP: Blocking and Washing buffer (immunostaining)-100 ml 
      10% FCS    10 ml 
      0.25% Triton-X100  0.25 ml 
      10X PBS    10 ml 
 
• 4x Lysis buffer (cell lysate): 200 mM Tris/HCl, pH 7.4, 4 mM EDTA, 4 mM β-
Mercaptoethanol, 600 mM NaCl, 4% Igepal 
and one tablet of Protease Inhibitor Cocktail (Roche Molecular Biochemicals, 
Mannheim, Germany) per 50 ml 
 
• 1x Lysis buffer (cell lysate)-8 ml 
 
• 4x lysis buffer     2 ml 
      0.5 M EDTA    400 µl 
      EDTA-free complete   160 µl 
      proteinase inhibitor cocktail  
      H2O       5.44 ml 
 
• 60% Acrylamid/Bis-100 ml 
 
       Acrylamid     58.4 g 
       N,N‘-Methylen-bisacrylamid  1.6 g 
 
• Resolving buffer (SDS-PAGE-Laemmli): 750 mM Tris/HCl, pH 8.8 
 
• Stacking buffer: 250 mM Tris/HCl, pH 6.8 
 
• SDS solution: 10% (w/v) SDS in H2O 
 
• PER solution: 10% (w/v) Ammoniumperoxodisulfat in H2O 
 
• 4x Laemmli Sample buffer: 500 mM Tris/HCl, pH6.8, 8% SDS, 40% Glycerol 
 
• 5x Laemmli Running buffer: 125 mM Tris, 960 mM Glycine, 0.5% SDS, pH 8.5 
 
• 1x Transfer buffer (for Laemmli gels with NC membrane): 25 mM Tris, 192 mM 
Glycine, 20% (v/v) Methanol 
 
• 100 mM CAPS [3-(Cyclohexylamino)-1-propansulfonic acid] /NaOH, pH 11 
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• 1x Transfer buffer (for Laemmli gels with PVDF membrane): 10% (v/v) Methanol, 10 
mM CAPS/NaOH 
  
• Membrane Stripping buffer: 62.5 mM Tris, pH 6.8, 100 mM β-Mercaptoethanol, 2% 
SDS 
 
• 20% Protein A slurry : 1 ml 1x PBS and 4 µl 10% sodium azide 
 
• Lysis buffer (for yeast): 10 mM Tris/HCl, pH 8.0, 100 mM NaCl, 1mM EDTA, 2% 
Triton-X-100, 1% SDS. 
 
• Phenol- chloroform- Isoamylalcohol: 25:24:1 
 
• X-gal (stock solution)- 20 mg/ml in DMF. Stored at -20 C  
 
• Z buffer-1lt 
 
      Na2HPO4. 7H2O             6.1 g 
      NaHPO4.H2O  5.50 g 
      KCl    0.75 g 
      MgSO4.7H2O  0.246 g 
      pH 7.0 
 
• Z buffer/X-gal solution 
 
      Z buffer    100 ml 
      β-mercaptoethanol   0.27 ml 
      X-gal (20 mg/ml)             1.67 ml 
 
• PEG/LiAc (polyethylene glycol/ lithium acetate) 
 
                                   Final conc.                    For 10 ml soln 
      PEG 4000  40%    8 ml of 50% PEG 
      TE buffer  1x   1 ml of 10x TE 
      LiAc  1x   1 ml of 10x LiAc 
 
• 5xKCM buffer- 30 ml 
                                                                End concentration 
      3 M KCl     5 ml   0.5 M 
     1 M CaCl2   4.5 ml   0.15 M 
     1M MgCl2   7.5 ml   0.25 M 
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2.1.11.3  Microbial media 
 
• Luria bertini (LB)- 1 lt  
 
      Bacto-tryptone   10 g  
      Bacto yeast extract    5 g                                          
      NaCl    10 g 
      pH 7.0 
      bacto agar (for plates)  15 g 
      Ampicillin              100 µg/ml (final conc.) 
      Kanamycin    50 µg/ml  (final conc.) 
 
• YPDA-1 lt 
 
      Difco peptone   20 g 
      Yeast extract   10 g 
      0.2% Adenine hemisulfate 15 ml (final conc.= 0.003%) 
      pH 5.8 
      40% Glucose   50 ml (final conc.= 2%) 
      bacto agar (for plates)  20 g 
      kanamycin    10-15 µg/ml (final conc.) 
 
• SD minimal media- 1 lt 
 
     Yeast nitrogen base w/o amino acids  6.7 g 
     10X Dropout (DO) solution      100 ml solution / appropriate  amount  of DO powder 
             
      pH 5.8 
     40% Glucose     50 ml (final conc.= 2%) 
     bacto agar (for plates)     20 g 
 
• SOC –250 ml 
 
      Bacto tryptone  5 g 
      Yeast extract  1.25 g 
      NaCl   0.15 g 
      KCl    0.125 g 
     1M Glucose   5 ml    (final 20 mM) 
     1M MgCl2                  2.5 ml (final 10 mM) 
     1M MgSO4    2.5 ml (final 10 mM) 
 
•  
•  
•  
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• TSB buffer-150 ml 
                                                                        End concentration 
       2x LB-media  75 ml  1x LB 
       DMSO   7.5 ml  5% 
      1 M MgCl2                  1.5 ml  10 mM 
      1 M MgSO4                  1.5 ml  10 mM 
      PEG 4000             15 g  10% 
     Sterile filtered with 0.2µm Filter 
 
• 2xLB-100 ml 
      bacto tryptone  2 g 
      Yeast extract  1 g 
      NaCl   2 g 
      pH 7.0-7.4            
 
• 10 x -His/-Trp DO supplement- 500 ml  
       Lysine    0.3 g  
      Adenine hemisulphate  0.2 g 
      Leucine    1.0 g              
 
 28
 
2.1.12 Oligonucleotides  
   
(Synthesized by MWG, Biotech, Erbesberg, Germany) 
 
2.1.12.1  PCR Primers 
 
Gene 
Product 
Accession 
No. 
Primer sequence  
(5’→ 3’) 
Position Tm (°C) PCR 
product 
(bp) 
PAR-1 M81642 CCTATGAGACAGCCAGAATC 
(S) 
14
6 
55°C 355 
  GCTTCTTGACCTTCATCC (AS) 50
0 
  
PAR-2 U61373 GCGTGGCTGCTGGGAGGTATC 
(S) 
19 59°C 742 
  GGAACAGAAAGACTCCAATG 
(AS) 
76
0 
  
PAR-3 AF310076 GTGTCTCTGCACACTTAGTG (S) 18 55°C 581 
  ATAGCACAATACATGTTGCC 
(AS) 
59
8 
  
PAR-4 AF310216 GGAATGCCAGACGCCCAGCAT
C (S) 
54 64°C 559 
  GGTGAGGCGTTGACCACGCA 
(AS) 
61
2 
  
GAPDH M17701 GTGAAGGTCGGTGTCAAC (S) 34 51°C 835 
  CAACCTGGTCCTCAGTGTAGC 
(AS) 
86
8 
  
α-crystallin A NM_012534 GGAACATGGACGTCACCAT (S) 8 58°C 526 
  CAGGACGAGGGTGCCGAGC 
(AS) 
53
3 
  
α-crystallin B NM_012935 GGACATAGCCATCCACCA (S) 3 56°C 512 
  CTGCAGTGACAGCAGGCT (AS) 51
4 
  
hsGAPDH NM_002046 TCCAAAATCAAGTGGGGCGAT
GCT (S) 
322 55°C 600 
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  ACCACCTGGTGCTCAGTGTAG
CCC (AS) 
920   
 
 
 
2.1.12.2 Cloning Primers 
 
Gene Product Accession 
No. 
Primer sequence  
(5’→ 3’) 
Position Tm 
(°C) 
PCR 
product 
(bp) 
C-tail PAR-2 U61373 TTTGTTGAATTCATGTCGAA
AGATTTCAGG (S) 
1036 58°C 186 
  CTCAGACCCGGATCCAGCTC
AGTAGGAGGT (AS) 
1206 
Full PAR-2 U61373 CCACGTCTCGAGCCGGGGAT
GCGAAGTCTCAGC (S) 
1 58°C 1224 
  CCCAGCTCAAAGCTTGTAGG
AGGTTTTAACACT (AS) 
1200 
Full α- 
crystallin A 
NM_012534 GAATTCCGGCTCGAGAACAT
GGACGTCACCATC (S) 
1 63°C 552 
  GCCTGCTCAAAGCTTGGACG
AGGGTGCCGAGCT (AS) 
540 
Full α- 
crystallin A 
NM_012534 GAATTCCGGGGATCCAACAT
GGACGTCACCATC (S) 
1 63°C 552 
  GCCTGCTCAGATATCGGACG
AGGGTGCCGAGCT (AS) 
540 
α-crystallin A 
Domain 1 
(CD1) 
 
NM_012534 GAATTCCGGGGATCCAACAT
GGACGTCACCATC (S) 
1 60°C 198 
  GTCCAACACGATATCTGTGC
GGAAGAGAGACTG (AS) 
186  
α-crystallin A 
Domain 2 
(CD2) 
NM_012534 ACAGTGTTGGGATCCGACAT
GTCCGGCATCTCTGAG (S) 
175 60°C 348 
  CTCCTCCCGGATATCTGACA
CGGGAATGGCCCT (AS) 
507  
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2.1.12.3 Sequencing Primers  
 
Annealing temperature in all cases: 55°C 
 
Gene Product 
/ plasmid 
vector 
Accession 
No. 
Primer sequence  
(5’→ 3’) 
Position Comment 
pGBKT7 Clontech GGAGCAGAAGCTGATCTC (S) 1250 
  TATGCTAGTTATGCGGCC  (AS) 1345 
pGADT7-Rec 
Matchmaker 
AD LD-Insert 
Screening 
Amplimer 
Clontech CTATTCGATGATGAAGATACCCC
ACCAAACCC (S) 
published 
  GTGAACTTGCGGGGTTTTTCAGT
ATCTACGAT (AS) 
T7 promoter Invitrogen GTAATACGACTCACTATAGGGC 
(S) 
published 
BGH seq Invitrogen CTAGAAGGCACAGTCGAGG (AS) published 
PAR-2 seq U61373 GCGCTCTGCAAGGTGCTCATT (S) 436 
PAR-2 seq U61373 CTCAACAGCTGCATAGACCC (S) 1003 
PAR-2 seq U61373 GTAGACGTGGCTCTGCCTCTG 
(AS) 
969 
α-crystallin A 
seq 
NM_01253
4 
GGCATGCTGACCTTCTCTGG (S) 421 
pEGFP-N1 
seq 
Clontech GGTCTATATAAGCAGAGCTG (S) 550 
  CCATGGTGGCGACCGGTGGAT 
(AS) 
682 
pCMV-HA Clontech GATCCGGTACTAGAGGAACTGA
AAAAC (S) 
published 
 
 
 
2.1.13   Molecular weight markers 
 
2.1.13.1 Nucleic acid standard marker 
 
GeneRuler 100bp DNA Ladder   (1 kb)      MBI Fermentas, Germany             
                                                                                                       
GeneRuler DNA Ladder Mix (10 kb)  
 
 
2.1.13.2   Protein standard marker 
 
Precision Plus (All Blue) (250-10 kDa)                            Bio-Rad, München, Germany 
SeeBlue Plus2 Pre-stained  (for Nupage pre-cast)            Invitrogen, Netherland 
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2.2 Methods 
 
2.2.1.1 Optic nerve crush (ONC) 
 
Adult male Hsdcpb:WU rats were kept two animals per cage on a 12 h / 12 h 
dark/light cycle at a relative humidity of 40-50% at 22°C with food and water 
available ad libitum. 12 weeks old animals were anaesthetised intra-peritoneally with 
Ketanest and Rompun (50 mg/kg and 20 mg/kg, respectively). A partial nerve crush 
was done with a cross-action forceps as previously described (Sautter and Sabel, 
1993). The tips of the forceps were spaced 0.2 mm apart. The left optic nerve was 
approached from the orbit by a lateral canthotomy under the guidance of a surgical 
microscope. The optic nerve was exposed by blunt dissection, leaving both retinal 
blood supply and dura intact. The nerve was then crushed at a distance of 2-3 mm 
from the eye for a duration of 30 s. After completion of the crush, the canthotomy was 
sutured and an antibiotic eye ointment was topically applied to prevent inflammation. 
The right nerve remained untouched. Control (untreated) and optic nerve crush (ONC) 
treated (after different post-injury time intervals) rats were killed with 7% chloral 
hydrate, after perfusion with 10 mM phosphate buffered saline, pH 7.0, for 10 min and 
both eyes were dissected out of the animal. A cut in the cornea released the lens and 
vitreous body and the retina was separated from the complex of retinal pigment 
epithelium and choroid-eye cup .  
Tissues were immediately frozen in liquid nitrogen and stored at –70°C. In 
case of pups, eyes were removed from the animals after giving them 7% chloral 
hydrate and were immediately frozen in liquid nitrogen and stored at –70°C. All 
animal experiments were performed in compliance with the relevant laws and 
institutional guidelines. 
 
2.2.1.2 Transient focal ischemia 
 
Endothelin-1-induced transient focal ischemia in rats (e-MCAO): done in co-operation 
with Dr. Petra Noack and Prof. K.G Reymann (Forschungsinstitut Angewandte 
Neurowissenschaften (FAN), 39120 Magdeburg, Germany). Induction of ischemic 
damage was done by Dr. Noack  
 
Male Sprague Dawley rats (300-360 g) were used. The animals were fed with 
laboratory chow and water ad libitum and maintained in a thermo-regulated 
environment (17-21°C) during a 12/12 hr light/dark cycle. Animals were anaesthetised 
with sodium pentobarbitone (40-50 mg/kg) and placed in a stereotaxic frame. A scalp 
 32
incision of approximately 1 cm in length was made from a point between the eyes, 
along the midline towards the back of the skull. The periosteum was then removed 
from the surface of the skull by scraping, and the surface was swabbed with 3% 
hydrogen peroxide to dry and clean it. A stainless steel screw (1.5 mm diameter) was 
inserted into the skull via a drill hole, without piercing the dura. A second drill hole 
was made for the guiding cannula for endothelin injection (endothelin-cannula: 0.9 
mm posterior to bregma and 4.8 mm lateral to midline). The dura was pierced through 
the hole and the cannula was lowered with the tip located near to the MCA. The entire 
assembly was sealed and fixed to the skull with dental cement. The animals were 
allowed to recover for at least 7 days before any further intervention. Throughout the 
endothelin application, the animals could move freely in their cage, with an injector 
connected by a flexible tube to a Hamilton syringe. To induce MCAO, rats were given 
an injection of 250 pmol endothelin-1 in 2 µl 0.9% NaCl solution over a time period of 
2 min. After a further minute the cannula was slowly withdrawn. 
After the survival time of 12 h, 48 h and 7 days after ischemia, the animals 
were anaesthetised (chloralhydrate), perfused with 60 ml saline and then decapitated. 
Brains were taken out under sterile conditions and placed into a rodent brain matrix. A 
4 mm thick coronal slice was taken out 7 mm from the frontal pole, dissected along 
fissura longitudinalis cerebri in ispsilateral and contralateral hemisphere and 
immediately frozen in liquid nitrogen. The slice from the ipsilateral hemisphere 
comprises the infarct volume evaluated in a standard ischemic brain, 7 days after 
induction of damage (Nissl-staining). Nissl-stain and infarct areas were quantified on a 
Nikon microscope using Lucia software. The infarct volume was calculated by linear 
trapezoidal extrapolation. As expected, the histological evaluation of the brains 
showed a time-dependent increase in damage. The infarct volume increased directly 
proportional to survival time after ischemic injury: The infarct volume at 12 h survival 
was 30 mm3, at 48 h survival 42.6 mm3 and at 7d survival it was 77.5 mm3 (data not 
shown). All animal experiments were performed in compliance with the relevant laws 
and institutional guidelines. 
 
2.2.2 Isolation of Nucleic acids 
 
2.2.2.1 RNA isolation from Animal tissue 
 
Total RNA was isolated from rat retina with the RNA isolation kit (RNeasy 
Mini kit, Qiagen). Briefly, the frozen tissue was homogenised completely in 350 µl 
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Buffer RLT containing β-Mercaptoethanol (10 µl β-ME/1 ml Buffer RLT). Lysate was 
pipetted directly onto a QIAshredder column sitting in a 2-ml collection tube, and 
centrifuged for 2 min at maximum speed to homogenise. The lysate was centrifuged 
again for 3 min at maximum speed and only the clear supernatant from this step used 
in subsequent steps. Added 1 volume of 70% ethanol to the cleared lysate, and mixed 
well by pipetting for precipitating the RNA. Applied 700 µl of the sample to a RNeasy 
mini spin column sitting in a 2-ml collection tube, and centrifuged for 1 min at 10,000 
rpm. Pipetted 350 µl Buffer RW1 onto the RNeasy column, and centrifuged for 1 min 
at 10,000 rpm to wash the lysate. Now On-column DNase digestion was performed to 
remove genomic DNA using the RNase-Free DNase kit (Qiagen, Hilden). Added 10 
µl of DNase I stock solution (2.73 Kunitz units/ µl) mixed in 70 µl Buffer RDD 
(DNase I incubation mix) directly onto the spin-colum membrane and incubated at 
room temperature for 15 min. Pipetted 350 µl Buffer RW1 into the spin column and 
centrifuged for 1 min at 10,000 rpm. Transferred the RNeasy column into a new 2-ml 
collection tube. Pipetted 500 µl Buffer RPE onto the RNeasy column, and centrifuged 
for 1 min at 10,000 rpm. Pipetted 500 µl Buffer RPE again onto the RNeasy column 
and centrifuged for 2 min at maximum speed to dry the RNeasy membrane. 
Transferred RNeasy column into a new 1.5-ml collection tube, and pipetted 30 µl 
RNase-free water onto the RNeasy membrane. Incubated at room temperature for 10 
min and then centrifuged for 2 min at 12,000 rpm to elute. Stored at –80°C. 
To isolate total RNA from rat brain, RNeasy Midi or Maxi kit (Qiagen, Hilden) 
was used depending on the amount of the tissue. The volume of all the solutions and 
centrifugation time were adjusted accordingly. 
 
2.2.2.2 RNA isolation from Animal cells 
 
Total RNA was isolated from cultured cells (wild type and transfected) using 
the RNeasy Mini kit (Qiagen, Hilden). The medium was aspirated from the culture 
dish (6 cm) and cells were lysed with 600 µl Buffer RLT. Cells were homogenised 
completely by pipetting with 1 ml tip, and to this homogenised suspension 700 µl of 
70% ethanol added and mixed well by pipetting. Rest of the procedure was done as 
described above for total RNA isolation from animal tissue.  
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2.2.2.3 Plasmid DNA isolation from bacteria (mini-preparation) 
 
Plasmid DNA from transformed bacteria was harvested using the Invisorb Spin 
Plasmid Mini Kit (Invitek, Berlin). E.coli culture (single colony) was grown under 
appropriate antibiotic selection pressure in 3 ml LB media overnight at 37°C with 
shaking at 250 rpm. 2 ml of overnight grown culture was transferred to 
microcentrifuge tube and centrifuged for 1 min at maximum speed to pellet the cells 
down. Supernatant was removed completely and pellet was resuspended in 200 µl of 
Solution I by vortexing. Added 250 µl of Solution II, closed the tube and mixed 
carefully by inverting the tube only 5 times (no vortexing since it can lead to shearing 
of chromosomal DNA which contaminates the plasmid DNA). Added 250 µl of 
Solution III and mixed gently, but thoroughly, by shaking the tube 4-6 times. 
Centrifuged for 3 min at maximum speed. Decanted the clarified supernatant into the 
Spin Filter placed in a 2.0 ml Receiver tube. Added 200 µl of Binding Solution to the 
filled Spin Filter and closed the tube. Inverted the tube one time and centrifuged for 1 
min at 10,000 rpm. Discarded the filtrate and added 750 µl of Wash Buffer PL. 
Centrifuged for 1 min at 10,000 rpm and discarded the filtrate. Then centrifuged for 2 
min at maximum speed for complete removal of residual Wash Buffer PL. Placed the 
Spin Filter into a new 1.5 ml Receiver Tube and allowed the Spin Filter to air dry for 1 
min for complete removal of ethanol in Wash Buffer. Then 30 µl of Elution Buffer 
added directly onto the membrane of Spin Filter and incubated at room temperature 
for 10 min. Finally centrifuged for 2 min at 10,000 rpm to recover the plasmid DNA. 
Stored at -20°C. 
 
2.2.2.4 Plasmid DNA isolation from bacteria (Midi-preparation)   
 
Plasmid DNA from transformed bacteria was harvested using the HiSpeed 
Plasmid Midi Kit (Qiagen, Hilden). 50 ml of overnight grown transformed bacteria 
culture was centrifuged for 1 min at 5000 rpm to recover cell pellet. Bacterial pellet 
was resuspended in 4 ml of Buffer P1 containing RNase A. Added 4 ml of Buffer P2, 
mixed gently, and incubated at room temperature for 5 min. Then added 4 ml of 
chilled Buffer P3, mixed immediately but gently and poured the lysate into the barrel 
of the QIAfilter Midi Cartridge. Incubated at room temperature for 10 min to allow 
precipitation of protein and genomic DNA at the top of the solution. In the mean time 
applied 4 ml of Buffer QBT to equilibrated a Qiagen-tip 500 and allowed the column 
to empty by gravity flow. Then removed the cap from the QIAfilter outlet nozzle and 
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gently inserted the plunger into the cartridge and filtered the cell lysate into already 
equilibrated Qiagen-tip. Allowed the cleared lysate to enter the resin by gravity flow. 
Washed the Qiagen-tip with 2 x 10 ml Buffer QC. After washing was done cartridge 
was placed in a fresh falcon tube and plamid DNA was eluted with 5 ml of Buffer QF. 
DNA was precipitated with 3.5 ml of Isopropanol (room temperature) and centrifuged 
immediately for 30 min at 5000 rpm. Supernatant was carefully discarded and DNA 
pellet was washed with 2 ml of 70% ethanol and centrifuged for 10 min at 5000 rpm. 
Again supernatant was discarded carefully and pellet was allowed to air-dry. Dried 
DNA pellet was redissolved in 100-200 µl TE buffer depending on size of bacterial 
pellet initially obtained. Stored at -20°C.  
 
2.2.2.5 Plasmid DNA isolation from Yeast 
  
Plasmid DNA was isolated from yeast using the method of Hoffmann and 
Winston (1987). Briefly, 10 ml of appropriate SD- media (SD/-Leu) was inoculated 
with a single colony (transformed yeast) in a 50 ml Erlenmayer flask and grown for 3 
days at 30°C, 250 rpm. Cells were harvested by centrifuging for 5 min at 5000 rpm. 
Pellet was resuspended in 200 µl of yeast lysis buffer. Added 0.3 g of acid washed 
glass beads (soaked in nitric acid, washed briefly in distilled water and dried). Added 
200 µl of Phenol-Chloroform-Isoamylalcohol (PCI) (25:24:1). Vortexed 3-4 times 
thoroughly. Centrifuged for 5 min at maximum speed. Transferred supernatant 
(aqueous phase) very carefully to a fresh tube. Performed the PCI extraction one more 
time. To the supernatant added 15 µl of 3M sodium acetate (1/10 vol) and 116 µl of 
Isopropanol (0.77 volume). Incubated for 5 min at room temperature. Centrifuged for 
5 min at maximum speed. Discarded the supernatant and washed the DNA pellet with 
300 µl of 70% ethanol. Ethanol washing did twice. Allowed the DNA pellet to air-
dried and then redissolved in 25 µl of 10 mM Tris. Stored the plasmid DNA at -20°C.  
 
2.2.2.6 Isolation of DNA fragment from agarose gel 
 
To isolate DNA fragment (PCR or cDNA-insert in plasmid) from agarose gel, 
Concert Rapid Gel Extraction Kit (Gibco BRL) was used. The area containing the 
DNA fragment was cut from the gel. Care was taken to minimized the surrounding 
agarose excised with the fragment. For 1% agarose gel maximum 400 mg of gel slices 
used per 1.5 ml tube. Added 30 µl of Gel solubilization buffer (L1) for every 10 mg of 
gel. Incubated the gel slices in buffer at 50°C for minimum 15 min. Mixed the tube 
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every 3 min. After gel slice appeared dissolved, incubated the tube for 5 min more. 
Pipetted the dissolved gel slices solution  into a cartridge placed in a 2.0 ml wash tube. 
Centrifuged for 1 min at maximum speed. Discarded the flow-through. Added 500 µl 
of Solubilization buffer (L1) to the cartridge and centrifuged again. Discarded the 
flow-through. Added 700 µl of Wash buffer (L2) (containing ethanol) to the cartridge 
and incubated for 5 min at room temperature. Centrifuged for 1 min at 14,000 rpm. 
Discarded the flow-through. Centrifuged at maximum speed to remove residual wash 
buffer. Placed the cartridge into a fresh 1.5 ml recovery tube and added 30 µl of pre-
warmed TE buffer (70°C) directly to the center of the cartridge. Incubated for 10 min 
at room temperature and then centrifuged for 2 min at 12,000 rpm. Discarded the 
cartridge and stored the DNA at -20°C.  
 
2.2.2.7 Cleaning of DNA fragment 
 
DNA fragments after PCR amplification and restriction digestion were cleaned 
using the Concert Rapid PCR Purification kit (Gibco BRL). Added 400 µl of Binding 
Solution (H1) to ≤ 100 µl of amplification reaction. For higher amount adjusted the 
volume of Binding Solution (H1) 4:1 amplification reaction. Added the sample mix 
into the cartridge placed in a 2.0 ml wash tube. Centrifuged for 1 min at 12-14, 000 
rpm. Discarded the flow-through. Added 700 µl of Wash Buffer (H2) (containing 
ethanol) to the cartridge and centrifuged for 1 min at 12,000 rpm. Discarded the flow-
through and centrifuged again to remove the residual wash buffer. Placed the cartridge 
into a new 1.5 ml receiver tube and added 30 µl of pre-warmed TE buffer (70°C) 
directly onto the center of cartridge. Incubated for 10 min at room temperature and 
then centrifuged for 2 min at 12,000 rpm. Discarded the cartridge and stored the 
cleaned DNA at -20°C. 
 
2.2.2.8 Precipitation of Sequencing PCR DNA 
 
Sequencing PCR product was precipitated with sodium acetate and 100% 
ethanol. Briefly, to 80 µl H2O added 10 µl of 3M Sodium Acetate. To this 20 µl of 
sequencing PCR reaction mixture was added and mixed thoroughly. Then added 250 
µl of chilled 100% ethanol and incubated on ice for 5 min. Centrifuged for 15 min at 
14,000 rpm. Supernatant discarded and pellet resuspended in 300 µl of 70% ethanol. 
Centrifuged again for 15 min at 14,000 rpm. Discarded the supernatant carefully and 
allowed the pellet to air-dry or at 37°C. DNA sample prepared for Sequencer (ABI 
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PRISMTM 310 Genetic Analyzer). DNA pellet was then resuspended in 25 µl of 
Template Suppression Reagent (TSR) buffer (ABI PRISM, Applied Biosystems 
Division, Foster City, CA, USA). Vortexed and centrifuged briefly. Sample denatured 
for 2 min at 95°C and then kept on ice for 2 min. Reaction mixture then transferred to 
the small 0.5 ml sequencing tube (without lid) and capped with rubber stopper suitable 
for the capillary in the sequencing machine. 
 
2.2.2 Quantification of Nucleic acids  
 
Quantity of Isolated DNA and RNA was measured by the UV absorption ratio 
260 nm /280 nm using an Ultrospec 2000 UV/visible spectrophotometer (Pharmacia 
Biotech, Freiburg, Germany). Prepared 1:10 dilution of sample and measured in quartz 
cuvette (5.00 mm thickness). Measurement at 260 nm gave the absorption of nucleic 
acid, at 280 nm the protein absorption and 320 nm gave the salt present in the sample. 
The sample concentration was obtained in µg/ ml. A factor of 2 was used to calculate 
the actual concentration of the nucleic acid present in sample in µg/ ml. Absorption 
ratio of 260 nm/ 280 nm gave the quality of the nucleic acid ( ratio > 1.7 considered 
okay). Quality of the nucleic acid was checked on a 1% agarose/TBE gel pre-stained 
with ethidium bromide (10 mg/ml). 
 
2.2.3 Biochemical analysis of Nucleic acids 
 
2.2.3.1 Hydrolysis of DNA with restriction endonucleases 
 
Restriction digestion of DNA was done with restriction enzyme and its 
appropriate 10x reaction buffer. Recombinant plasmids were cut either with one or 
two enzymes simultaneously. For single digestion appropriate reaction buffer (10x) 
was used at a final concentration of 1x, while for double digestion Y+/Tango buffer 
(10x) used at a final concentration of 2x. 
                                       Single digestion                              Double digestion 
 
DNA                                    1-2 µg                                                5 µg 
Enzyme 1 (10 u/µl)               1 µl                                                   2 µl 
Enzyme 2 (10 u/µl)                -                                                       2 µl 
Buffer (10x)                          1x                                                      2x 
H2O                                  variable                                              variable 
                                     ----------------                                ------------------------ 
                                        30 µl                                                 30 µl 
 
Incubation time             3-4 h at 37°C                                    10-12 h at 37°C  
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In case of double digestion involving Sfi I enzyme, DNA was first digested 
with enzyme 1, cleaned, quantified and then digested with Sfi I at 50°C in the presence 
of BSA (10 mg/ml-100x) at a final concentration of 100 µg/ml. After digestion, 
reaction mix was cleaned using Concert Rapid PCR Extraction kit (Gibco BRL), DNA 
quantified as described previously and 100 ng DNA checked on 1% agarose/TBE gel 
pre-stained with ethidium bromide in case of PCR DNA or plasmid vector digestion 
for cloning. To check for the presence of DNA insert in the recombinant plasmid 
whole of digestion mix was loaded on the gel. For subcloning purpose, after digestion 
of recombinant plasmid whole of digestion mixture was loaded on the gel and then the 
desired DNA fragment was cut from the gel and purified for further processing.  
 
2.2.3.2 Gel electrophoresis 
 
2.2.3.2.1 Agarose gel electrophoresis of DNA 
 
To check the quality of DNA (PCR product, recombinant plasmid DNA, 
restriction analysis) 1% agarose (SIGMA) gel in 0.5x TBE buffer made. Gel was pre-
stained in ethidium bromide (10 mg/ml) (SIGMA). DNA samples were prepared in 6x 
loading buffer (containing bromophenol blue dye) (MBI Fermentas). Gel was run in 
0.5x TBE for 60 min at 80 V for PCR samples and at 100 V for plasmid DNA. 
Depending on the fragment size either GeneRuler 100bp DNA Ladder (1 kb) or 
GeneRuler DNA Ladder Mix (10 kb) (MBI Fermentas) used. DNA bands were 
visualised under UV-Transilluminator in an Eagle Eye II video system (Stratagene, 
Heidelberg, Germany). 
For Semi-quantitative analysis of the PCR product, 10 µl of each reaction was 
used for electrophoresis. PCR signals were quantified in arbitary units (A.U) from 
optical density x band area. PCR signals were normalized to the GAPDH signal of the 
corresponding RT product to get a semi-quantitative estimate of the gene expression. 
PCR data were obtained for each sample and for each gene from two independent 
experiments and the results were averaged for statistical analysis of n animals. 
 
2.2.3.2.2  Agarose gel electrophoresis of RNA 
 
Quality of isolated RNA was checked in a 1% agarose / MOPS (N-
Morpholino-3-propansulphonic acid) gel. 0.1% DEPC-H2O was used for making all 
the solutions required for RNA gel including the sample preparation. 3% Hydrogen 
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peroxide (H2O2) used for decontaminating the gel assembly. RNase-free agarose 
(SIGMA) gel made in 1x MOPS buffer (SERVA, Heidelberg). Gel pre-stained with 
ethidium bromide (10 mg/ml). 200 ng of RNA used with 6x Loading buffer. Gel was 
run in 1x MOPS buffer for 1 h at 80 V. 18S and 28S RNA bands were visualised 
under UV-transilluminator in an Eagle Eye II video system (Stratagene, Heidelberg, 
Germany). 
 
2.2.3.3 Polymerase Chain Reaction (PCR) 
 
To check for the presence of the gene of interest either in the animal tissue or 
cell line (wild type and transfected), PCR was performed. PCR signal was amplified 
using the gene-specific primers (PAR-1-4, GAPDH, -crystallin A and B) designed 
from the sequence available in the Genbank. For standard PCR, 20-22 bp long primers 
were designed, AT and GC content was checked and the difference in the melting 
temperature (Tm) between the forward and reverse primers was kept not more then 2-
4ºC. The primer sequence was checked using the NCBI BLAST search for probable 
similarity with unrelated genes. In all cases forward and reverse primers were 
designed flanking an intron to make sure that the amplification signal comes from 
mRNA and not genomic DNA.  
PCR reaction was done in 0.2 ml thin wall tubes in T3 Thermocycler 
(Biometra). Negative control without template performed to check for self-annealing 
of primer pair. PCR with RNA was also done to check the intron-flanking primers. 
Each primer pair was checked with several annealing temperatures depending on the 
Tm of the primer pair to get a single and specific PCR band. For semi-quantitative 
analysis of PAR mRNA expression different amounts of starting material and different 
number of cycles: 20, 25, 30, 32, 35 and 40 cycles checked for each primer pair to get 
the linear range of the amplification product. Finally PCR was done for 35 cycles.    
 
2.2.3.3.1 Reverse Transcription- Polymerase Chain Reaction (RT-PCR) 
 
To reverse transcribe the isolated total RNA from either animal tissue or cells 
Omniscript Reverse Transcription kit (Qiagen, Hilden) was used. 1 µg of total RNA 
was used to make cDNA in a 0.5 µl tube. RT reaction was set as follows: 
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RNA                                                                         1 µg 
RT Buffer (10x)                                                       2 µl 
dNTP mix  (5 mM each)                                          2 µl 
Oligo-dT primer (0.5 µg/µl) (Gibco BRL)              2 µl 
Omniscript Reverse Transcriptase (4 u/µl)              1 µl 
RNasin (10 u/µl)   (Promega)                                   1 µl 
H2O                                                                        variable 
                                                                         ------------------- 
                                                                                 20 µl 
 
RT was done in T3 Thermocycler (Biometra). The reaction was incubated for 1 
h at 37°C, followed by 5 min at 95°C and then rapidly cooled at 4°C. cDNA was 
stored at -20°C. 
 
PCR reaction was done with the cDNA generated from the RT step using the Hotstar 
Taq Master Mix kit (Qiagen, Hilden). The reaction mixture was pipetted as follows: 
cDNA                                               1-2 µl 
Hotstar Taq Master Mix                    25 µl 
5‘ primer (10 pmol/µl)                        2 µl 
3‘ primer (10 pmol/µl)                        2 µl 
H2O                                                  variable 
                                                    ------------------- 
                                                          50 µl 
The PCR reaction was done using the following programme (for Hotstar Taq 
polymerase): 
Lid temperature = 110°C  
Preheating =          On 
Initial denaturation =            95°C                      15 min 
35 cycles: Denaturation        94°C                      30 sec 
                 Annealing            variable                 1 min 30 sec 
                 Extension             72°C                     1 min 
Final extension =                  72°C                      10 min 
                                              4°C                        pause 
10 µl of reaction used for gel electrophoresis to check for the presence of the desired 
gene product.  
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2.2.3.3.2  Sequencing PCR 
 
For sequencing reaction, either 100 ng of cleaned PCR DNA or 1 µg of 
recombinant plasmid DNA used with 2 µl primer (10 pmol/µl) and 4 µl Big dye 
(contains DNA polymerase, fluorescent dye-labelled dNTPs, buffer) (Applied 
Biosystems, Warrington, UK), added H2O to a final volume of 20 µl. The PCR 
conditions were: Denaturation                   98°C  for  2 min 
                     25 cycles:  Denaturation          96°C  for  30 sec 
                                      Annealing               55°C  for  30 sec 
                                      Extension                60°C  for  4 min + 25 sec increament/cycle  
                                      Pause                       4°C  
After PCR, DNA was precipitated and prepared for Sequencing . 
 
2.2.4 Cloning 
 
2.2.4.1 Generation of DNA insert by PCR 
 
To clone a particular DNA fragment into plasmid vector for generating a 
recombinant plasmid, PCR was done to amplify either the full coding sequence or 
particular region of interest from the gene. Cloning primers were designed from the 
sequences available in the Genbank. 30-33 bp long primers were designed flanking the 
5‘ and 3‘ region of interest. Care was taken to have similar annealing temperature for 
the primer pair. Suitable restriction enzyme sites were included in the primer based on 
the multiple cloning site (MCS) of the plasmid vector into which the fragment was to 
be cloned. DNA fragment to be cloned was checked for the presence of sequence 
matching the restriction site. Primers were designed in a way to ensure that the right 
amino acid codon frame remained intact in the recombinant plasmid. For cloning the 
full cDNA, stop codon was mutated in the 3‘primer when cloned into a vector with a 
3‘ detection tag. 1 µl of cDNA used for generating the required cDNA fragment with 2 
µl of each primer (10 pmol/µl) using the Hotstar Taq Master Mix kit (Qiagen, Hilden). 
PCR cycling conditions were similar to described above for normal PCR with 
appropriate annealing temperature. 
5 µl of amplified fragment was loaded on the agarose gel to check for the 
correct fragment size. PCR reaction mix cleaned using Concert Rapid PCR 
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purification kit (Gibco BRL), quantified, restriction digested, again cleaned to remove 
digestion buffer, quantified and checked on the gel for correct size.     
 
2.2.4.2 Dephosphorylation of digested plasmid  
 
The restriction enzyme treated plasmid was dephosphorylated with Shrimp 
Alkaline Phosphatase (Boeringer Mannheim) to remove the phosphate groups from the 
linear plasmid and avoid self-ligation during the ligation process.  
 
Restriction digested  DNA                              1-2 µg 
Shrimp Alkaline Phosphatase (1 u/µl)            1 µl  
Dephosphorylation buffer (10x)                       1x  
H2O                                                              variable               
                                                                       20 µl 
Incubated for 1 h at 37°C followed by 10 min at 65°C for denaturing the 
enzyme. After phosphatase reaction, plasmid vector was cleaned again to remove the 
reaction buffer. 
 
2.2.4.3 Ligation of plasmid and DNA insert 
 
To generate recombinant plasmid, dephosphorylated restriction digested 
plasmid was ligated with the DNA insert having the same restriciton sites at their 5‘ 
and 3‘ end using the T4 DNA Ligase (Gibco BRL). All the restriction enzymes used in 
the present study generate sticky ends. 
 
Plasmid vector                      1x 
DNA insert                           3x 
T4 DNA Ligase (1 u/µl)       1 µl                                                                             
Ligase buffer (5x)                 4 µl (1x)                                                                         
H2O                                     variable  
                                            20 µl  
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Ligation was done in (T3) Thermocycler (Biometra) using following reaction 
conditions:  
            16°C   8 h          
            22°C   4 h          
            37°C   2 h          
            Pause             4°C 
 
Ligation mixture was then used to transform bacteria to generate recombinant plasmid. 
 
2.2.5 Microbiological techniques 
 
2.2.5.1 Transformation of bacteria with plasmid DNA 
 
2.2.5.1.1 Transformation of E.coli by heat-shock method (CaCl2 based) 
 
For transformation of E.coli, XL1-Blue strain was used. To make competent 
cells single colony of XL1-Blue was grown in 5 ml LB media overnight at 37°C with 
shaking at 250 rpm. 1 ml of overnight bacterial culture was then transferred to 100 ml 
of fresh LB media and continued to grow at 37°C with shaking till the cells reached 
their logarithmic phase i.e, OD 600= 0.3-0.4. Then the bacterial suspension was 
centrifuged at 6000 rpm in SS 34 Rotor in Sorvall centrifuge (pre-cooled) for 5 min at 
4°C. Supernatant was discarded and cell pellet was resuspended in 10 ml of ice-cold 
100 mM CaCl2 solution. The cell suspension was then incubated on ice in cold room 
(4°C) for 1 h. Centrifuged for 5 min at 6000 rpm at 4 °C. Supernatant discarded 
carefully and pellet resuspended in 1 ml of ice-cold 100 mM CaCl2 containing 30% 
glycerine (1 ml solution= 700 µl 100 mM CaCl2+ 300µl of 100% glycerine). From this 
competent cell suspension aliquots of 200 µl made, frozen in liquid nitrogen and 
stored at -80°C.  
To transform bacteria, 200 µl of CaCl2 competent cells for each reaction 
thawed on ice. To the cells added 100 µl of cold TCM buffer and either 10-20 ng of 
super-coiled plasmid DNA or 20 µl of ligation mix. Incubated on ice for 20 min and 
then heat –shock given for 90 sec at 42°C. Transformation reaction mix immediately 
incubated on ice for 1 min. 700 µl of LB media (pre-warmed at 37°C and without any 
antibiotic) added to transformation mix and incubated for 30-60 min with shaking at 
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37°C. 100 µl of the transformation mixture in case of super-coiled DNA plated on the 
LB-agar plate containing suitable antibiotic. For ligation transformation, reaction mix 
was centrifuged briefly, supernatant discarded and pellet resuspended in the residual 
volume and plated on LB-agar containing suitable antibiotic. LB-agar plates incubated 
up-side down at 37°C to facilitate growth of tranformants under appropriate antibiotic 
selection pressure.  
 
2.2.5.1.2 Transformation of E.coli KCM competent cells with plasmid DNA 
 
Transformation of KCM competent cells with plasmid DNA is another method 
for chemical transformation of E.coli. Briefly, single colony of XL1-Blue E.coli strain 
grown overnight in 5 ml of LB media (without antibiotic) at 37°C with shaking. 150 
ml of fresh media then inoculated with 1 ml of overnight bacterial culture and allowed 
to grow till the OD600 of the culture reached 0.6. Cell suspension was then centrifuged 
for 10 min at 5000 rpm at room temperature. Supernatant discarded and pellet 
resuspended in 15 ml (1/10 volume) of TSB buffer. Incubated the suspension on ice 
for 10 min and then aliquoted 500 µl each of cell suspension. Freezed in liquid 
nitrogen and stored at -80°C. To transform KCM competent cells using plasmid DNA, 
20 µl of KCM buffer added to either 20 µl of ligation mix or 10-20 ng of super-coiled 
plasmid DNA. H2O added to made-up the volume till 100 µl. Mixed nicely and 
incubated on ice. In the mean time thawed the KCM competent cells on ice. 100 µl of 
cells used per transformation reaction. Mixed properly the cells with DNA and buffer 
mix and incubated on ice for 30-40 min. Then incubated the reaction mix for 10 min at 
room temperature (very important). 800 µl of LB media (without antibiotic) added and 
incubated for 1 h at 37°C with shaking. Either 100 µl of transformation mixture or 
pellet plated on LB-agar containing suitable antibiotic. Plates incubated up-side down 
at 37°C overnight to allow transformants to grow. 
 
2.2.5.1.3 Transformation of E.coli by electroporation (electro-transformation) 
 
Transformation efficiency of electroporation method is several folds higher as 
compared to the chemical transformation. Yeast plasmid DNA was transformed into 
E.coli by electroporation because isolation of plasmid from yeast results in genomic 
DNA contamination which reduces the transformation efficiency of the plasmids by 
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chemical based transformation. For electroporation the salt concentration of plasmid 
DNA is an important factor. DNA with high salt concentration cannot be 
electroporated because it interferes with the electrical resistance. To prepare electro-
competent cells, E.coli XL1-Blue strain used. Single colony of XL1-Blue inoculated in 
5 ml LB media and grown overnight at 37°C with shaking. To fresh 250 ml LB media 
2.5 ml of overnight grown culture added and allowed to grow till the OD600 of culture 
media reached 0.5-0.6. Culture media kept on ice for 30 min. All subsequent steps 
were done at 4 °C. Centrifuged the cold bacterial suspension in GSA-Rotor (Sorvall 
centrifuge) (pre-cooled) for 10 min at 5000 rpm. Supernatant discarded and cell pellet 
resuspended in 250 ml of ice-cold sterile H2O. Centrifuged the suspension in GSA-
Rotor for 10 min at 5000 rpm. Supernatant discarded. Pellet resuspended in 100 ml of 
ice-cold sterile H2O. Centrifugation step repeated and supernatant discarded. Cell 
pellet now resuspended in 30 ml ice-cold 10% (v/v) Glycerine (50 ml Glycerine+450 
ml H2O, autoclaved). Centrifuged in SS34-Rotor for 10 min at 10,000 rpm. 
Supernatant discarded and cell pellet resuspended in 2.5 ml of ice-cold 10% (v/v) 
Glycerine. 300 µl each of suspension aliquoted in sterile tubes and immediately 
freezed in liquid nitrogen. Stored at -80°C. For electroporation, competent cells were 
thawed on ice. 50 µl of cells were taken for each transformation reaction. 5 µl of yeast 
plasmid DNA added to the competent cells, mixed, transferred to electroporation 
cuvette (bacterial-0.2 cm gap) and incubated on ice for 10 min. Electric pulse was 
applied with Gene pulser (Bio-Rad). Electric pulse was given under following 
conditions: Voltage- 2.5 kV, Capacitance-25 µF and Resistance- 200 ohms to get a 
time constant of ~4.5 msec. These conditions gave a field strength of 12.5 kV/cm 
(voltage set/ gap of cuvette). The samples showing resistance either less or more then 
200 ohms were discarded (high salt concentration which may result in bursting of 
cuvette). After the electric pulse 500 µl of SOC media given to cells in cuvette and 
then transferred the suspension into a fresh tube. One more time 500 µl of SOC media 
given to clean and remove all the cells from the cuvette and then transferred the rest to 
the tube. Incubated for 1 h at 37°C with shaking and then plated 100 µl of the 
transformation mix to the LB-agar plate containing the appropriate antibiotic. Plates 
incubated up-side down at 37°C overnight to allow transformants to grow.  
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2.2.5.2 Transformation of Yeast by LiAc (small-scale) 
  
Transformation of Saccromyces cerevisae  strains AH109 and Y187 was done 
according to the Clontech yeast protocol handbook. Inoculated 1 ml of YPDA or SD 
dropout media with several colonies, 2–3 mm in diameter and from ~2 week old plate 
(SD dropout media used in case of pre-transformed host strain to maintain the 
selection pressure). Vortexed vigrously for 5 min to disperse the cell clump. 
Transferred this suspension into a flask containing 50 ml of YPDA or appropriate SD 
dropout medium. Incubated at 30°C  for 16-18 h with shaking at 250 rpm to stationary 
phase, OD 600> 1.5. Transferred the 10 ml of overnight culture to a flask containing 
100 ml of YPDA. Checked the OD600 of the diluted culture and, if necessary, added 
more of the overnight culture to bring the OD600 upto 0.2-0.3. Incubated at 30°C with 
shaking at 250 rpm till the OD600 reached 0.4-0-6. Placed cells in 50-ml tubes and 
centrifuged at 1000 x g for 5 min at room temperature. Discarded supernatant and 
added 50 ml of steril distilled H2O to resuspend the cell pellet. Pooled the cells into 
one tube and centrifuged at 1000 x g for 5 min at room temperature. Decanted the 
supernatant and resuspended the cell pellet in 1.5 ml of freshly prepared, sterile 1X 
TE/1X LiAc. The cells were ready for transformation. Yeast competent cells should be 
used within 1 h of preparation for high transformation efficiency. Added 100 ng of 
plasmid DNA (for single or equimolar amount for co-transformation of two plasmids) 
and 5 µl (0.1 mg) herring testes carrier DNA to a fresh 1.5 ml tube (carrier DNA 
denatured at 100°C for 5 min and then chilled on ice. Repeated denaturation two 
times). Added 100 µl of competent cells and mixed thoroughly followed by addition 
of freshly prepared 600 µl of sterile PEG/LiAc/TE solution. Vortexed well. Incubated 
at 30°C for 30 min with shaking at 200 rpm. Added 70 µl of DMSO. Mixed by gentle 
inversion (no vortexing). Cells were given a Heat shock for 15 min in a 42°C water 
bath and then chilled on ice for 2 min. Centrifuged for 30 sec at 14,000 rpm at room 
temperature. Supernatant removed and cells were resuspended in 300 µl of sterile 1X 
TE buffer. Plated 100 µl on each SD minimal medium agar plate lacking particular 
amino acid (s) to select for the desired transformants. In yeast, transformants are 
selected on the basis of the auxotrophic nutritional markers instead of antibiotic 
selection used for bacteria. To obtain single colonies, also spreaded 100 µl of  1:1000, 
1:100, and 1:10 dilution on 100-mm SD agar plates. Incubated plates, up-side-down, at 
30°C until colonies appeared (2–4 days).  
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To calculate the transformation efficiency, colonies (cfu) growing on the dilution   
plates were counted. 
Transformation efficiency =   cfu x total suspension vol. (ml)  
                                         ------------------------------------------------ = cfu/mg DNA 
                                          Vol. plated (ml) x dilution factor x mg  
                                          of DNA used  
To make the master plate, largest colony was picked and restreaked on the same 
selection medium. Sealed plates with Parafilm and stored at 4°C for 3–4 weeks.  
 
2.2.5.3 Preparation of Microbial culture stock solution 
 
To make stock culture from bacteria, 850 µl of overnight grown culture mixed 
in 150 µl of sterile 100% glycerine. Vortexed briefly to mix thoroughly and 
immediately freezed in liquid nitrogen. Stored at -80°C. 
To prepare stock culture from yeast, single colony from agar plate was 
resuspended in 500 µl of YPD medium (or the appropriate SD dropout medium for 
transformed yeast strains). Vortexed vigrously to disperse the cells. Added  sterile 
50% glycerine to a final concentration of 25% (125 µl of 50% glycerine to 500 µl 
YPD). Mixed thoroughly, immediately freezed in liquid nitrogen and stored at -80°C. 
 
2.2.5.4 Testing of DNA-BD fusion protein for toxicity in yeast 
 
To compare the growth rate in liquid culture of Y187 and AH109, cells 
transformed with the "empty" DNA-BD vector and with the DNA-BD/bait plasmid 
using the small scale yeast transformation protocol. Transformants were selected on 
SD/–Trp (since DNA-BD vector can synthesise tryptophan on ist own and hence does 
not require in the growing medium). An overnight culture was prepared by inoculating 
one large colony in 50 ml of SD/–Trp/Kana (20 g/ml). Incubated 16-24 h at 30°C with 
shaking at 250 rpm. Checked the OD600 to test the difference in growth rate of 
transformed AH109 and Y187 with empty plasmid or recombinant plasmid (OD600 ≥ 
0.8 is okay, less means bait protein might be toxic).  
 
2.2.6  Generation of cDNA library  
 
To generate a cDNA library for yeast two-hybrid interaction, Matchmaker 
Library construction and screening protocol (Clontech, Heidelberg) followed. 
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2.2.6.1 Checking of RNA 
 
Rat retina Poly A+RNA and Human Placenta Poly A+RNA (positive control) 
checked for quality on agarose/ MOPS gel. mRNA mixed with RNA loading buffer 
denatured at 65°C for 15 min. Both the native and denatured mRNA samples run on 
gel at 80 V.  
 
2.2.6.2  First-Strand cDNA Synthesise using a Random Primer 
 
First-strand cDNA was made from rat retina poly A+ RNA (1 µg/µl) (Clontech, 
Heidelberg) and Human Placenta poly A+ RNA (control). Following reagents were 
combined in a sterile 0.25-ml microcentrifuge tube: 
        1 µl RNA sample (1 µg of poly A+RNA) 
        1.0 µl CDS III/6 Primer 
        2 µl Deionized H2O  
        4.0 µl Total volume 
Mixed the contents and centrifuged briefly. Incubated at 72°C for 2 min and 
immediately chilled on ice for 2 min. Centrifuged briefly again. Kept the tube at room 
temperature and added the following: 
     2.2 µl 5X First-Strand Buffer 
     1.0 µl DTT (20 mM) 
     1.0 µl dNTP Mix (10 mM ) 
     1.0 µl PowerScript Reverse Transcriptase 
     9.0 µl Total volume 
Mixed gently by tapping and centrifuged briefly. Incubated for 10 min at room 
temperature (25–30°C). Added 1.0 µl (5 milliunits) of RNase I (5 units/ml). Incubated 
at 42°C for 10 min. Add 1.0 µl of SMART III Oligonucleotide. Incubated at 42°C for 
1 h (hot-lid T3 thermal cycler, Biometra). Placed the tube at 75°C for 10 min to 
terminate first-strand synthesis. Cooled the tube to room temperature, then added 1.0 
µl (2 units) RNase H. Incubated at 37°C for 20 min. Proceeded directly with the LD-
PCR and stored rest of the first-strand cDNA reaction mixture at –20°C. 
 
2.2.6.3 Amplification of ds cDNA by Long Distance PCR (LD-PCR) 
 
ds cDNA (both the rat retina and Human placenta) were amplified by LD-PCR. 
Amplification done for 20 cycles (optimum for 1.0 µg starting mRNA to minimize 
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nonspecific PCR products). T3 thermocycler (Biometra) preheated to 95°C. To 
prepare sufficient ds cDNA for transformation, two 100-µl PCR reactions set for each 
experimental sample (rat retina). Set one reaction for the Control sample (Human 
placenta). In each reaction tube, combined the following components: 
     2 µl First-Strand cDNA 
     70 µl Deionized H2O 
     10 µl 10X Advantage 2 PCR Buffer 
     2 µl 50X dNTP Mix 
     2 µl 5' PCR Primer 
     2 µl 3' PCR Primer 
     10 µl 10X GC-Melt Solution 
     2 µl 50X Advantage 2 Polymerase Mix 
     100 µl Total volume 
Mixed gently by flicking the tube. Centrifuged briefly and placed the tubes in 
preheated (95°C) thermal cycler. For T3 hot-lid thermal cycler, following program 
was used: 
                       
                      95°C     30 sec 
20 cycles:      95°C    10 sec 
                      68°C     6 min + 5 sec increment with each successive cycle 
                      68°C     5 min 
                      4°C       Pause 
Analyzed a 5-µl aliquot of the PCR product from each sample alongside 1-kb 
DNA size marker on a 1.2% agarose/EtBr gel. Stored ds cDNA at –20°C until further 
use. 
 
2.2.6.4 Purification of ds cDNA with a CHROMA SPIN+ TE-400 Column 
 
CHROMA SPIN Columns are packed with resins that fractionate molecules 
based on size. Molecules larger than the pore size are excluded from the resin and 
moves quickly through the gel bed when the column is centrifuged, while molecules 
smaller than the pore size are held back. CHROMA SPIN TE-400 Column was used to 
select for DNA molecules >200 bp. Swinging bucket rotor used for these columns. 
Performed the following steps for each experimental and control sample. Inverted the 
CHROMA SPIN column several times to resuspend the gel matrix completely. Used 
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one column for each 95 µl cDNA sample. Holding the column upright, grasped the 
break-away end between the thumb and index finger and snapped off. Placed the end 
of the spin column into the 2-ml microcentrifuge (collection) tubes, and lifted off the 
top cap. Centrifuged at 700 x g for 5 min (placed the column-2 ml collection tube into 
a 15 ml falcon tube for convenient placement in the swinging rotor). Removed spin 
column and discarded the collection tube and column equilibration buffer. Placed the 
spin column into the second 2-ml microcentrifuge tube. Carefully and slowly applied 
the cDNA sample (95 µl) to the center of the gel bed’s flat surface. Centrifuged at 700 
x g for 5 min. Removed the spin column and collection tube from the rotor and 
detached them from each other. The purified sample remained at the bottom of the 
collection tube. At this point combined duplicate experimental samples in a single tube 
and added the following reagents for cDNA precipitation: 
  1/10 vol. 3 M Sodium Acetate (pH 4.8) 
  2.5 vol. 95% ethanol (–20°C) 
Mixed gently by rocking the tube back and forth. Placed the tube in –20°C 
freezer overnight (for better recovery). Centrifuged the tube at 14,000 rpm for 20 min 
at room temperature. Carefully removed the supernatant with a pipette without 
disturbing the pellet. Briefly centrifuged the tube to bring all remaining liquid to the 
bottom. Carefully removed all liquid and allowed the pellet to air dry for ~10 min. 
Resuspended the pellet in 20 µl of Deionized H2O and mixed gently. The cDNA 
obtained was ready for in vivo recombination (Library Construction) with pGADT7-
Rec. Store the cDNA at –20°C until used for Two-Hybrid Library Construction. 
 
2.2.6.5 Sequential transformation (Library construction and screening) 
 
To construct AD (Activation Domain) fusion library by in vivo homologous 
recombination and subsequent library screening in yeast, sequential transformation 
was done. AH109 was first transformed with DNA-BD/bait protein (C-tail rPAR-
2/pGBKT7) using the small-scale yeast transformation protocol and cells containg the 
DNA-BD/bait protein were selected on SD/-Trp medium. Then the Bait protein 
containing AH109 (pre-transformed) used for making competent cells and Library 
scale transformation done with rat retina  ds cDNA (CHROMA Spin colume cleaned) 
and linear pGADT7-Rec vector (sequential transformation).  
To prepare competent cells for library transformation, one colony of 
AH109/bait protein from SD/-Trp plate (~one week old) inoculated in 5 ml of liquid 
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SD/-Trp medium (to maintain selection pressure) and incubated with shaking at 30°C 
for 8 h. Then transferred bait containing cell culture to fresh 50 ml SD/-Trp medium in 
250 ml flask and continued incubation at 30°C with shaking for 16-20 h (overnight). 
OD600 checked for 0.15-0.3 value. Centrifuged overnight culture at 700 x g for 5 min 
at room temperature. Discarded the supernatant and resuspended the bait protein 
containing AH109 cell pellet in 150 ml of YPDA medium. Incubated at 30°C with 
shaking till the OD600 reached 0.4-0.5. Centrifuged at 700 x g for 5 min at room 
temperature. Discarded supernatant and resuspended cell pellet in 60 ml of sterile 
H2O. Repeated the centrifugation step. Discarded the supernatant and resuspended 
cells in 3 ml of 1x TE/LiAc solution. Resuspension divided into two tubes (1.5 ml 
each) and centrifuged at high speed for 15 sec. Discarded the supernatant and 
resuspended each pellet in 600 µl of 1xTE/LiAc solution. Competent cells used 
immediately for transformation.  
Large-scale transformation of AH109/bait protein cells with rat retina ds cDNA 
and linear pGADT7-Rec plasmid was done. In a sterile 15 ml falcon tube added the 
following reagents:  
   20 µl ds cDNA 
   6.25 µl (3 µg) pGADT7-Rec (Sma-linearized) 
   20 µl Herring Testes Carrier DNA (10 mg/ml), denatured (100°C for 5 min, then, 
immediately chilled on ice for 5 min. Repeated two times). 
To these, added 600 µl of competent cells (AH109/bait protein) and gently 
mixed by vortexing. Added 2.5 ml PEG/LiAc solution. Again gently mixed by 
vortexing. Incubated at 30°C for 45 min. Mixed cells every 15 min. Added 160 µl 
DMSO, mixed, then placed the tube in 42°C water bath for 20 min. Mixed cells every 
10 min. Centrifuged at 700 x g for 5 min. Discarded the supernatant and resuspended 
the cell pellet in 3 ml of YPD+ medium (specially formulated to promote 
transformation). Incubated at 30°C with shaking for 90 min. Centrifuged at 700 x g for 
5 min. Discarded the supernatant and resuspended in 6 ml of 0.9% NaCl solution. To 
select for transformants expressing interaction protein, 150 µl of transformation mix 
plated per 150 mm plate of SD/TDO (triple dropout medium i.e, -Trp-Leu-His) ~40 
plates. To determine the transformation efficiency, 30 µl aliquot from 6 ml 
transformation mix removed and diluted with 720 µl of NaCl solution for a final 
volume of 750 µl. 150 µl of this diluted solution plated on SD/-LW (3) and SD/-Leu 
(2) plates. Incubated all the plates up-side down at 30°C until colonies appeared (2-3 
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days till 6 days). Counted the colonies grown on SD/-Leu plates for No. of 
transformants/ 3 µg pGADT7-Rec: 
  No. of colonies x 1000= No. of transformants/ 3 µg pGADT7-Rec 
  Colonies growing on SD/-LW gave the No. of clones / library: 
  No. of colonies x 1000= No. of clones screened. 
 
2.2.6.6 Screening for interacting clones 
 
The colonies that grew on the SD/TDO plates (library transformation) after 6 
days were streaked on SD/TDO medium again to select for true His+ clones and 
incubated at 30°C for 5 days. Clones growing on second round of SD/TDO plates 
were then restreaked on a more stringent medium lacking adenine i.e, SD/QDO 
(quadruple dropout medium: -Trp-Leu-His-Ade) and incubated at 30°C for 5-7 days to 
allow for growth of Ade+, His+ clones. The clones grown on SD/QDO plates were 
used for checking of third reporter gene, lacZ expression by performing Blue/white 
filter assay on QDO plates. Clones giving either a strong or weak blue color after filter 
test were  picked from second SD/TDO plates and restreaked again on fresh SD/QDO 
plates and incubated at 30°C for 5-7 days. Blue/white filter test repeated on SD/QDO 
plates containing true Ade+, His+ clones. The clones which survived the selection for 
all the three reporter genes after second filter test were used for further analysis. The 
clones finally selected for further analysis were also restreaked on SD/QDO plates and 
stored as master plates. 
 
2.2.6.7 Controls for library transformation  
 
For control experiment, competent cells were made in an identical manner and 
along with competent cells for library transformation from a single colony of AH109 
(wild type) picked from YPDA plate (culture grown in in YPDA medium only). One 
positive and one negative control reaction was done. Added the following components 
in 1.5 ml centrifuge tubes: 
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Component Positive Control (µl) Negative Control (µl) 
SV40 Large T PCR 
Fragment (25 ng/µl) 
5.0 5.0 
pGADT7-Rec (Sma I-
linearized; 480 ng/µl) 
0.52 0.52 
pGBKT7-53 (500 
ng/µl) 
0.5 — 
pGBKT7-Lam (500 
ng/µl) 
— 0.5 
Herring Testes Carrier 
DNA (10 mg/ml), 
denatured 
5 5 
AH109 Competent 
Yeast Cells 
50 50 
PEG/LiAc Solution 500 500 
 
Mixed thoroughly by gently vortexing. Incubate in a water bath at 30°C for 30 
min. Vortexed gently every 15 min. Added 20 µl of DMSO to each tube, mixed, and 
then placed the tube in a 42°C water bath for 20 min. Vortexed gently every 5 min. 
Centrifuged at high speed for 15 sec. Removed supernatant and resuspended in 1 ml of 
YPD + medium. Incubated in a water bath at 30°C for 90 min. Mixed every 15 min by 
gently vortexing. Centrifuged at high speed for 15 sec. Discarded the supernatant and 
resuspended in 1 ml of NaCl Solution by gently pipetting up and down. Plated 100 µl 
of a 1:10, 1:100, and 1:1,000 dilution onto 100-mm SD agar plates: 
  SD/–Leu/–Trp    =  To check the cotransformation efficiency 
SD/QDO (–Ade/–His/–Leu/–Trp) = To select for cotransformants expressing    
interacting proteins Incubated the plates at 30°C up-side down for 3–4 days, until 
colonies appeared. Colonies grown on the SD/QDO were used for blue/white filter 
assay. 
 
2.2.6.8 Colony-lift Filter Assay 
 
This assay was performed to screen the cotransformants that survived the HIS3 
growth selection in a GAL4 two hybrid library screening. Also, the bait protein was 
tested initially before undergoing library transformation for self-activation and 
subsequent expression of lacZ reporter gene. The protocol followed was as mentioned 
in Yeast Protocol Handbook (PT-3024-1). Briefly, Fresh transformed yeast colonies 
(i.e., grown at 30°C for 2–4 days in appropriate SD dropout medium), 1–3 mm in 
diameter were used. For each plate of transformants to be assayed, presoaked a sterile 
Whatman filter by placing it in 2.5–5 ml of Z buffer/X-gal solution in a clean 100- or 
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150-mm plate. Using forceps, placed a clean, dry filter over the surface of the plate of 
colonies to be assayed. Gently rubbed the filter with the side of the forceps to help 
colonies cling to the filter. Made marks on the filter to orient the filter to the agar. 
When the filter was evenly wetted, carefully lifted it off the agar plate with forceps 
and transferred it (colonies facing up) to a pool of liquid nitrogen. Using the forceps, 
completely submerged the filter for 15 sec. After the filter was freezed completely, 
removed it from the liquid nitrogen and allowed it to thaw at room temperature (the 
freeze/thaw treatment was necessary to permeabilized the cells.). Then carefully 
placed the filter, colony side up, on the presoaked filter avoiding trapping of air 
bubbles under or between the filters. Incubated the filters at 30°C and checked 
periodically for the appearance of blue colonies. The time taken for colonies to 
produce β-galactosidase to turn blue varies, typically from 30 min to 8 h in a library 
screening. Prolonged incubation (>8 hr) may give false positives. Positive control was 
included in the assay. Identified the β-galactosidase-producing colonies by aligning 
the filter to the agar plate using the orienting marks.  
 
2.2.7 Yeast Mating 
 
This procedure was done to analyze the protein interaction observed after 
sequential transformation. Yeast mating is a convenient method of introducing two 
different plasmids into the same host cells. Reporter gene expression only possible 
when the AD/library plasmid introduced by mating with the plasmid encoding the 
DNA-BD/bait protein. For this, transformed AH109 (MATa) with the AD/library 
plasmids and selected on SD/-Leu and SD/-LH (to check for self-activation of 
AD/library plasmids). Also transformed Y187 (MATα) with the following three 
plasmids- empty DNA-BD (pGBKT7), DNA-BD/bait (C-tail rPAR-2/pGBKT7) and 
pGBKT7-Lam (control) and selected on SD/-Trp. After the Trp+ and Leu+ 
transformants were ready yeast mating procedure was done in microtiter plate (small-
scale): 
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DNA-BD  
plasmids   ↓ 
AD/library 
plasmids   → 
    
Empty DNA-BD x  clone 1 x  cl.2 x  cl.3 x  cl.4 x  cl.5 
DNA-BD/bait x  clone 1 x  cl.2 x  cl.3 x  cl.4 x  cl.5 
pGBKT7-Lam x  clone 1 x  cl.2 x  cl.3 x  cl.4 x  cl.5 
 
Aliquoted 160 µl of YPDA medium to each well. For each AD/library plasmid 
to be tested, placed a single transformant colony in a 1.5 ml microfuge tube containing 
1 ml YPDA. Vortexed vigrously. For each type of DNA-BD plasmid used, placed 
several transformant colonies in 3 ml of YPDA medium in a sterile, 10 ml conical 
tube. Vortexed vigrously. Aliquoted 20 µl of AD/library cell suspension and DNA-BD 
cell suspension to either horizonzal or vertical wells according to the scheme. In 
between the pipetting, plate was covered with a sterile lid. Placed the microtiter plate 
on a platform shaker and incubated at 30°C for ~14 h (required 6-18 h) at 200 rpm. 
Plated 100 µl of each mating culture on 100 mm SD/-LW plates and SD/TDO plates. 
Incubated the plates up-side down at 30°C for 3-5 days until the diploid cells formed 
visible colonies. Diploids were marked for His+ from TDO plates, then filter lifted to 
SD/QDO plates to check for Ade+ clones. β-gal activity assay (blue/white filter test) 
was done on SD/QDO plates.   
 
2.2.8 Cell culture 
 
The medium used for culturing of cells was sterile and ready-to-use 
(Biochrom). For culturing of cells (HEK-293, N2A, NG-108 and RGC-5), frozen cells 
were thawed in 37°C water bath. 1 ml of cryo-preserved cell suspension and 9 ml of 
complete cell culture medium centrifuged at 1000 rpm for 3 min at room temperature. 
Pellet resuspended in tissue culture dish (10 cm) (Nunc, Denmark) and incubated in 
cell culture incubator (Heraeus) in a humidified atmosphere of 95% air, 5% CO2 at 
37°C. HEK-293 (Human embryonic kidney, epithelial) cells were cultured in DMEM 
(Dulbecco minimum essential medium) / HAM’S F12 (1:1) with 2 mM Glutamine, 
10% FCS (fetal calf serum), 100U/ml Penicillin and 100 µg/ml Streptomycin 
(Biochrom). Mouse N2A (neuronal) cells were cultured in DMEM containing 3.7 g/L 
NaHCO3, 4.5 g/L D-glucose, 1.028 g/L N-Acetyl L-alanyl-L-glutamine and 10% 
FCS, 100U/ml Penicillin, 100 µg/ml Streptomycin. NG-108 (mouse neuroblastoma x 
rat glioma hybrid cells) were cultured in same culture medium as N2A cells but were 
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selected for hybridoma cells in HAT supplement (50x) (Hypoxanthine aminopterine 
thymidine) selection pressure (200 µl HAT used/ 10 cm dish) . RGC-5 cells too were 
cultured in same complete medium as N2A but in the DMEM containing only 1.0 g/L 
glucose. Culture medium was changed every 2-3 days.  
For cell passage, HEK-293 cells were detached with HBSS without Ca2+ and 
Mg2+ (Biochrom) for 5 min at room temperature after the medium was aspirated out; 
for N2A, NG-108 and RGC-5 cells, first the cells were washed with HBSS and then 
incubated in cell incubator with Accutase (PAA) 1 ml per 6 cm dish for 5 min at 37°C. 
Cells were splitted 1:20 to 1:50 in fresh complete medium.   
 
2.2.8.1 Freezing of cells 
 
Cells (either wild type or transfected with fusion protein constructs) were 
frozen in DMSO and FCS for long storage when not required in culture. Briefly, cells 
grown in 10 cm culture dish were frozen in 2 cryo tubes (Nunc). To each cryo tube 
added 50 µl DMSO (sterile, room temperature) and 450 µl fetal calf serum (FCS-
37°C). Closed the lid and kept at 4 °C. Meanwhile aspirated out the medium from the 
cells and pipetted Hanck’s medium to dissociate the cells at room temperature (in case 
of HEK cells, but for N2A cells Accutase used at 37°C). Cells detached from the dish 
and centrifuged at 1000 rpm for 5 min at room temperature. Discarded the medium 
and resuspended the cells in 1 ml of appropriate complete culture medium. Transferred 
500 µl of cell suspension to each of cryo tube containing DMSO and FCS, mixed well 
and immediately stored at -20°C for 24 h. Then shifted to -80°C for long storage or 
liquid nitrogen. 
 
2.2.8.2 Lipotransfection 
 
To express the protein of interest  as a fusion protein in mammalian expression 
system, recombinant plasmid was transfected into mammalian -HEK, N2A, NG-108 
and RGC cell lines using the Liposomal transfection reagent DOTAP (Roche 
Diagnostic). Plasmid DNA was isolated using the Invisorb mini plasmid kit (Invitek, 
Berlin) to obtain clean DNA. Cells were grown 60-80% confluent. 5-10 µg of DNA 
made to 50 µl with 20 mM HEPES in a tube (for double transfection 5 µg of each 
plasmid DNA used). In another tube, 30 µl DOTAP mixed with 70 µl of 20 mM 
HEPES. Mixed the solutions nicely. Then DNA-HEPES solution was mixed with 
DOTAP-HEPES solution and incubated for 30 min at room temperature. After 30 min, 
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5 ml of pre-warmed appropriate culture media (depending on the cell type) without 
serum and antibiotic taken in a fresh tube and mixed with DNA-DOTAP-HEPES 
solution. The cells were removed from incubator and medium aspirated out. 
Transfection media containing DNA-DOTAP-HEPES pipetted into the dish very 
slowly so as not to detach the cells from the surface of the dish. Cells incubated in the 
transfection media for 8 h and then full medium containing serum and antibiotic given 
to cells. 48 h after transfection cells were visualised under the fluorescent microscope 
to check for expression of fusion protein in case of vector containing GFP tag (GFP 
fusion protein showed green fluorescence). Cells were made stable transfected after 48 
h by giving them G418 Sulphate antibiotic (kanamycin and neomycin derivative) 
(Calbiochem) at a rate of 1 µl/ ml culture medium of 500 µg/ml (stock- 500 mg/ml). In 
HA-fusion protein transfection, empty pEGFP vector was used as a carrier DNA since 
pCMV-HA plasmid contains neither kanamycin nor neomycin resistance gene.  
  
2.2.8.3 Subcloning  
 
Cell were selected for 100% transfection by subcloning. In case of GFP-
construct transfected cells, cluster of cells exhibiting high fluorescence selected using 
a plastic ring and propogated as independent clones in culture under antibiotic 
pressure. Since it was not possible to visualise MycHis -tag fusion protein, cluster of 
cells seemingly originating from a single cell were selected in a similar way as GFP-
fusion protein and propogated as independent clones under antibiotic selection 
pressure. HA-tag fusion proteins clones were selected on the basis of carrier GFP 
fluorescence. Independent clones of MycHis fusion and HA-fusion proteins were 
verified at the transcription and translation level by RT-PCR and western blot or 
immunostaining, respectively.    
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2.2.9 Protein chemistry 
 
2.2.9.1 Cell lysate  
 
To make whole cell lysate for protein measurement and subsequent protein 
studies, confluent cells (10 cm dish) were washed 1x with ice-cold PBS (1x) and lysed 
in 1 ml of 1x lysis buffer. The cell lysate was gently mixed on a rotator for 15 min at 
4°C. Lysate was then sonificated 3x10 sec (40% power) in Ultrasonificator on ice. 
Then centrifuged at 14,000 rpm in a pre-cooled centrifuge for 15 min. Supernatant was 
transferred into a fresh tube and pellet discarded. Protein concentration was 
determined by Bradford method using 1% bovine serum albumin as standard. Lysate 
stored at -20°C. 
 
2.2.9.2 SDS-PAGE and immunoblotting 
 
Confluent cells stably transfected with Cryaa-MycHis were lysed in cold 1x 
lysis buffer and lysate made and measured for protein content. 30 µg of each sample 
precipitated with ice-cold acetone/methanol solution (1:1), denatured in NuPAGE 
sample buffer system and were loaded to NuPAGE Novex 10% Bis-Tris Pre-cast gels 
and electrophoresed for 1.30 min at 120 V. Samples were transferred to nitrocellulose 
membrane (0.2 µm) using a semi-dry transfer system (Biorad) at a constant voltage 
(10V) and 200 mA  for 40 min at room temperature. Membrane stained for protein 
bands with 0.2% Ponceau S and then blocked in 5% non-fat dry milk overnight at 4°C. 
Membrane incubated with monoclonal mouse antibody against myc (1:2500) 
(Invitrogen) for 1 h at room temperature. Membrane washed three times in 
PBS+Tween (0.1%) (30 min total). Secondary antibody incubation done with 
peroxidas-conjugated anti-mouse IgG (1:10,000) (Dianova, Hamburg) for 1 h at room 
temperature. Washing step repeated. Proteins were visualised with enhance 
chemiluminiscence (Amersham Pharmacia Biotech). 
 
2.2.9.3 SDS-PAGE and immunoblotting for small size protein 
 
To visualise < 10 kDa protein bands, cell lysate prepared from confluent stably 
transfected cell in two different ways: Firstly as described above and second, with 1x 
Laemmli sample buffer. Briefly, cells were lysed directly in 1x Laemmli sample buffer 
containing β-mercaptoethanol and sonificated three times for 10 sec each (40% 
power). Then the lysate was denatured for 10 min and centrifuged at 14000 rpm for 10 
min in a pre-cooled rotor. To the supernatant added equal volume of chloroform. 
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Centrifuged as before. Upper phase removed to a fresh tube and protein measured 
using Bradford assay. 1% bovine serum albumin used as a standard. Samples 
containing 50 µg protein (acetone/methanol precipitated) or 25 µg chloroform 
extracted lysate were electrophoresed in a NuPAGE Novex 10% Bis-Tris Pre-cast gel 
using 1x MES running buffer to resolve small size proteins till 3 kDa. Gel 
electroblotted using a horizontal transfer system (Tankblot). 0.1 µm nitrocellulose 
membrane (Protran BA79) used in an electroblot for 1 h at 100 V at 4°C. Protein 
bands stained with Ponceau S and then incubated in 0.2% Glutaraldehyde at room 
temperature for 30 min to cross-link small proteins to membrane. 5% non-fat dry milk 
used for blocking the membrane overnight at 4 °C. Membrane incubated with rabbit 
polyclonal affinity purified antibody against HA-tag (1:300) (Sigma) for 1 h at room 
temperature followed by 3x 10 min washing in PBS-Tween (0.1%). Then membrane 
incubated with peroxidase-conjugated anti-rabbit IgG (1:10,000) for 1 h at room 
temperature. Washing step repeated. Protein bands visualised by enhanced 
chemiluminescence (Amersham Pharmacia Biotech).  
To successfully transfer small sized proteins, several alternatives tried: 15% 
pre-cast gel and semi-dry transfer system using nitrocellulose membrane (0.1 µm, 0.2 
µm); PVDF membrane (CAPS buffer)-different transfer times (40, 30 and 15 min) and 
current conditions.  
 
2.2.9.4 SDS PAGE (Laemmli) Gel preparation  
( for 2 gels with 1 mm thickness and 8 cm width) 
 
Components 12.5% Resolving gel (ml) 15% Resolving 
gel    (ml) 
4% Stacking 
gel  (ml) 
60% acrylamide/Bis 
 
2.5 3.0 0.335 
Resolving gel buffer 
 
6.0 6.0 - 
Stacking gel buffer 
 
- - 2.5 
H2O 3.3 2.8 2.065 
10% SDS solution 0.12 0.12 0.05 
1x PER solution 
 
0.06 0.06 0.04 
TEMED  
 
0.024 0.024 0.01 
Bromophenol blue - - 0.002 
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2.2.9.5  Immunoprecipitation and immunoblotting 
 
Confluent cells (HEK-293) stably transfected with both C-tail PAR2-
HA+CryaaMycHis were lysed in 1x lysis buffer and lysate was made and measured as 
described above. 2 mg of lysate was incubated with 10 µg of rabbit polyclonal affinity 
purified antibody against HA-tag (Sigma) for 4 h at 4°C and then with 20% protein A-
conjugated agarose beads overnight with shaking at 4°C [negative controls also run 
simultaneously-transfected cells with protein A only (no antibody) and HEK-WT with 
both antibody and protein A]. Immune complex was washed three times with cold 1x 
lysis buffer, denatured in 1x Laemmli sample buffer, and resolved in 15% SDS-
PAGE. Protein transferred to nitrocellulose membrane (Protran BA79, 0.1 µm) using a 
semi-dry transfer system (Biorad) at constant voltage (10V) and 200 mA current for 
40 min. Protein bands visualised on the membrane by 0.2% Ponceau S. Membrane 
was blocked in 5% non-fat dry millk (made in PBS-Tween, 0.1%) overnight at 4°C. 
Membrane incubated with mouse monoclonal antibody against myc (1:2500) 
(Invitrogen) for 1 h at room temperature. After three rinsed (in total 30 min), 
membrane incubated with peroxidase-conjugated anti-mouse IgG (1:10,000) 
(Dianove, Hamburg) for 1 h at room temperature. Washing step repeated and protein 
was visualised by enhanced chemiluminiscence (Pierce supersignal kit).   
 
 
2.2.9.6 Silver staining 
 
To visualise < 10 kDa bands protein gel stained using this method since its 
more sensitive then Ponceau S staining. Electrophoresed gel stored in 10% (v/v) 
methanol and 5% (v/v) acetic acid solution overnight at 4°C. All subsequent steps 
performed at room temperature with shaking. Incubated  the gel in Fixing solution 2 
(5% acetic acid and 10% ethanol solution in H2O) for 30 min. Then two times for 15 
min each in Fixing solution 3 (10% ethanol in H2O). Coloring solutions always 
prepared fresh. Incubated in color solution A [25 µl 37% (v/v) Formaldehyde in H2O, 
21 µl 43% (w/v) sodiumthiosulfate in H2O in 50 ml H2O] for 60 sec. Washed three 
times in H2O. Then incubated in color solution B [25 µl 37% (v/v) Formaldehyde in 
H2O, 50 ml 0.2% (w/v) silver nitrate in H2O] for 6 min. Repeated the washing step 
(2x). Incubated in color solution C [25 µl 37%  (v/v) Formaldehyde in H2O, 0.5 µl 
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43% (w/v) sodiumthiosulfate in H2O, 50 ml 6% (w/v) sodium carbonate] till the 
desired intensity of color developed. Washed gel two times in H2O. Finally incubated 
gel in stop solution [3% (v/v) acetic acid and 5% (v/v) glycerine in H2O]. Stored in 
stop solution at 4°C. Scaned the gel and then dried for storage. 
 
2.2.9.7 Stripping of membrane for reprobing 
 
To reprobe the membrane with a second primary antibody this procedure was 
followed: Washed out enhanced chemiluminiscence solution from membrane by 
washing in PBS-Tween (0.1%). Incubated in stripping buffer for 30 min at 50°C. 
Washed extensively in PBS-Tween to remove β-mercaptoethanol from the membrane. 
Blocked overnight in 5% non-fat dry milk at 4°C. Probed with another primary 
antibody as described above. 
 
2.2.10 Immunocytochemistry 
 
Cells (wild-type or transfected) cultured on coverglass were fixed in 4% 
paraformaldehyde for 25 min at room temperature, then washed and stored in PBS. All 
the following steps were perfomed at room temperature. Fixed cells were blocked and 
permeabilised in FTP buffer for 1 h. Then incubated in either one or two of the 
primary antibodies together [ mouse monoclonal anti-PAR-2 (SAM-11)-1:100 (Santa 
Cruz); rabbit polyclonal anti- crystallinA-1:100 (Biomol); mouse monoclonal anti-
GFAP-1:2000 (Boehringer); rabbit polyclonal affinity purified anti-HA-1:100 
(Sigma); mouse monoclonal anti-myc-1:100 (Invitrogen); mouse monoclonal anti-
synaptotagmin-1: 200] for 2 h. Washed the cells 3x10 min in FTP buffer. Secondary 
antibodies used were fluorescent Alexa IgG [Goat-anti-mouse A555-1:100 and Goat 
anti-rabbit A488-1:100 (Molecular Probes)] for 2 h. Washing step repeated and in case 
of Hippocampal astrocytes, nucleus was stained with Hoechst 33342 (1:1000) 
(Molecular Probes) for 7 min in the last washing step. Cells mounted in SIGMA 
mounting media and visualised with a LSM510 Confocal laser scanning microscope 
(Carl Zeiss).  
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2.2.11 Statistics, NCBI-Blast and expasy search 
 
Statistical evaluation for semi-quantitative expression studies were done using 
the Student’s t-test, and ANOVA with Dunnett post test (compare all columns Vs 
control column) and P < 0.05 was considered significant. Data are given as mean 
values ± standard error of the mean (SEM).  
To search for mRNA, protein and primer homology, NCBI genbank 
programm-BLAST used. Exon-intron distribution found using NCBI Locuslink 
programm. Identification of protein done using ExPASy Proteomics tools programm.  
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3. Results  
 
3.1 Expression of PARs after CNS injury  
 
3.1.1 mRNA expression of the 4 PAR subtypes in the rat developing eye and adult 
retina  
 
The mRNA expression was studied using semi-quantitative RT-PCR method. 
For this purpose total RNA was isolated from the tissue and checked for quantity and 
quality before being processed further. As shown in Figure 3.1, only those RNA 
samples revealing intense fluorescence bands of 18S and 28S rRNA on ethidium 
bromide stained 1% agarose/ MOPS gel were used further.  
 
 
  For PCR amplification of the receptor mRNA, gene specific primer pairs were 
designed from the published rat sequences in the data bank (Table 2.1.12.1 in Materials 
& Methods). The receptor DNA consists of two exons flanking a very long single intron 
in the case of PAR-1, PAR-2 and PAR-3, whereas PAR-4 has a very small single intron 
(Table 3.1). The use of intron-flanking primers in all cases guaranteed that the 
amplification product was due to mRNA transcript and not to genomic DNA signal. To 
check this aspect PCR was also carried out with RNA as a starting material and in case 
of PAR-1, -2 and –3 was negative compared to single band obtained with cDNA. 
Sequence analysis of the PCR band from cDNA matched completely with the rat 
sequences published for PAR-1-3 from which the primers were designed. For PAR-4, 
RNA PCR gave a single band of  approximately 850 bp, while with cDNA two bands 
appeared corresponding to 559 bp and 850 bp (Figure 3.2). On sequencing, PAR-4 PCR 
band (lower band of 559 bp) matched exactly with the published rat mRNA sequence 
while PCR band from RNA (850 bp) also gave an in between unmatched sequence of 
approximately 280 bp corresponding to the small PAR-4 intron. Since it was not 
➔ 28s rRNA
➔ 18s rRNA
♦ 
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possible to avoid the amplification of 850 bp PAR-4 genomic DNA band during PCR, 
only the 559 bp mRNA band of PAR-4 considered during analysis of PAR-4 mRNA 
expression. 
 
  
 
 
 
 
 
 
Table 3.1 Exon-intron structure of human PARs 
 
Gene Exon 1 Intron Exon 2 Chromosome Reference 
PAR-1 1-29 amino 
acids 
22 kb 30-425 amino 
acids 
5q13 Cupit et al, 
1999 
PAR-2 1-27 amino 
acids 
14 kb 28-397 amino 
acids 
5q13 same 
PAR-3 1-22 amino 
acids 
4 kb 23-374 amino 
acids 
5q13 same 
PAR-4 1-37 amino 
acids 
274 bp 38-385 amino 
acids 
19p12 Kahn et al, 
1998 
 
 
  RT-PCR analysis revealed the presence of mRNA transcripts for all four PAR 
subtypes in the developing rat eye and adult rat retina. A qualitative estimate of PAR 
mRNA expression was made in the pup eye at three post-natal stages (P1, P9 and P16). 
As shown in Table 3.2, PAR-2 and PAR-4 mRNA were clearly expressed in eyes of P1, 
P9 and P16 animals. While 1 µl cDNA (~ 450 pg) in case of PAR-2 gave a highly 
pronounced PCR signal (++) in all the 3 stages studied, for the same amount of starting 
material the PAR-4 signal was moderately detectable (+) in all cases. PAR-1, however, 
showed a low mRNA expression level in P16 (+/-), since it required 4 µl of cDNA (~ 
RNA         cDNA
~ 850 bp ➔ ➔ ~850 bp
➔ 559 bp
Figure 3.2. PCR with intron-flanking PAR-4 primers. 
PCR using RNA gave a single band of ~850 bp including the
small intron of ~274 bp. cDNA made from the same RNA 
gave two bands of ~850 bp and 559 bp  
 1.8 ng) to achieved a comparable intensity of PCR signal. PAR-1 was highly expressed 
in P1 and P9 eye (++) using 1 µl cDNA (~ 450 pg). PAR-3 mRNA was expressed at 
low levels during all the time points studied (+/-), since 5 µl cDNA (~ 2.25 ng) were 
required for a PCR signal. In adult retina (12 weeks old), PAR-1 mRNA was highly 
expressed, PAR-2 and PAR-3 were moderately expressed, as compared to low 
expression of PAR-4.  
  
 
 
 
Table 3.2 Developmental expression of PAR-1-4-mRNA in post-natal rat eyes and 
adult rat retina. Detection of PARs in P1, P9 and P16 post-natal rat eye and 12 weeks old 
rat retina by RT-PCR. Expression levels: ++: pronounced signal (1µl cDNA), +: detectable
signal (1µl cDNA), +/-: low levels (5µl cDNA). In all the cases cDNA was prepared
identically with same amount of total RNA and the same cDNA was used for PCR of all 
PARs for a particular developmental stage. 65
 
 
3.1.2 the mRNA levels of PAR receptors in retina in response to ONC 
 
Only PAR-1 expression has been studied following nerve injury in the CNS and 
PNS (Niclou et al., 1998; Citron et al., 2000). In the present study the effect of nerve 
injury was investigated on the mRNA expression of all 4 receptor subtypes in a partial 
neurotrauma model. For that purpose,  controlled optic nerve crush (ONC) as a model 
of diffuse axonal injury (Sautter and Sabel, 1993) was used. The mRNA expression 
pattern of PARs in retina was studied after unilateral ONC using semi-quantitative RT-
PCR method. The mRNA levels of all the 4 PAR subtypes altered (upregulated) in both 
the ipsilateral and contralateral retina as a result of unilateral nerve crush (Figure 3.3 a-
d). 
 
12 W retina                  ++                     +                    +                    +/- 
Developmental             PAR-1           PAR-2              PAR-3           PAR-4 
Stage 
P1 eye                  ++ (450 pg)    ++ (450 pg)      +/- (2.25 ng)    + (450 pg) 
P9                         ++ (450 pg)    ++ (450 pg)      +/- (2.25 ng)    + (450 pg) 
P16                        +/- (1.8 ng)    ++ (450 pg)      +/- (2.25 ng)    + (450 pg) 
 
Optic nerve                  +                      +                    +                      + 
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(a)
(b)
(c)
(d)Figure 3.3. RT-PCR detection of PAR-1-4 mRNA expression in retina, 
control and after ONC. 10 µl of each PCR amplified product was loaded 
on a 1% agarose gel prestained with ethidium bromide (10 mg/ml). The 
gels show the mRNA levels of PAR-1(a), PAR-2 (b), PAR-3 (c) and PAR-
4 (d) along with GAPDH in control retina (C), and after ONC in ipsilateral
(i) and contralateral retina (c) at 6 h, 12 h, 1 d, 7 d and 21 d after crush.
Note: In case of PAR-4 only lower 559 bp band considered for mRNA
expression analysis.  66
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In retina ipsilaterally injured by ONC, PAR-1 mRNA expression increased 
moderately (1.5-fold) 6 h after the crush and reached a significantly high, 2.3-fold 
elevated level on day 7 (P < 0.001). By day 21 the mRNA levels were down to 1.2-fold 
of control values (Fig. 3.4a). Similar to PAR-1 behaviour, PAR-2 mRNA expression 
increased significantly (1.9-fold; P < 0.001) 6 h after the crush, elevated little further to 
2.3-fold at 12 h (P < 0.05), then decreased to 1.4-fold by the end of one week, but was 
up to a significantly high value of 1.9-fold (P < 0.01) again by day 21 (Fig. 3.4b). PAR-
3 mRNA expression remained at basal levels 6 h after the crush, but showed a 
substantial and significant peak-like increase (2.3-fold; P < 0.05) 12 h post-injury, and 
then declined steadily below the control level at the end of 3 weeks (Fig. 3.4c). Unlike 
the other PARs, PAR-4 mRNA levels showed a dramatic up-regulation already at 6 h 
post ONC (3.5- fold; P < 0.01) which reached a further peak of 6.1-fold increase at 12 h 
(P < 0.001) and then, just like PAR-1, declined to little above basal levels (1.4-fold) by 
21 days (Fig. 3.4d). 
In the uninjured contra-lateral retina, surprisingly the mRNA expression for all 4 
PAR subtypes was found altered to an extent almost comparably to that of the 
ipsilateral, injured side. PAR-1 mRNA levels were found elevated (1.8-fold) and 
remained so till 21 days (1.3-fold; P < 0.05) (Fig. 3.5a), similar to PAR-1 mRNA 
behaviour in the injured side. PAR-2 expression increased significantly (1.8-fold; P < 
0.001) 6 h after crush and was then maintained elevated around 1.4-fold till day 1 (Fig. 
3.5b). On day 7 the mRNA level dropped slightly below basal value but was back at 
1.5-fold by day 21 (P < 0.05). PAR-3 mRNA levels increased steadily till day 1 and 
then slowly returned to 0.8-fold of basal levels by day 21 (Fig. 3.5c). In case of PAR-4 
the elevated mRNA levels were not as high as found in the crushed injured side, but 
were still significantly high enough until 12 h (1.9-fold; P < 0.05 at 6 h and 2.2-fold; P 
< 0.01 at 12 h), but then a decline pattern excluding day 1 was observed, ending at 
lower than basal levels by day 21 (Fig. 3.5d).  
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Figure 3.5. Time course of PAR-1 (a), PAR-2 (b), PAR-3 (c) and PAR-4 (d) 
mRNA expression in the retina on the contralateral uninjured side after
ONC. Details as in Figure 3.4  
             
             
3.1. 3 PAR mRNA levels after transient focal ischemic  
  
  To further examine the effect of CNS injury on PAR mRNA expression 
Endothelin-1-induced focal brain ischemia model was used to asses whether stroke 
affects the PAR mRNA expression. The change in receptor mRNA expression was 
assayed by semi-quantitative RT-PCR technique. In the brain of naive animals (control), 
PAR-1 and PAR-2 mRNA were abundantly expressed, as compared with the moderate 
expression of PAR-3 and low PAR-4 mRNA levels. Endothelin-1-induced transient 
focal ischemia in brain near middle cerebral artery (MCA) affects the PAR mRNA 
expression (Figure 3.6 a-d).  
 
 
 
 
 
 
 
 
      PAR-1                   GAPDH
 C  12 h   48 h    7 d   M
       i     c     i     c    i    c
355 bp
835 bp
(a)
835 bp742 bp
      PAR-2                 GAPDH
C   12 h   48 h   7 d  M
        i    c    i     c    i    c
(b)
581 bp
835 bp
      PAR-3                      GAPDH
 C  12 h    48 h   7 d   M
       i     c     i     c      i    c
(c)
835 bp
559 bp
      PAR-4                    GAPDH
C   12 h   48 h    7 d   M
       i     c    i    c     i    c
(d)Figure 3.6. RT-PCR detection of PAR-1-4 mRNA expression in rat brain, control 
(naive), and after transient focal ischemia. 10 µl of each PCR amplified product was 
loaded on a 1% agarose gel prestained with ethidium bromide (10 mg/ml). The gels
show the mRNA levels of PAR-1(a), PAR-2 (b), PAR-3 (c) and PAR-4 (d) along with 
GAPDH in control (C), and after cerebral ischemia in ipsilateral (i) and contralateral 
brain hemisphere (c) at 12 h, 48 h, and 7 d after insult. Note: In case of PAR-4 only 
lower 559 bp band considered for mRNA expression analysis.  70
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Endothelin-induced MCAO yielding focal ischemia results in significant down-
regulation of PAR-1 mRNA expression at 12 h after the insult (Fig. 3.6a). Quantitative 
analysis showed that the mRNA level declined to 0.4-fold of the control value (P<0.05) 
at 12 h after the insult (Fig. 3.7a). This level further dropped at 48 h after injury to 
almost negligible values (< 0.1-fold), which was highly significantly reduced 
(P<0.001). However, PAR-1 showed an upward recovery trend and reached 0.7-fold of 
control on day 7 (Fig. 3.7a). PAR-2 mRNA expression, like PAR-1, was also down-
regulated after the ischemic insult (Fig. 3.6b), but unlike PAR-1, the PAR-2 mRNA 
levels decreased, but not significantly, and remained static around 0.6-fold during the 
time course of the study (Fig. 3.7b). PAR-3 showed a transient up-regulation, giving an 
increase of 1.4-fold at 12 h after injury. Then followed a significant decrease of the 
PAR-3 mRNA levels to 0.3-fold (P<0.05) at 2 and 7 days after the insult (Fig. 3.7c). 
PAR-4 mRNA levels were most dramatically increased after endothelin-induced focal 
ischemia, as compared to the other PARs. PAR-4 mRNA levels increased to a 
significantly high value of 2.7-fold (P<0.05) at 12 h post-injury and showed a sustained 
up-regulation (1.5-fold) up to one week following the ischemic insult (Fig. 3.7d). 
GAPDH expression was used as control standard, because GAPDH remains constant 
after MCAO in rat (Harrison et al., 2000). 
 
PAR mRNA levels in the contra-lateral hemisphere  
Interestingly, also in the contra-lateral brain hemisphere PAR-1, -2 and -3 all 
revealed a change in mRNA expression patterns. The mRNA levels of all three receptor 
subtypes were down-regulated to 0.5-fold or less at 12 h after ischemia (P<0.05- 0.001) 
and then underwent a brief recovery period up to the 48 h time point, but subsequently 
declined to 0.2–0.3-fold on day 7 after injury (P<0.05-0.01), as shown in Fig. 3.8a, b, c. 
Hence, the mRNA levels for PAR-1, -2 and –3 were found to be substantially reduced 
in the contra-lateral brain region. In case of PAR-1 (0.37-fold) and PAR-2 (0.5-fold), 
the decrease in mRNA levels was as high as in the ipsilateral ischemic hemisphere. 
PAR-4 mRNA behaved differently. Unlike the other three PAR subtypes in the contra-
lateral side, the PAR-4 mRNA levels showed a slight up-regulation of 1.2-fold at 12 h 
and maintained this increased level until 48 h, but then declined to 0.4-fold (P<0.01) 
one week after ischemia (Fig. 3.8d). 
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♦♦ Figure 3.7. Time course of PAR-1 (a), PAR-2 (b), PAR-3 (c) and PAR-4 (d)
mRNA expression in the ipsilateral ischemic hemisphere of rat brain after
endothelin-1-induced transient focal ischemia. Semi-quantitative determination
of mRNA level was obtained by densitometric analysis of the PCR product. mRNA
signal for each gene was normalized to the GAPDH signal from the same RT
product. The expression of the control (naive) was set as 100%. The PCR data were
obtained for each sample and for each gene from two independent experiments and
the results were averaged. The cumulative  normalized data are presented as mean
value ± SEM (n ≥ 3 per group). The statistical significance level (Student t-test: *
and Dunnett post test: ♦) for difference from control value is given as *P < 0.05, **
P < 0.01, *** P < 0.001. 72
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Figure 3.8. Time course of PAR-1 (a), PAR-2 (b), PAR-3 (c) and PAR-4 (d) 
mRNA expression in the contra-lateral uninjured hemisphere after endothelin-
induced in vivo transient focal ischemia. Details as in Figure 3.7. 
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3.2 Identification of a putative interacting protein for PAR-2 using yeast 
two hybrid system 
 
3.2.1 Construction of DNA-BD/bait fusion protein 
 
To identify a protein which interacts with PAR-2 and thus may be involved in 
PAR-2 signalling pathway, yeast two hybrid screening was performed with a self-made 
library. Since PAR-2 is a 7-transmembrane domain G protein-coupled receptor only the 
C-terminus of the receptor was cloned into the yeast expression plasmid to generate a 
DNA-BD/bait fusion protein. For this, rat PAR-2 C-tail (Accession No. U61373) from 
base 1042 until 1197 base, corresponding to 50 amino acids was used. The 152 bp C-tail 
of rat PAR-2  was cloned between Eco RI and Bam HI restriction sites of yeast DNA-
BD vector pGBKT7. Cloning sites and start codon were incorporated before the 1042 
bases of the fragment (Figure 3.9) via primers designed for PCR amplifying the C-tail 
fragment of PAR-2 from rat brain RNA. Since the GAL4 DNA-BD is upstream of 
pGBKT7 MCS, the original stop codon of the PAR-2 insert was not mutated and used 
as such. Both the pGBKT7 and C-tail PAR-2 fragment which was generated by PCR 
were digested, ligated and subsequently transformed into E.coli XL1 blue competent 
cells. Positive transformants containing the fusion protein were grown under kanamycin 
selection pressure. The correct sequence of the fusion protein was verified by DNA 
sequencing. The cloning resulted in a DNA-BD/bait fusion protein containing C-tail of 
PAR-2 (50 amino acids).  
 
5’GAATTC ATG TCGAAAGATTTCAGGGACCAGGCCAGAAACGCGCTCCTCTG 
      Eco RI    Start  ↑ 1042 base  
 
CCGAAGCGTCGCACCGTGAAACGCATGCAGATATCGCTCACCTCCAACAAG 
TTCTCCAGGAAATCCAGCTCTTACTCCTCCAGCTCAACCAGTGTTAAAACCT
CCTACTGAGCT GGATCC-3‘                                                                                                            
             Stop       ↑   Bam HI  
                        1197 base 
 
Figure 3.9. Cloning strategy to create DNA-BD/bait fusion protein. Cloning sites 
and start codon were incorporated via primers (Table 2.1.12.2 in Materials & Methods) 
into the PAR-2 fragment. The C-tail PAR-2 fragment was PCR amplified (186 bp) from 
rat brain, digested and sticky-end ligated into pGBKT7 plasmid having compatible 
restriction sites. Bacterial transformants were selected for fusion protein by kanamycin 
selection. 
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3.2.2 Checking of yeast strains 
 
Yeast strains required for the present work (AH109 and Y187) were checked for 
proper growth on complete YPDA and several amino acid dropout (DO) media.  
 
3.2.3 Checking of DNA-BD/fusion protein for toxicity 
 
To check if the bait fusion protein is toxic to the yeast strains or not, first both 
the empty DNA-BD vector and fusion protein were transformed into AH109 and Y187 
strains and plated on minimal medium lacking tryptophan (SD/-Trp), since pGBKT7 
plasmid can synthesise tryptophan on its own. Growth on SD/-Trp  medium was used as 
a selection marker for pGBKT7 plasmid. Well grown transformed colonies from both 
the empty plasmid and fusion protein were grown in liquid SD/-Trp culture under 
kanamycin pressure. Comparison of OD600 showed that the DNA-BD/bait fusion protein 
is not toxic to yeast. The growth rate of fusion protein containing Y187 was slower as 
compared to transformed AH109 strain.  
 
3.2.4 Checking of DNA-BD/bait fusion protein for transcriptional activation 
 
Since the bait fusion protein should be able to initiate transcription of reporter 
genes on yeast chromosome only when it was interacting with a protein fused to 
Activation domain (AD) plasmid, it was important to verify, whether the bait fusion 
protein was capable of transcriptional activation by itself or not. For this purpose 
AH109 and Y187 were co-transformed with bait fusion protein and empty AD plasmid 
(several combinations) as shown in Table 3.3 and plated on different DO media to 
check for transcriptional activation. 
 
Table 3.3 Testing of bait fusion protein for transcriptional activation. Yeast strains 
were either single transformed with bait fusion protein, or co-transformed with empty 
AD plasmid to check if either of the plasmids by itself or in combination could activate 
the transcription of the reporter genes. Self-activation by bait fusion protein was tested 
on SD/-HW since bait fusion protein on its own cannot grow in medium lacking 
histidine. Presence of both the DNA-BD and AD plasmid was checked on SD/-LW 
(since DNA-BD can grow on –Trp medium and AD plasmid can grow on –Leu 
medium). To check transcriptional activation with empty AD plasmid, were 
transformants plated on SD/ -AWLH since growth on -AWLH medium indicates 
reporter gene expression (His and Ade) and hence probable interaction between the 
plasmids. Positive blue test indicates expression of 3rd reporter gene, lacZ. +: growth of 
transformed yeast; negative: no growth of transformed yeast; inactive: negative for 
transcriptional activation.   
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AH 109 and  
Y187 were  
transformed  
with the following  
↓ 
SD/-Trp  
(-W) 
SD/-Leu 
(-L) 
SD/-
Leu-Trp 
(-LW) 
SD/- 
Trp-His  
(-WH) 
SD/-Ade-
Trp-Leu-
His  
(-AWLH) 
Blue/
white 
filter 
test 
for 
lac Z 
gene 
Conclusion 
Empty DNA-BD v
(pGBKT7) 
+  negative negative    
DNA-BD/bait 
fusion protein  
(C-tail-PAR-2- 
pGBKT7) 
+  negative negative negative  Bait fusion 
protein 
inactive 
Empty DNA-BD  
+ Sma I-linear AD v
(pGADT7-Rec) 
 + +   negative  inactive 
DNA-BD/bait 
fusion protein  
+ linear AD vector 
 + +   negative  inactive 
DNA-BD/bait 
 fusion protein  
+ linear AD  
vector + control 
 PCR fragment 
 + +  negative  inactive 
Positive control   +  + +  
   
 
 
 
The series of experiments, as described in Table 3.3, verified that DNA-BD/bait 
fusion protein cannot initiate transcriptional activation of reporter genes by itself or 
together with empty linear AD plasmid. 
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3.2.5 Generation of ds cDNA for library construction 
 
To fish out a probable interacting protein for PAR-2, a cDNA library was 
generated as an AD fusion library in yeast utilising in vivo homologous recombination 
technique. Rat retina PolyA+ RNA (from Clontech, Heidelberg, Germany) was used for 
generating cDNA library. Quality of PolyA+ RNA was checked on agarose/MOPS gel 
along with the control tissue ie., Human placenta PolyA+ RNA. Intact PolyA+ RNA 
both from retina and human placenta (1 µg each) used for synthesising First-Strand 
cDNA using random primer and SMART III oligonucleotides (as described in Materials 
& Methods). Use of random primers made sure that the resulting cDNA contained a 
variety of 5’ and 3’-end sequences in equal proportion due to the ability of the random 
primer to hybridise to many different sequences on the RNA template. Use of SMART 
III oligonucleotide during cDNA synthesis resulted in generation of ss cDNAs with an 
anchor sequence, which served as a universal priming site in the subsequent 
amplification by long-distance PCR. 2 µl of first-strand cDNA used for each LD-PCR 
reaction. As recommended, LD-PCR was performed for 20 cycles to reduce the 
generation of non-specific PCR products. 5 µl aliquot of the PCR product was checked 
on 1.2% agarose gel prestained with ethidium bromide. As expected, the LD-PCR 
product appeared as a smear on the gel. The ds cDNA was purified using the CHROMA 
SPIN+TE-400 column. This column allowed retention of DNA molecules >200 bp. For 
precipitation, the purified ds cDNA recovered from  2 columns (each started with 95 µl 
of cDNA sample) mixed and processed further. The DNA pellet was resuspended in 
deionized H2O and used for in vivo recombination with pGADT7-Rec to generate the 
AD fusion library in yeast. The steps performed to generate the ds cDNA are outlined in 
Figure 3.10. 
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                                         Rat retina polyA+ RNA checked on gel 
                                                                           ↓ 
                First-strand cDNA synthesised using random primers and Smart III oligos
                                                                           ↓ 
               Amplification of ds cDNA by Long Distance PCR (LD-PCR) (20 cyc) 
                                                                           ↓ 
                        Purification of ds cDNA with chroma spin+TE columns 
                                                  (select DNA  molecules > 200bp) 
                                                                           ↓ 
        ds retina cDNA ready for in vivo recombination with Sma I-linear AD    
         vector 
  
 
Figure 3.10. Schematic presentation of steps performed to generate ds cDNA from 
retina for library construction. Details with regard to experimental procedure 
explained in Materials & Methods. 
 
 
 
3.2.6 Construction and Screening of AD fusion library 
 
To construct the AD fusion library and subsequent screening for interacting 
clones sequential transformation was performed. For this AH109 competent cells were 
transformed with DNA-BD/bait fusion protein and positive transformants were selected 
on SD/-Trp medium. Then competent cells from the pre-transformed AH109 (with 
DNA-BD/bait fusion protein) were made. For this the pre-transformed AH109 was 
grown in SD/-Trp medium to maintain selection pressure for the recombinant plasmid. 
These AH109 competent cells were then re-transformed with ds cDNA from retina and 
Sma I-linear AD plasmid i.e, pGADT7-Rec. Hence AH109 cells were sequentially 
transformed in the first step with bait fusion protein and then the bait containing cells 
re-transformed with ds cDNA and linear AD plasmid. In vivo homologous 
recombination between ds cDNA and Sma I-linear AD vector in yeast resulted in a 
recircularized AD fusion library plasmid. 
Transformants were plated on Triple dropout medium (SD/-TDO ie., -Trp-Leu-
His) to select for probable interacting clones. Transformants plated on SD/-Leu gave a 
transformation efficiency 0.6 x 106 transformants / 3µg AD vector and on SD/-Leu/-Trp 
gave the number of clones screened, which was calculated to be 3.86 x 105 clones / 
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library. The values obtained matched closely with the expected numbers. 
Simultaneously both the positive and negative controls performed.  
Sequential transformation and subsequent library screening gave 336 big clones 
and 252 small clones on TDO plates. To eliminate false-positive clones initial 588 
clones were picked completely from the source and restreaked in a grid fashion on fresh 
TDO plates. All except 27 clones grew on restreaked TDO plates. To further eliminate 
false-positive the 561 clones were streaked on a more stringent dropout media lacking 
adenine also to check for Ade+ clones. Clones lacking ability to grow in –Ade 
conditions turned pink and subsequently red. Hence the 561 clones streaked on 
Quadruple Dropout Medium (QDO ie., -Ade-Trp-Leu-His). To further select the clones 
positive for all 3 reporter genes (Ade+, His+, lacZ) 3rd reporter gene ie., lacZ selection 
made by performing β-gal filter lift assay. Colonies grown on QDO plates were filter 
lifted and incubated with X-gal, a substrate for β-galactosidase. LacZ+ colonies turned 
blue while negative remained white. From 561 clones only 13 clones turned blue within 
4 hrs while 98 more turned blue after longer incubation time (8-12 hrs). For  further 
verification all the 111 blue clones were fresh restreaked on QDO plates and blue/white 
filter test was performed for the second time. In second round 38 clones turned blue 
within 5 hrs while 27 more were tentative blue after a little longer. 3 clones from the 
first round of filter test were negative second time around (Figure 3.11). The 65 positive 
clones after initial library screening were then verified further to identify the probable 
interacting protein or proteins for PAR-2. 
 
 
             Initial transformants on TDO plates - 336 big clones and 252 small clones 
                                                        ↓ 
                                    All 588 clones restreaked on fresh TDO plates  
                                                        ↓ 
                                    All except 27 clones grew ( 561 clones) 
                                                        ↓ 
                  IInd round positive TDO clones streaked onto a more stringent media 
                                      QDO (SD/-Ade/-Leu/-His/-Trp)  
                                                        ↓ 
           To check for 3rd reporter gene-lacZ, blue/ white filter assay performed on  
           QDO plates using X-gal as a substrate. ß-galactosidase expressing clones  
           turned blue 
                                                        ↓ 
       13 clones turned blue within 4 hrs and 98 clones blue after 8-12 hrs incubation   
                                                        ↓  
                   All 111 clones restreaked on fresh QDO plates      
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                                                        ↓ 
        Blue/ white filter test performed :38 clones turned blue within 5 hrs and 27  
         tentative blue in-between 8-10 hrs 
                 (3 previous blue clones -ve in second round) 
                                                        ↓ 
    Further verification of 65 positive blue clones for identifying the PAR-2   
    Interacting protein.  
 
 
 
          Figure 3.11. Schematic presentation of library screening results. 
 
3.2.7 Analysis of positive clones 
 
Positive yeast clones were grown in SD/-Leu medium to select for AD library 
plasmids and subsequent plasmid isolation. Plasmid DNA isolated from yeast is always 
contaminated with genomic DNA due to breakage of yeast chromosome during 
isolation procedure resulting in low plasmid yields. Hence yeast plasmid DNA is not 
pure enough for direct sequence or restriction digestion analysis but sufficient to 
transform E.coli. The isolated yeast plasmid DNA were electroporated into E.coli 
electro-competent cells and  transformants were grown under ampicillin selection 
pressure to select for AD/library plasmids. Plasmid DNA was isolated from transformed 
bacteria and restriction digested with Hind III enzyme (since pGADT7-Rec contains 2 
Hind III sites) to look for the presence of same AD/library plasmid or inserts. For 
restriction digestion, 4-2 bacterial clones were checked from each transformed 
AD/library plasmid. To identify the insert in positive AD/library plasmid, DNA isolated 
from E.coli was sequenced using the Matchmaker 5’ and 3’ AD LD-insert screening 
amplimers. Sequences were checked for probable homology at both the nucleotide and 
protein levels. Out of 65 positive blue clones only 27 clones gave a meaningful 
sequence homology both at nucleotide and protein level as described in Table 3.4. 
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Table 3.4 Nucleotide and Protein homology of positive AD/library plasmid clones. 
AD/library clones positive for all the 3 reporter gene assay in yeast were further 
analysed by sequencing after transformation in bacteria. 
 
YTH 
clone 
Nucleotide and Protein homology (rat) Nucleotide Gene 
bank Accession 
number  
3/9 B Crystallin α polypeptide A mRNA (Cryaa) NM_012534 
4/3 A ATPase, Na+/ K+ transporting, β 2 polypeptide (Atp1b2) 
mRNA 
NM_012507 
6/2 A Iron-regulatory protein 2 (Ireb 2) (Aconitate hydratase or 
Aconitase) 
NM_022863 
6/5 D Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) XM_216453 
6/8 A Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) XM_216453 
2/2 B Fibronectin 1 or fibronectin precursor (Fn1) NM_019143 
11/21 A Polyubiquitin mRNA NM_138895 
12/8 C Crystallin, α-polypeptide 2 (Cryab) NM_012935 
16/1 B Crystallin, α-polypeptide A  (Cryaa) NM_012534 
20/2 A Procollagen, type I, alpha 2 (Colla 2) NM_053356 
22/11 B Cytoplasmic- gamma isoform of actin mRNA        And 
Cytoplasmic β actin (Actx), mRNA 
X52815    And 
NM031144 
25/12 A Crystallin, α polypeptide A (Cryaa), mRNA  NM_012534 
33/3 A Galectin-related inter-fiber protein (Grifin), mRNA (lectin, 
galactoside-binding) 
NM057187 
33/20 B (clone gamma-3) ATP synthase gamma-subunit (ATP5c) 
mRNA, 3’ end cds 
L19927 
34/19 B Crystallin, α polypeptide A (Cryaa), mRNA NM_012534 
4/14 A Mitochrondrial ATP synthase beta subunit mRNA M19044 
6/6 A Alpha-tubulin (Tuba 1), mRNA NM022298 
11/6 A mRNA for MEGF8 (multiple EGF-like motifs)  AB011534 
17/8 B Galectin-related inter-fiber protein (Grifin), mRNA NM057187 
23/1 A Crystallin, α polypeptide A (Cryaa), mRNA NM_012534 
29/11 B Prohibitin (Phb) mRNA NM_031851 
30/4 A Myosin heavy polypeptide 3, skeletal muscle, embryonic 
(Myh3), mRNA        And  
NM_012604   
And 
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mRNA for alpha cardiac myosin heavy chain  
X15938 
30/5 A Crystallin, α polypeptide A (Cryaa), mRNA NM_012534 
25/3 A Mitochrondrial ATP synthase beta subunit mRNA         And  
F1-ATPase subunit (beta) mRNA, 3’end  
M19044    And 
M57634 
27/19 A mRNA for MHC class I cell-surface antigen, A1 (F) alpha 
chain 
X99767 
23/3 B Protein phosphatase 2A B regulatory subunit delta isoform 
mRNA 
AF180350 
23/3 C Procollagen, type I, alpha 2 (Colla 2) NM_053356 
 
 
 
3.2.8 Yeast mating 
 
27 clones giving a meaningful nucleotide and protein homology were retested 
for protein interaction by mating in yeast. For this the DNA/BD-bait fusion protein 
was transformed in Y187 (Mat α and  AD/library plasmids isolated from bacteria  
were retransformed into AH109 (Mat a) as described in material and methods and 
selected on SD/-Trp and SD/-Leu respectively. Each AD/library plasmid was mated 
with DNA/BD-bait fusion protein, empty DNA/BD plasmid and a control plasmid 
DNA/BD plasmid (pGBKT7-Lam). Diploids were selected on SD/-LW and screened 
for interaction on TDO and QDO medium. Clones from QDO plates were tested for 
blue/white filter assay for β-galactosidase (Figure. 3.12). 
 
   
                                                
 
 
 
 
 
 
 
 
  AH 109 transformed with                            Y187 transformed with                             Screening 
                                             Mating 
   AD/library plasmids                                   1) empty DNA/BD-plasmid                          SD/-LW 
                                                                    
                                                                      2)DNA/BD-bait fusion protein                         TDO 
 
                                                                      3) DNA/BD-control plasmid                            QDO 
                                                                                                                         
                                                                                                                                  blue/white filter test       
Figure 3.12. Schematic presentation of  mating procedure in yeast and subsequent
screening for positive clones.   
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Of the 27 AD/library clones only 1 clone ie., cl. 34/19 B was positive for all 3 
reporter gene expression ie., Ade+, His+ and lacZ+ when mated with DNA/BD-bait 
fusion protein and not with empty or control DNA/BD plasmid. 
 
3.2.9 Identification of the positive clone after mating 
 
Clone 34/19 B was identified as rat  crystallin, α polypeptide A (Cryaa) mRNA 
both at nucleotide and protein level (Table 3.4).  
 
TTTTTTGGGANCCATNNTTNTTNCTTTAATACGACTCACTATAGGGCGAGCG 
             ↓ 
CCGCCATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATGG
AGGCCAGTGAATTCCACCCAAGCAGTGGGTATCAACGCAGAGTGGGCCATT
ATGGCCGGGCACCATCCAGCACCCTTGGTTCAAGCGCGCCCTGGGGCCCTT
CTACCCCAGCCCGATGTTCGACCAGTTCTTCGGCGAGGGCCTTTTTGAATAC
GACCTGCTTGCCCTTCCTGTCTTCCACCATCAGCCCTTACTACCGGCCAGTCT
CTCTTCCGACAGTGTTGGACTCCGGCATCTTCTGAGGTCCGATCTTGACCGG
GACAAGTTGGCATCTTCTTGGATGTGAAGCACTTNTNTCTGAGGACCCACCG
TGAAGGACTGGAANATTCGTGGAAATCATGGCAACCACAGAGGCAGGATG
ACATGNTNATTTNCCGGAATTACGNCGTNCCGTTGCTTCAAGNGACATCCGC
TTCTGTCTTGTGGGATGATGTACTTTTGGCCAAGGCATTGGTTGATCTGCNA
NAAAGGCTTCCGTNCGAGNAACATTGNCTNCTAAGCTNTGN     
 
Figure 3.13. Sequence of AD/library clone 34/19 B using Matchmaker 5’ AD LD-
insert screening amplimer. ↓ shows the in vitro START site of pGADT7-Rec, 
underlined nucleotides show the homologous recombination site between pGADT7-Rec 
and SMART III oligo of cDNA followed by bp 21 (in bold) of AD clone 34/19 B ie., rat 
α-crystallin A nucleotide sequence. 
 
 
As mentioned in Table 3.4, six AD/library clones gave α-Crystallin A protein on 
sequencing. Since only 1 clone ie., 34/19 B was positive after mating, all 6 clones 
representing the same α−crystallin A protein were checked for their fragment size in 
AD/library plasmid (Table 3.5). 
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Table 3.5 Comparison of fragment size of AD/library clones representing  
a-crystallin A protein.  
 
AD/library clones of  
α-crystallin A 
Fragment size of α-crystallin 
A in AD clones (from - till 
base of available nucleotide 
sequence) 
Fragment size of  
α-crystallin A in AD 
clones (in amino acids) 
3/9 B 9-361  116  
16/1 B 9-367  118  
25/12 A 63-330   89  
34/19 B 21-955  170 
23/1 A 15-363  116  
30/5 A 15-370  118 
 
 
 
3.2.10 Checking of a-crystallin A clones 
 
Sequence analysis of 6 α-crystallin A clones obtained with Matchmaker 5’ AD 
LD-insert screening amplimer showed two different kinds of patterns. In case of AD 
clones 34/19 B, 25/12 A and 30/5 A the homologous recombination site between 
pGADT7-Rec and SMART III oligo of cDNA was immediatelyfollowed by α-crystallin 
A sequence in-frame. In clones 3/9 B, 16/1 B and 23/1 A the homologous 
recombination site was followed by ~45-70 bp corresponding to unknown sequence and 
then in-frame α-crystallin A nucleotide sequence followed.  
To recheck for positive clones within the 6 α-crystallin A clones, three of the 
clones including the positive one from the mating round (25/12 A, 34/19 B and 30/5 A) 
were checked for interaction with DNA-BD/bait fusion protein both by sequential 
transformation and mating. For this the AD/library plasmid DNA was amplified by PCR 
using the Matchmaker 5’ and 3’ AD LD-insert screening amplimers. AD/library 
plasmid DNA (α-crystallin A) and Sma-I-linear pGADT7 were co-transformed in 
DNA/BD-bait fusion protein containing AH109. For mating, AD/library plasmid DNA 
(α-crystallin A) and Sma-I-linear pGADT7 were transformed in AH109 and then mated 
with DNA/BD-bait fusion protein containing Y187. In both cases empty DNA/BD 
plasmid was used as a control. To check for transcriptional activation by AD/library 
clones itself, AH109 transformed with the AD/library plasmid PCR DNA and Sma-I-
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linear pGADT7 were also plated on SD/-LH and were found to be negative indicating 
that AD/library clones cannot activate transcription of reporter gene Histidine by itself. 
Sequential transformation and mating transformants were screened for positive 
interaction on SD/-LW, TDO, QDO plates and blue/ white filter assay as described 
earlier in the section for library screening.  Only PCR DNA fragment of 34/19 B was 
found to be positive for all the 3 reporter gene assays with DNA/BD-fusion protein in 
case of both sequential transformation and mating. For verification of the clone, plasmid 
DNA of 34/19 B isolated from yeast, electro-transformed into bacteria and sequenced. 
Sequencing of clone 34/19 B gave the original mRNA and protein sequence.  
These experiments with different clones of α-crystallin A gave only clone 34/19 
B as positive similar to mating results obtained with different AD/library clones. 
Databank search about α-crystallin A showed that the protein has a coding region 
spanning from 13-534 bases ie., 522 bps and 174 amino acids. 
 
3.2.11 Checking for interaction with PAR-2 cytoplasmic loops 
 
Since PAR-2 is a 7-transmembrane domain receptor with 3 cytoplasmic loops 
apart from the C-terminus region it was important to verify if the interaction observed 
between C-terminus PAR-2 and AD/library clone 34/19 B was confined to C-tail only 
or whether clone 34/19 B could interact with cytoplasmic loops as well, since 
interaction between the third cytoplasmic loop of PARs and G-proteins is known (Chen 
et al., 2001). For this, rat PAR-2 cytoplasmic loops, Cl-2 (21 amino acids) and Cl-3 (23 
amino acids) were cloned between Eco RI and Bam HI site of DNA/BD vector 
pGBKT7 similar to C-tail fusion protein (this cloning was done by (ATG: biosynthetics, 
Freiburg, Germany) but sequences of the Cl-2/DNA/BD-fusion protein and Cl-
3/DNA/BD fusion protein were verified (Figure 3.14). The Cl-2 and Cl-3 DNA/BD 
fusion proteins were mated with 3 α-crystallin A clones (25/12 A, 34/19 B and 30/5 A). 
Appropriate controls were also performed. Mating mixture was screened for all 3 
reporter gene expressions. Both the Cl-2 and Cl-3 DNA/BD fusion proteins were found 
to be negative for all the reporter genes. From these experiments AD/library clone 34/19 
ie., α-crystallin A came out as an interacting protein for C-tail of PAR-2 and  this 
interaction seemed to be confined to only the C-tail of PAR-2 and not with PAR-2 
cytoplasmic loops.   
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(A) 
5’GAATTCGTGCAGAGGTACTGGGTGATCGTGAACCCCATGGGACACTCCAG
GAAGAGGGCCAACATCGCTTAAGGATCC-3’ 
 
(B) 
5’GAATTCATCAAAACGCTCCGCTCTTCCGCCATGGACGAGCACTCGGAGAA
GAAAAGGCGGAGGGCTATCCGCCTCTAAGGATCC-3’ 
 
Figure 3.14. Cloning strategy of rat PAR-2 cytoplasmic loop 2 and 3. (A) shows the 
nucleotide sequence of Cl-2 (511-573 bp), and (B) shows the nucleotide sequence of Cl-
3 (796-864 bp). In both cases double stranded nucleotide oligos were synthesised and 
cloned between Eco RI and Bam HI of pGBKT7 plasmid by ATG: biosynthetics, 
Freiburg, Germany.  
 
 
3.2.12 Checking for presence of α-crystallin A in different tissues, cell types and 
cell lines 
 
After identification of a putative interacting protein for C-tail of PAR-2 in yeast, 
our next step was to identify the tissues and cell types where it occurs under normal 
conditions. For this, PCR primers were designed (Materials & Methods) from the 
published nucleotide sequence of  rat α-crystallin A and also α-crystallin B isoform 
(since α-crystallin B is ubiquitously present and shares a high sequence homology with 
the A isoform). Using the standard RT-PCR technique several tissues, cell types and 
cell lines were checked for the presence of both isoforms of α-crystallin (Figure 3.15) 
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 Figure 3.15. Detection of α-crystallin A, α-crystallin B and GAPDH mRNA
expression in tissues and cell types. RT-PCR performed to detect presence of α-
crystallin A and α-crystallin B in several tissues, cell types and cell lines. Gel A: α-
crystallin A, Gel B: α-crystallin B and Gel C: GAPDH. Same cDNA was used for PCRs.
Lane 1: retina, lane 2: optic nerve, lane 3: brain, lane 4: Hippocampal neurons, lane 5:
Hippocampal astrocytes, lane 6: whole brain astrocytes, lane 7: retinal ganglion cell line
(RGC), lane 8:oligodendrocyte cell line (OLN-93), lane 9: N2A cell line, lane 10: mouse 
neuroblastoma x rat glioma hybrid cell line (NG-108), lane 11: human embryonic kidney
cell line (HEK). M: 1 kb DNA ladder.  87
able 3.6 Summary of RT-PCR for α-crystallin A and B isoform in different 
issues, cell types and cell lines. 
Tissue or cell type α-crystallin A α-crystallin 
B 
Retina (total RNA and poly A+ mRNA) + + 
Optic nerve + + 
Brain + + 
Rat hippocampal neuronal culture  (primary) - + 
Rat hippocampal astrocyte culture  (primary) + + 
Rat whole brain astrocyte culture (primary)  + + 
Rat retinal ganglion cell line (RGC) - + 
Rat oligodendrocyte cell line (OLN 93) - + 
Rat N2A cell line - + 
NG108 cell line (mouse neuroblastoma x rat glioma hybrid) - + 
 RT-PCR analysis of several tissues showed the presence of α-crystallin A 
RNA to be abundant in retina and optic nerve, while it is also expressed in brain. 
mong the cell types checked it is expressed by rat hippocampal astrocytes and whole 
rain astrocytes (primary cultures), but not by hippocampal neurons since primary 
euronal cultures (mixed) were negative for RT-PCR. Among the cell lines rat RGC 
nd N2A cell lines which are both neuronal were also negative for the α-crystallin A 
RNA. Rat oligodendrocyte cell line (OLN-93) and neuroblastoma x glioma hybrid 
ell line (NG108) too were negative. HEK which is a human epithelial cell line was also 
 88
found negative but this may be due to the fact that rat α-crystallin A primers were used 
for PCR. α-crystallin B isoform was however expressed by all tissues and cell types 
except HEK (as summarised in Table 3.6).  
  Primary cultures of rat whole brain astrocytes, hippocampal astrocytes and 
neurons were also checked by immunocytochemistry for the presence of α-crystallin A 
(Figure 3.16). 
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V
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Immunocytochemical analysis of the primary cultures showed the presence of 
α-crystallin A in hippocampal astrocytes (Figure 3.16-I) and whole brain astrocytes 
(Figure 3.16-II) (co-localised with astrocytic marker-GFAP). Hippocampal neuronal 
cultures (mixed) stained positive for α-crystallin A (co-localised both with astrocytic 
marker-GFAP and neuronal marker-synaptotagmin) (Figure 3.16-III, IV and V), 
unlike the negative RT-PCR results.  
 
 
3.2.13 Generation of PAR-2 and α-crystallin A fusion proteins 
 
The next step in confirming the interaction observed between the C-tail of rat 
PAR-2 and its putative interacting protein α-crystallin A in yeast was to recheck the 
interaction either in prokaryotic or eukaryotic expression systems. A eukaryotic 
expression system was selected since in mammalian cells, proteins are more likely to be 
in their native conformations with appropriate post-translational modification and, 
therefore, results represent biologically significant interactions. To this end rat PAR-2 
and α -crystallin A were cloned into several mammalian expression vectors with tag as 
fusion proteins (Table 3.7).  
 
Table 3.7 List of PAR-2 and α-crystallin A fusion proteins with several expression 
vectors suitable for mammalian cell culture systems. The gene fragments of interest 
were amplified by PCR (primers in Material & Method) from rat brain. In all cases the 
sequence of the fusion protein was verified by sequencing. Normally for transfection 5 
µg of plasmid DNA was used but in unsuccessful cases even 10 µg plasmid were tried 
for transfection. Cells were made stable with fusion protein constructs under suitable 
antibiotic selection pressure. 
 
Figure 3.16: Detection of a-crystallin A by immunocytochemistry in primary
cultures of rat hippocampal astrocytes (I), whole brain astrocytes (II), and
hippocampal neurons (mixed) (III, IV, V). I-V (A): cells were stained for the presence 
of α-crystallin A using specific antibody (1:100). Fluorescent detection with Alexa A488 
(green). I-III (B): cells were stained for the presence of GFAP (astrocytic marker)
(1:2000) and IV-V (B) with synaptotagmin (neuronal marker) (1:200) using specific
antibody. Fluorescent detection with Alexa A555 (red). I-V (C): co-localisation of both 
proteins in cells. Hippocampal astrocytes were also stained with Hoechst for nuclear
staining. 
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Gene Cloning vector Restriction sites Cell lines used 
for transfection 
Transfection 
results 
Full PAR-2 pEGFP-N1 Xho I & Hind III HEK   &  N2A successful 
   NG 108 & RBL  unsuccessful 
Full PAR-2 pDsRed2-N1 Xho I & Hind III HEK & RBL unsuccessful 
C-tail 
PAR-2 
(subcloned 
from 
pGBKT7) 
pCMV-HA Sfi I & Sal I HEK  (with 
empty pEGFP-
N1 as carrier 
DNA) 
successful 
C-tail 
PAR-2 
(subcloned 
from 
pGBKT7) 
pEGFP-C2 Eco RI &  
Bam HI 
HEK  successful 
Full α-
crystallin A 
pEGFP-N1 Xho I & Hind III N2A 
RGC 
successful 
unsuccessful 
Full α-
crystallin A 
pDsRed2-N1 Xho I & Hind III HEK & RBL unsuccessful 
Full α-
crystallin A 
pcDNA3.1/Myc
-His (B) 
Bam HI &  
Eco RV 
HEK successful 
α-crystallin 
A Domain 
1 (CD1) 
pcDNA3.1/Myc
-His (B) 
Bam HI &  
Eco RV 
HEK successful 
α-crystallin 
A Domain 
2 (CD2) 
pcDNA3.1/Myc
-His (B) 
Bam HI &  
Eco RV 
HEK successful 
 
 
 
3.2.14 Cellular localisation of PAR-2 and α-crystallin A 
 
The first step in confirming the interaction outside of the yeast system was to 
localise both proteins in cells since for any biological interaction to be feasible in a 
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natural system both proteins should be either in the same cellular compartment or 
localised in adjacent cell compartments. For this purpose full rat PAR-2-pEGFP-N1 was 
stably transfected in HEK and N2A cells. PAR-2 fusion protein was localised on the 
basis of green fluorescence of the GFP vector. Before transfection, wild type cells were 
checked for endogenous receptor expression. HEK cells endogenously expresses PAR-
2, while N2A cells do not. In both HEK and N2A cells, PAR-2-GFP fusion protein 
could be localised to the plasma membrane with little cytoplasmic distribution, as 
previously described (Dery et al., 1999) (Figure 3.17 a and 3.17 b). 
 
 
 
 
 
 
 
α-crystallin A-pEGFP-N1 fusion protein was stably transfected in N2A cells and 
green fluorescence of the fusion protein could be localised to the cytosol excluding the 
Figure 3.17 a. Subcellular localisation of PAR-2-GFP in N2A cells. Full rat PAR-2 -
GFP construct was stably transfected into N2A cells (rat neuronal cells). Membrane 
localisation of fusion protein detected by GFP fluorescence on confocal laser scanning
microscope.  
Figure 3.17 b. Subcellular localisation of PAR-2-GFP in HEK cells. Full rat PAR-2 
-GFP construct was stably transfected into HEK cells (human embryonic kidney
epithelial cells). Membrane localisation of fusion protein detected by GFP 
fluorescence on confocal laser scanning microscope. 
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nucleus (Deretic et al., 1994) (Figure 3.17 c). α-crystallin A-MycHis construct stably 
transfected in HEK cells on immunostaining with anti-myc antibody gave similar 
cytosolic distribution of α-crystallin A as pEGFP-N1 construct in N2A cells (Figure 
3.17 d). 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.15 Checking for expression of non-fluorescent fusion protein in mammalian 
cell culture system 
 
Figure 3.17 c. Subcellular localisation of α-crystallin A-GFP in N2A cells. 
Full rat α-crystallin A-GFP construct was stably transfected into N2A cells (rat
neuronal cells). Cytosolic localisation of fusion protein detected by GFP
fluorescence on confocal laser scanning microscope.  
Figure 3.17 d. Subcellular localisation of α-crystallin A-MycHis in HEK cells. 
Full rat a-crystallin A -MycHis construct was stably transfected into HEK cells.
Subcellular localisation of a-crystallin A was detected by immunostaining with
mouse monoclonal anti-myc antibody (1:100). Alexa 488 anti-mouse IgG (1:100) 
depicting green fluorescence of a-crystallin A cytosolic distribution in the cell on 
confocal laser scanning microscope. 
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Before proceeding for any biochemical assay to confirm PAR-2 and α-crystallin 
A interaction in vitro in mammalian cell culture system it was important to verify the 
expression of fusion proteins with non-fluorescent tags (MycHis and HA tag). For this 
cells were made stable (as described in Materials & Methods). Several individual clones 
seemed to be originating from one cell source each were propagated under antibiotic 
selection pressure. The clones were verified both at the transcriptional and the 
translational level. To check for the presence of insert in the clones at mRNA level RT-
PCR was done with the same primer pair used for cloning. The clones positive for 
mRNA were used for analysis at the protein level by western blot or immuno-staining.  
 
(a) Cryaa-MycHis-HEK:  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
           α-Crystallin A-MycHis                  GAPDH 
 
                 1     2    3    4    5    6    M   7     8    9   10  11  12 
552 bp   600 bp 
Figure 3.18 a. Detection of α-crystallin A-MycHis PCR signal in transfected HEK 
cells. 4 independent cell clones were checked for presence of α-crystallin A-MycHis 
fusion construct mRNA in stably transfected HEK cells by RT-PCR. Lane 1-4: α-
crystallin A-MycHis clones, lane 5: untransfected HEK cells, lane 6: negative control
(H2O), lane 7-10: GAPDH signal in transfected clones, lane 11: GAPDH signal in
HEK-WT, lane 12: negative control (H2O).M: 1 kb DNA molecular ladder.  
α-crystallin A-       PL  HEK-
MycHis-HEK               WT
20 kDa
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(b) C-tail PAR-2-HA+GFP-HEK: As described in materials and methods it was not 
possible to make stable transfection with C-tail PAR-2-HA construct in HEK since 
pCMV-HA vector has no kanamycin/neomycin resistance site for selection with G418 
antibiotic. Hence empty pEGFP-N1 plasmid DNA was used as a carrier DNA in this 
particular transfection and then cells were stably selected on the basis of green 
fluorescence of the GFP vector. Individual clones were checked for mRNA expression 
of C-tail PAR-2-HA fusion protein (Figure 3.19 a). It was not possible to check the 
clones at the protein level by western blot detection due to small size of the protein of 
~6.7 kDa. For detection of such a small protein several modifications were applied in 
western blot and detection including preparation of protein sample, use of 10% precast 
gel with appropriate buffer (Materials & Methods), 15% Laemmli gel, small pore size 
nitrocellulose membrane (0.1 µm), PVDF membrane, several different transfer times 
and conditions in semi-dry transfer system, electroblot using tank transfer system, and 
anti-HA primary antibody from several companies. To check if the protein was actually 
expressed or not cell lysate was prepared from transfected cells in different ways (as 
described in Material & Method) and run on a 10% precast gel (with MES buffer). The 
gel was then proceeded for Silver staining. It was possible to detect the presence of 
small 6.7 kDa C-tail PAR-2-HA fusion protein by silver staining technique (Figure 3.19 
b).  
 
 
 
 
 
 C-tail PAR-2-HA              GAPDH
  1    2    3   4   5   6   M   7    8   9   10  11  12
      186 bp
600 bp
Figure 3.19 a. Detection of C-tail PAR-2-HA PCR signal in transfected HEK 
cells. 4 independent cell clones were checked for presence of C-tail PAR-2-HA fusion 
construct mRNA in stably transfected HEK cells by RT-PCR. Lane 1-4: C-tail PAR-2-
HA clones, lane 5: untransfected HEK cells, lane 6: negative control (H2O), lane 7-10: 
GAPDH signal in transfected clones, lane 11: GAPDH signal in HEK-WT, lane 12: 
negative control (H2O). M: 1 kb DNA molecular ladder.  
Figure 3.18 b. Detection of α-crystallin A -MycHis by western blot in transfected 
HEK cells. Independent clones of a-crystallin A -MycHis were checked for protein 
expression on SDS-PAGE and detected by anti-myc antibody on western blot (20 
kDa). Untransfected HEK cells were negative for myc antibody. Details in Material &
Methods.   
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Another way to detect the C-tail PAR-2-HA fusion protein was to perform 
immuno-staining of the transfected HEK cells. Stable transfected cells exhibiting 
green fluorescence from GFP vector were stained for the presence of HA fusion 
protein with anti-HA primary antibody and fluorescent Alexa 555 secondary antibody 
and were found positive for the HA fusion protein (not shown).   
 
(c) C-tail-PAR-2-HA+Cryaa-MycHis-HEK: HEK cells were double transfected with 
HA and MycHis fusion proteins. RT-PCR analysis of the double transfected cells 
showed equal expression of both constructs at the mRNA level (Figure 3.20 a). At the 
Figure 3.19 b. Silver stained gel for detection of C-tail PAR-2-HA in single 
and double transfected HEK cells. C-tail PAR-2-HA was transfected either 
alone or together with α-crystallin A-MycHis in HEK cells. Whole cell lysate 
prepared by different methods (Materials & Methods) to detect the small ~6.7
kDa protein by silver staining of SDS-PAGE. Lane 1: Protein ladder, Lane 2 & 3: 
single transfected clone (Acetone/Methanol precipitated), Lane 4 & 5: single 
transfected clone (lysate prepared by chloroform extraction and then precipitated),
Lane 6 & 7: single transfected clone (chloroform extracted lysate), Lane 8 & 9:
double transfected clone (acetone/methanol precipitated). 
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protein level it was possible to detect Cryaa-MycHis fusion by western blot using 
monoclonal anti-myc antibody (Figure 3.20 b) but again C-tail PAR-2-HA could not be 
detected by blotting due to its small size. Silver staining of the double transfected cell 
lysate showed the presence of the C-tail PAR-2-HA fusion protein as shown in Figure 
3.19 b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) α-crystallin A Domain1/Domain 2-MycHis-HEK: HEK cells were stably transfected 
with either Domain1 (N-terminal) or Domain 2 (C-terminal) of α-crystallin A cloned in 
Figure 3.20 a. Detection of α-crystallin A-MycHis and C-tail PAR-2-HA PCR 
signal in double transfected HEK cells. 4 independent cell clones were checked 
for presence of α-crystallin A-MycHis and C-tail PAR-2-HA fusion construct 
mRNA in stably transfected HEK cells by RT-PCR. Lane 1-4: α-crystallin A-
MycHis clones, lane 5: untransfected HEK cells, lane 6: negative control,lane 7-
10: C-tail PAR-2-HA clones, lane 11: untransfected HEK cells, lane 12: negative
control (H2O), lane 13-16: GAPDH, lane 17: GAPDH signal in HEK-WT,  lane 
18: negative control. M: 1 kb DNA molecular ladder.  
Figure 3.20 b. Detection of α-crystallin A -MycHis by western blot in double 
transfected HEK cells. Independent cell clones of α-crystallin A -MycHis and C-
tail PAR-2-HA double transfected cells were checked for α-crystallin A-MycHis
protein expression on SDS-PAGE and detected by anti-myc antibody on western 
blot (20 kDa). Untransfected HEK cells were negative for myc antibody. PL: 
protein ladder. Details in Materials & Methods.   
     α-crystallin A-MycHis     PL  HEK-WT
   + C-tail-PAR2-HA-HEK
20 kDa
α-crystallin
A-MycHis
   α-crystallin A-MycHis    Ct-PAR-2-HA                GAPDH
       1     2    3    4    5    6    7    8     9    10  11  12  M   13   14  15   16  17  18
552 bp
186 bp
   600 bp
 pcDNA-MycHis(B) vector similar to full α-crystallin A. RT-PCR analysis of α-
crystallin A Domain1-MycHis transfected cells gave the PCR band of 198 bps as 
expected (Figure 3.21 a), but due to small size (~ 7 kDa) it was not possible to detect the 
protein expression on SDS-PAGE. However, both mRNA (Figure 3.21 b) and protein 
expression (Figure 3.21 c) of α-crystallin A Domain 2-MycHis in transfected cells 
could be detected.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α-crystallin A           GAPDH
Domain 1-MycHis
 1    2    3    4    5    6   7   8    M
600 bp
198 bp
Figure 3.21 a. Detection of α-crystallin A Domain 1-MycHis PCR signal in 
transfected HEK cells. 2 independent clones were checked for presence of α-
crystallin A Domain 1-MycHis fusion construct mRNA in stably transfected HEK
cells by RT-PCR. Lane 1-2: α-crystallin A Domain 1-MycHis clones, lane 3: 
untransfected HEK cells, lane 4: negative control, lane 5-6: GAPDH signal in 
transfected clones, lane 7: GAPDH signal in HEK-WT, lane 8: negative control 
(H2O).M: 1 kb DNA molecular ladder.  
α-crystallin A Domain 2                    GAPDH
-MycHis
  1      2      3      4     5      6      M     7      8      9    10    11   12
600 bp
348 bpFigure 3.21 b. Detection of α-crystallin A Domain 2-MycHis PCR signal in 
transfected HEK cells. 4 independent clones were checked for presence of α-
crystallin A Domain 2-MycHis fusion construct mRNA in stably transfected HEK
cells by RT-PCR. Lane 1-4: α-crystallin A Domain 2-MycHis clones, lane 5: 
untransfected HEK cells, lane 6: negative control (H2O), lane 7-10: GAPDH signal
in transfected clones, lane 11: GAPDH signal in HEK-WT, lane 12: negative 
control.M: 1 kb DNA molecular ladder. 97
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e) C-tail PAR-2-GFP-C2-HEK: C-tail of PAR-2 was subcloned into pEGFP-C2 vector 
from pGBKT7 in-between EcoRI and BamHI restriction sites. HEK cells were transfected 
with the construct and were made stable on the basis of green fluorescence of GFP vector. 
Unlike C-tail PAR-2 HA-HEK construct it was possible to detect the GFP construct 
because GFP by itself is ~27 kDa. Transfected cells were checked for the expression of 
fusion protein by western blot using polyclonal anti-GFP antibody (Figure 3.22).  
 
  
 
 
 
 
 
 
 
  C-tail-PAR-2-         GFP-C2       PL
  GFP-C2-HEK          -HEK
Figure 3.22. Detection of C-tail-PAR-2-GFP-C2 by western blot in transfected 
HEK cells. Independent clones of C-tail-PAR-2-GFP-C2-HEK (~34 kDa) were
checked for protein expression on SDS-PAGE and detected by anti-GFP antibody on 
western blot. GFP-C2 (empty vector) transfected HEK cells were used as positive 
control for GFP antibody. PL: protein ladder. Details in Materials & Methods.   
Figure 3.21 c. Detection of α-crystallin A Domain 2-MycHis (CD2) by western 
blot in transfected HEK cells. Independent clones of α-crystallin A Domain 2-
MycHis-HEK were checked for protein expression on SDS-PAGE and detected by 
anti-myc antibody on western blot (13 kDa). Detection of α-crystallin A -MycHis-
HEK used as a positive control for anti-myc antibody. PL: protein ladder. Details in 
Materials & Methods.  
 PL   α-crystallin A Domain 2-MycHis (CD2)-HEK      α-crystallin 
                                                                                   A-MycHis-
                                                                                   HEK 
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3.2.16 Co-immunoprecipitation 
 
To confirm the protein-protein interaction observed in yeast it was important to 
perform a biochemical assay showing the interaction in another system and thus 
validating the results obtained in yeast-two hybrid. For this, co-immunoprecipitation 
assay was done in mammalian expression system. Both the bait and prey constructs 
after verification for protein expression in double transfected HEK cells were used for 
co-immunoprecipitation assay. 2 mg of whole cell lysate was used. Double transfected 
clones precipitated with anti-HA antibody and protein A on detection with anti-myc 
antibody gave a positive signal indicating that α-crystallin A-MycHis binds to bait C-
tail PAR-2-HA and hence could be detected on blot. This proves that there exists 
interaction between α-crystallin A-MycHis and C-tail PAR-2-HA. The specificity of 
this interaction was confirmed by negative results obtained when the same double 
transfected lysate was incubated with only protein A excluding anti-HA antibody. This 
negative control indicates that the binding of C-tail PAR-2-HA is specific with anti-HA 
antibody and not by means of protein A. Also incubation of HEK-WT cell lysate with 
both anti-HA antibody and protein A gave negative results again confirming specificity 
of interaction (Figure 3.23). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. Co-immunoprecipitation of double transfected HEK cells. HEK cells 
transfected with α-crystallin A-MycHis and bait C-tail PAR-2-HA were precipitated with 
anti-HA antibody (sigma) and protein A. α-crystallin A -MycHis was detected using anti-
myc antibody on western blot from the precipitated sample indicating positive interaction
between the two proteins. Double transfected lysate without anti-HA antibody and only 
protein A and HEK-WT lysate with both anti-HA antibody and protein A were negative on 
western hence indicating the specificity of the co-immunoprecipitation reaction. Single 
transfected α-crystallin A-MycHis and HEK-WT were used during western blot as a 
positive and negative control respectively for the anti-myc antibody.  
                       IP: Anti-HA   &   WB: Anti-Myc
Anti-HA Ab:        +        +        -         -         -
Protein A :          +        +        +        -         -
 DT       WT    DT       ST      WT
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3.2.17 Co-localisation of PAR-2 and α-crystallin A in Hippocampal astrocytes 
 
Out of the tissues and cell types studied, Hippocampal astrocytes apart from 
retina, optic nerve and brain were positive for α-crystallin A mRNA expression. 
Hence, to confirm the interaction between PAR-2 and α-crystallin A in a system 
endogenously expressing both proteins immunostaining of hippocampal astrocytes 
were done using PAR-2 and α-crystallin A specific antibodies. Hippocampus is 
known to express PAR-2 (Striggow et al., 2001). Double staining of hippocampal 
astrocytes with PAR-2 and α-crystallin A antibodies (1:100) and subsequent 
fluorescent detection by means of Alexa conjugated IgG (488 and 555) gave positive 
detection for both proteins in the system. Similar to its cellular localisation in 
transfected N2A cells, α-crystallin A was localised in cytosol of hippocampal 
astrocytes. PAR-2 showed both membrane and cytosolic localisation. Overly of green 
(α-crystallin A) and red (PAR-2) fluorescence gave yellow colour indicating that both 
the proteins are co-localised in hippocampal astrocytes (Figure 3.24). Appropriate 
negative controls were also done.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α-crystallin A                         transmission
           PAR-2                                  overlay                          
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Figure 3.24. Co-localisation of α-crystallin A and PAR-2 in hippocampal 
astrocytes by immunodetection. Hippocampal astrocytes were stained for the 
presence of both α-crystallin A and PAR-2 using specific antibodies (1:100). 
Fluorescent detection with Alexa A488 (green- α-crystallin A) and A555 (red-
PAR-2) (1:100) showed co-localisation of both proteins in hippocampal 
astrocytes. 
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4. Discussion 
 
4.1 Expression of PARs after CNS injury 
 
In recent years Protease-activated receptor has emerged as one of the key 
player involved in tissue injury and inflammation (Coughlin and Camerer, 2003). Data 
particularly on CNS injury, bring into focus the need to study the change in PAR 
expression after trauma and stroke induced by various stimuli since both serine 
protease thrombin, which is an agonist for PAR-1, -3 and –4, and PARs play an 
important role in the sequence of events leading to either brain damage or protection 
as a result of CNS injury (Gingrich and Traynelis, 2000; Xi et al., 2003). 
 
4.1.1 mRNA expression of the 4 PAR subtypes in the rat developing eye and adult 
retina  
Distribution of PAR-1-4 has been well studied and characterized in several 
tissues and cell types (Weinstein et al., 1995; Ishihara et al., 1998; Niclou et al., 1998; 
Steinhoff et al., 1999), but the presence and expression pattern of these receptor 
subtypes in retina are unknown. Previous studies from our laboratory had shown the 
presence of these receptors in different areas of brain (Striggow et al., 2001) and in 
brain astrocytes (Wang et al., 2002a). In the current study, presence and expression of 
PARs in post-natal rat eye and adult retina were detected for the first time using RT-
PCR. A comparison of expression patterns of these receptor subtypes during the 
different developmental stages of eye (P1, P9 and P16) clearly shows that each 
subtype is expressed to a different degree.  
Unlike for the other PARs, a decrease in PAR-1 mRNA expression from P1 
and P9 to P16 in the post-natal eye was observed. The results on PAR-1 mRNA 
expression during eye development presented in this study are consistent with an 
earlier study showing a decrease in PAR-1 mRNA intensity from embryonic (E14, 
E18), post-natal (P0) to adult brain (P28) by Northern analysis (Niclou et al., 1998). 
Nevertheless, in the same study it was found that in spinal cord the PAR-1 mRNA 
signal remained identically high throughout the different stages of embryonic and 
post-natal development (Niclou et al., 1998). However, Niclou et al. (1998) mention 
that the mRNA signal observed in neural tissue by Northern analysis was comparable 
to that observed for a neuroblastoma cell line. In the neuroblastoma cells, a 
physiological response to thrombin due to PAR activation could be found. This 
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observation suggests that even the low level of these receptors in the embryonic and 
post-natal stages is probably enough for functional activity. In the retina of the adult 
rat, we could detect strong signals for PAR-1, moderate signals for PAR-2 and PAR-3, 
while PAR-4 was expressed at low levels.  
 
4.1.2 The mRNA levels of PAR receptors in retina in response to ONC 
 
In last decade since the cloning of PAR-1, PARs have been studied quite 
extensively as an important factor in tissue injury (Friedmann et al., 2001a) and injury 
models (Napoli et al., 2002; Striggow et al., 2000; Xi et al., 2003). These receptor 
subtypes are also widely implicated in tissue repair (Striggow et al., 2000; Vaughan et 
al., 1995; Xi et al., 2003). Activation of PARs leads to several downstream processes, 
like Ca2+ influx from intracellular stores (Ubl and Reiser, 1997), various signalling 
cascades resulting in proliferation (Wang et al., 2002a; Wang et al., 2002b; O'Brien et 
al., 2001; Saifeddine et al., 1996; Bohm et al., 1998), apoptosis (Cunningham and 
Donovan, 1997; Turgeon et al., 1998) and inflammation (Steinhoff et al., 2000; 
Vergnolle et al., 2001a).  
In this study all 4 PAR subtypes were found to be upregulated in retina as a 
result of controlled ONC, a model of partial nerve crush (Sautter and Sabel, 1993). 
The mild ONC is enough to shear but does not completely axotomize the nerve axons. 
Studies using this model have shown a loss of almost 70-80% retinal ganglion cells 
(RGCs) as a result of an early necrosis and subsequent apoptosis within 2 weeks after 
injury (Sautter and Sabel, 1993; Kreutz et al., 1997; Bien et al., 1999). Near-complete 
spontaneous behavioural recovery was observed two to three weeks post-injury after 
the mild crush, but only 28% and 11% of RGCs survived at two and fourteen days, 
respectively, after crush (Sautter and Sabel, 1993). Upregulation of PAR mRNA levels 
6 h after ONC shows an early response to injury. A similar increase in PAR-1 mRNA 
expression has been reported to occur as a consequence of spinal cord injury (Citron et 
al., 2000) and non-neuronal sciatic nerve injury (Niclou et al., 1998). In ipsilateral 
retina after ONC, it was found that PAR-1 mRNA reached maximal levels of 2.3-fold 
one week post-crush and then came down to basal value by the end of 21 days. Citron 
et al., (2000) observed a maximal increase in PAR-1 mRNA levels of 4-fold at one 
day post-injury, then reduced levels by day 3, which declined to basal level by day 28 
post-injury. Also sciatic nerve lesion resulted in an increased PAR1 mRNA expression 
in the proximal and distal part of the lesioned nerve (Niclou et al., 1998). In the case of 
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sciatic nerve injury a rise in PAR-1 mRNA expression at day 1 with a subsequent very 
pronounced increase at day 4 and 7 after injury was observed by Niclou et al. (Niclou 
et al., 1998). In the same study, a substantial decrease in PAR-1 mRNA expression in 
the lesioned motoneurons of facial nerve was found, which is in contrast to increased 
PAR-1 mRNA expression after non-neuronal sciatic nerve injury.  
The varied behaviour of PAR-1 mRNA expression in response to different 
types of neuronal and non-neuronal lesions highlights the fact that the receptor 
expression is not static, but depends on lesion intensity and tissue type. Festoff and co-
workers (Citron et al., 2000) attributed the increase in PAR-1 mRNA levels to 
increased prothrombin mRNA levels at the site of injury. Increase in thrombin levels 
at the proximal site of injury have indeed been reported (Friedmann et al., 1999; 
Friedmann et al., 2001a). In these studies a partial ONC in adult rat was used, which is 
very similar to the approach we have used. In injured optic nerve an up-regulation of 
thrombin-like activity was found as early as 6 h after the crush (Friedmann et al., 
2001a; Friedmann et al., 1999), which peaked at day 1 (40-fold high) and then 
returned to basal levels by day 4 to 7. The observation of early thrombin up-regulation 
after crush provides strong support for functional implications of the present finding of 
PAR upregulation in retina 6 h after nerve crush.  
However, the amplitude and time course of increase in mRNA levels observed 
for the 4 PARs in retina after crush differ from each other. In case of ipsilateral retina, 
PAR-1 showed a maximal value of 2.3-fold observed on day 7, while PAR-2 and 
PAR-3 showed this level of mRNA expression only at 12 h post-crush. PAR-4 seems 
to be the most strongly affected receptor subtype, reaching a maximal level of 6.1-fold 
at 12 h after crush. The reason for this difference in the expression of the 4 subtypes is 
not yet clear, but this could be due to differences in the innate regulatory mechanism 
of these receptors. Detailed studies have already been done to explore the signalling 
pathways of PAR-1 (Wang et al., 2002a; Wang and Reiser, 2003a), whereas limited 
information pertaining to intracellular signalling from PAR-2 is available (Kanke et 
al., 2001), and almost nothing is known about the downstream signalling from PAR-3 
and PAR-4. 
Another important finding of this study is the fact that as a result of unilateral 
injury the contralateral uninjured side is also affected, as already seen before by others 
(Yew et al., 1990; Shibuya et al., 1993; Lam et al., 1996; Bodeutsch et al., 1999). The 
extent of change in receptor mRNA levels between injured and uninjured retina was 
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comparable in our study. Compared to the ipsilateral retina, mRNA levels of PAR-1 
and PAR-2 in the uninjured side showed a significant maximal increase of 1.8-fold 
during the time period of study. PAR-4 mRNA levels rose to a significantly high level 
of 2.2-fold, while increase in PAR-3 level was not so significant. Bodeutsch et al., 
(1999) observed a moderate c-jun immunoreactivity, up-regulation of astrocytes and 
microglial cells in the contra-lateral uninjured retina and optic nerve. Bodeutsch et al., 
(1999) presented interesting reasoning for such a bilateral effect after unilateral lesion: 
The retinotectal pathway is a very closely linked pathway and both sides behave 
identical to compensate for the loss of cells even when only one side is injured. 
According to them this effect of unilateral nerve lesion on the contra-lateral uninjured 
retina is rather confined to changes at the cellular level with little direct effect on the 
majority of axons. More recently, Bodeutsch et al., 2000 could demonstrate cell death 
in the contra-lateral retina as an outcome of unilateral ONC in adult mice. They 
showed a gradual decrease of retrogradely labeled RGC and their replacement by 
retinal microglia after ONC. They observed only 25% and 10% of RGCs at 5 and 7 d 
post-crush, respectively (Bodeutsch and Thanos, 2000).  
Schwartz and co-workers (Friedmann et al., 1999; Friedmann et al., 2001a) 
have shown that thrombin-like activity in the retina remains almost unchanged after 
the nerve crush, but they detected that prothrombin becomes activated at the site of 
injury by extravasation from the blood vessels and that injury-induced activity is 
restricted to the proximal part of injured nerve and associated to retrograde 
degeneration. This retrograde degeneration towards the optic disk may be somehow 
responsible for the exposure of retina to increased thrombin levels after injury and 
hence activation and up-regulation of PARs. Both necrosis and apoptosis have been 
reported as a cause for retrograde degeneration and cell death of RGCs as a result of 
optic nerve lesions including crush and axotomy (Garcia-Valenzuela et al., 1994; 
Rabacchi et al., 1994; Isenmann et al., 1997; Bahr, 2000; Cellerino et al., 2000; 
Friedmann et al., 2001b). Studies using PAR-1 knockout mice have shown increased 
RGC survival as compared to the wild-type mice after ONC (Friedmann et al., 2001b). 
In the same study T cell-induced decrease in endogenous thrombin activity and 
degeneration was observed when T cells were administrated to rat prior to ONC 
(Friedmann et al., 2001b). In the present study we can provide a hypothesis explaining 
cell death in the ONC model of mild trauma. According to data in (Citron et al., 2000), 
the increase in PAR-1 expression after injury and the presence of active thrombin at 
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the site of injury cause PAR-1 upregulation and activation. Activation of PARs leads 
to increased intracellular Ca2+, followed by caspase activation and subsequent 
apoptosis. Apoptosis of RGCs and its association with rise in intracellular Ca2+ is 
known to be a consequence of lesions of the optic nerve (Cellerino et al., 2000). Cell 
death in the contra-lateral retina as an outcome of unilateral ONC in adult mice has 
also been attributed to programmed cell death and subsequent phagocytosis by the 
retinal microglia cells (Bodeutsch and Thanos, 2000). Earlier studies from our 
laboratory using in vivo confocal neuroimaging technique have followed the time 
course and extent of change in soma size (Rousseau et al., 1999) and observed 
increased intracellular calcium activity after ONC (unpublished data). Also seen was 
an early necrosis followed by apoptosis of RGCs after ONC (Bien et al., 1999) and an 
increase in mRNA levels for interleukin converting enzyme (ICE; caspase-1) as a 
result of nerve crush (unpublished data).  
With findings from the present study we clarified further the series of events 
taking place as a result of mild nerve crush in retina. Thus, increase in thrombin 
activity at the site of injury as a consequence of nerve crush is associated with 
stimulation of upregulation of PARs. This, in turn, leads to intracellular Ca2+ 
mobilization followed by RGC degeneration due to necrotic and apoptotic 
mechanisms. Thus, PAR activation in this nerve crush model may act as effector of 
cell death by an early necrosis and subsequent apoptosis. The evidence pertaining to 
cell death mechanism in both the injured and uninjured retina and Ca2+ increase 
response rules out the possibility that the observed PAR mRNA increase is only a 
consequence of stress effects during or after nerve injury (Papadaki et al., 1998; 
Nguyen et al., 2001a; Nguyen et al., 2001b).  
The eventual decrease in the receptor mRNA levels by the end of three weeks 
after crush, except for PAR-2, to almost basal levels, as seen in this study, may also 
result from eventual decrease in thrombin activity. Hence, shutting-off the whole 
hyperactivity cascade that is triggered by an insult to the system, and return back to 
normal levels is required for basal activity and maintenance of the system.  
 
4.1.3 PAR mRNA levels after transient focal ischemic 
 
To further elucidate the behaviour of PAR mRNA expression in another type 
of CNS injury, transient focal ischemia as a model of stroke was studied. In the 
present work, microinjection of endothelin-1 was used as a tool to generate ischemia 
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with reperfusion resulting in a mild specific stroke damage in rat brain. Endothelin is a 
peptide of 21 amino acids and the most potent vasoconstrictor known (Levin, 1996). 
Application of endothelin near the MCA in a model of focal cerebral ischemia results 
in a dose-dependent, reversible vasoconstriction along with a considerable reduction in 
cerebral blood flow and causes subsequent cerebral infarction (Sharkey et al., 1994; 
Reid et al., 1995). Use of endothelin receptor antagonist had shown that endothelin is 
involved in the development of secondary brain damage (Gorlach et al., 2001). 
Endothelin levels were found to be elevated in the cerebrospinal fluid (CSF) and 
plasma of ischemic stroke patients (Lampl et al., 1997) and in patients suffering from 
subarachnoid hemorrhage and cerebral infarction (Zimmermann and Seifert, 1998). 
These studies highlight a possible role played by endothelin in the pathophysiology of 
ischemia and stroke.  
Ischemia induced by intracerebral microinjection of endothelin close to the 
MCA caused infarction in cortical areas. The environment, conditions and brain areas 
affected by MCAO are largely different from the conditions to which the organotypic 
hippocampal slices were exposed to during and after OGD (Striggow et al., 2001). 
Hence it was of no surprise that a different effect in terms of PAR mRNA expression 
was observed in the present experiments as compared to the study done before 
(Striggow et al., 2001). 
Semi-quantitative RT-PCR analysis of PAR-1-4 expression resulted in a 
substantial reduction in the mRNA levels of PAR-1 and PAR-2 after the insult in the 
ipsilateral hemisphere in this study, unlike the up-regulation observed by (Striggow et 
al., 2001) in the hippocampal slice cultures 24 hrs after 30 min OGD. The mRNA 
expression pattern of PAR-3 in the present in vivo study here and in the in vitro 
experiments (Striggow et al., 2001) both showed a transient increase. In the current 
study, we obtained a transient increase at 12 h, after which the mRNA levels 
subsequently declined to lower than half the control levels by the end of one week. In 
contrast to the results which we obtained for PAR-1 to -3, PAR-4 showed the most 
striking up-regulation at 12 h after ischemia which declined gradually, but was still 
maintained at substantially elevated level one week later. This behaviour of PAR-4 
after transient focal ischemia is similar to the results obtained for PAR-4 mRNA 
expression after ONC in retina. In the work by (Striggow et al., 2001), no RT-PCR 
analysis for PAR-4 was performed. Interestingly, in a recent study from our laboratory 
PAR-1-3 mRNA expression was found to be unaltered after global ischemia (Riek-
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Burchardt et al., 2002). A comparison between the OGD study (Striggow et al., 2001), 
global ischemia (Riek-Burchardt et al., 2002) and the present study involving transient 
focal ischemia highlights the specificity in the regulation of PAR mRNA expression as 
a consequence of different modes of inducing ischemia. Studies assessing the effect of 
focal ischemia emphasise the role of secondary mechanisms initiated by an acute 
inflammatory response, including breakdown of blood-brain barrier, edema, induction 
of proinflammatory cytokines, activation of leukocytes, macrophages and activation of 
microglial cells (Gehrmann et al., 1992; Buttini et al., 1994; Garcia et al., 1994). 
Cerebral ischemia exposes the brain tissue to reduced blood glucose in an endogenous 
immune reactive environment, while such interplay of blood borne immune cells is 
absent during in vitro OGD. The effect of inflammatory stimuli on PAR activation has 
already been demonstrated in epithelial and endothelial cells (Hamilton et al., 2001; 
Asokananthan et al., 2002).  
PAR-1 was also found to be down-regulated in a human neuronal cell line after 
hypoglycemia (Weinstein et al., 1998) and the authors proposed this response to be an 
effective way to attenuate the ability of thrombin to damage the neuronal cells during 
metabolic insult via PAR-1 activation (Weinstein et al., 1998). In the same study 
(Weinstein et al., 1998), it was shown that hypoxia and oxidative stress on the other 
hand had no effect on PAR-1 expression, demonstrating the difference in PAR-1 
behaviour following different metabolic insults (Weinstein et al., 1998). Evaluation of 
the role of PAR-2 in inflammation and tissue injury using a myocardial ischemia- 
reperfusion model revealed that PAR-2 activation protected against reperfusion-injury 
and resulted in significant recovery of myocardial function (Cirino et al., 2000).  
Besides the changes observed in PAR mRNA expression in the ipsilesional 
hemisphere, also the contralateral side was found to be affected. Here, PAR-1 to -3 
mRNA levels were down-regulated, while PAR-4 showed a transient up-regulation 
until 48 h and then declined to almost half the control levels. A recent fMRI study 
examined the bilateral changes and their relation to functional brain recovery after 
transient focal ischemia in rat (Dijkhuizen et al., 2003). There was a shifting of brain 
activation to the contralateral side initially after stroke which was directly proportional 
to the extent of tissue injury. However, the functional recovery was associated more 
closely with the restoration of activation in the ipsilateral hemisphere (Dijkhuizen et 
al., 2003). This means that the change in PAR expression on the contra-lateral side in 
the present study might be part of a compensatory reaction to a severe ischemic effect 
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resulting in a shifting in brain activity. The changes on the contralateral side could also 
reflect induction of tolerance. 
We found that especially the thrombin receptors PAR-1, 3 and 4 were affected 
as a result of endothelin-1-induced transient focal ischemia, which implies that 
thrombin should be produced or present at the site of injury (Smirnova et al., 1996). 
There is ample evidence in the literature which suggests that prothrombin as the 
precursor molecule of thrombin is present in brain under normal conditions (Dihanich 
et al., 1991). Prothrombin is upregulated after global cerebral ischemia (Riek-
Burchardt et al., 2002), spinal cord injury (Citron et al., 2000), sciatic nerve injury 
(Smirnova et al., 1996) and subarachnoid hemorrhage (Suzuki et al., 1999). Increased 
thrombin-like activity has been detected in CNS and PNS nerve injury models 
(Smirnova et al., 1996; Friedmann et al., 1999). In case of sciatic nerve injury in 
mouse it has been shown that injury induced an increase in prothrombin level and 
subsequently in thrombin enzymatic activity (Smirnova et al., 1996). An earlier study 
from our laboratory has shown the involvement of endogenous thrombin in ischemia-
induced degeneration in the hippocampus (Striggow et al., 2000) thus clearly 
demonstrating that thrombin is produced in brain in response to ischemia. 
Additionally, it is known that as a result of stroke, the blood-brain barrier is 
compromised, giving rise to the possibility of entry of thrombin from plasma into 
brain (Cunningham et al., 1993; Gingrich and Traynelis, 2000). Also, thrombin is 
generated at the site of inflammatory reactions after brain damage and PARs 
orchestrate an important role as mediators of inflammation (Cirino et al., 2000; Cocks 
and Moffatt, 2000). There are some reports about the role of PARs in inflammation 
which point to the fact that not only activation of PAR-1 contributes to the thrombin-
induced pro-inflammatory action but that also PAR-3 and –4 may be involved (Cirino 
et al., 2000; Cocks and Moffatt, 2000; de Garavilla et al., 2001; Vergnolle et al., 
2002). 
Taken together, the diverse roles of PARs including effect of change in PAR 
expression level in mechanisms related to tissue injury fit well with the results which 
we have obtained, indicating a possible role for PAR-1, PAR-3 and PAR-4 activation 
in the sequence of events leading to pathophysiology of focal ischemia. 
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4.2 Identification of a putative interacting protein for PAR-2 using yeast 
two hybrid system 
 
The second main aim of the present study was to further the knowledge with 
regard to trypsin-activated PAR-2, since this is the most well documented receptor 
subtype in the scenario of injury and inflammation (al-Ani et al., 1995; Damiano et al., 
1999a; Steinhoff et al., 2000; Knight et al., 2001; Shpacovitch et al., 2002). Inspite of 
being studied so thoroughly as an important component after tissue injury and repair 
little is known with regard to PAR-2 intracellular downstream signalling cascades 
(Macfarlane et al., 2001). To this effect we tried to identify probable interacting 
proteins for PAR-2 utilising the yeast two-hybrid screen and enhance our 
understanding of PAR-2 intracellular signalling mechanism. Already similar studies 
done with C-tail of PAR-1 have identified creatine kinase (Mahajan et al., 2000) and 
Hsp 90 (Pai et al., 2001) as PAR-1 interacting proteins.  
 
4.2.1 Library Construction and Screening 
 
The C-terminal of rat PAR-2 (50 amino acids) was cloned in DNA-BD vector 
pGBKT7 to generate a bait fusion protein. The reasons for selecting only the C-
terminus of the receptor as a bait in the present study were two-fold. First, since PAR-
2 is a 7-transmembrane receptor it was possible that the transmembrane (TM) region 
of the receptor might have had problems entering the yeast nucleus and second, there 
was a successful example in the studies done with PAR-1, which had used only the C-
tail of the receptor (Mahajan et al., 2000; Pai et al., 2001).  
Before starting with the library transformation and screening, bait protein was 
tested for proper growth in both solid and liquid complete medium. This was 
important as some proteins are either expressed in very low amount or are over-
expressed and toxic to the yeast cells. In the present study the C-tail of PAR-2 cloned 
in pGBKT7 i.e., the ‘bait’ grew at a comparable rate with the empty pGBKT7 vector 
and hence was suitable to be used for library screening. However, comparison between 
the two yeast strains AH109 and Y187 transformed with bait showed that bait grew 
better in AH109 as compared to Y187. Testing of the bait protein for transcriptional 
activation (Table 3.3) gave negative results, thus confirming that neither the bait 
protein by itself nor together with empty pGADT7-Rec (library plasmid) is capable of 
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transcriptional activation of reporter genes in yeast, and hence can be used for yeast 
library protocol. AH109 and Y187 transformed with bait protein on SD/-Trp/-His did 
not exhibit any background growth and were negative for HIS3 leaky expression. 
Therefore, for library transformant screening 3-AT (3-amino-1,2,4-triazole), a 
competitive inhibitor of yeast HIS3 protein was not used in the medium and since 
further selection of the positive clones was made for both HIS3 and ADE2 expression 
it eliminated the need to use 3-AT in the initial library screening. 
For screening procedure it was possible either to use a pre-transformed library 
or to make a cDNA library by itself. For this study it was decided to use the C-tail 
PAR-2 as a bait with self-made cDNA library. Rat retina poly A+ RNA was used to 
generate ds cDNA for the library. Since the PAR mRNA expression study showed the 
presence of PAR-2 in retina and sustained effect of ONC on PAR-2 mRNA expression 
unlike PAR-1, -3 and –4 (Figure 3.4) it was decided to use retina as the source for 
preparing ds cDNA for the library. 
At every point during library transformation and screening protocol suitable 
controls were performed simultaneously to keep a check on the whole procedure. 
During ds cDNA preparation care was taken to use random primer rather then oligo 
(dT) primer so as to generate cDNA with an equal proportion of 5’ and 3’ end 
different sequences instead of only 3’ end sequences. The use of SMART III oligo 
during cDNA synthesis resulted in generation of ss cDNA’s containing the complete 
5’ end of the mRNA as well as sequence complementary to the SMART III oligo, 
which then served as a universal priming site in the subsequent amplification by long-
distance PCR (LD-PCR). Thus, ds cDNA generated by LD-PCR containing 5’ 
SMART sequence and 3’ random primer sequence was suitable for in vivo 
homologous recombination with pGADT7-Rec during AD fusion library construction 
in yeast (Figure 4.1). 
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eFigure 4.1. Construction of AD fusion libraries by recombination-mediated cloning 
in yeast (Matchmaker Library construction and screening manual, Clontech,
Heidelberg, Germany). Co-transformation of ds cDNA with Sma I-linear pGADT7-Rec 
restores the plasmid with help of yeast repair enzymes to its circular form by
recombining sequences at the end of cDNA with homologous sequences at the ends of
pGADT7-Rec. The resultant vector is a fully functional GAL4 AD/cDNA expression
vector.  112
 
For library transformation in yeast, sequential transformation was done unlike 
the co-transformation as recommended by the Library construction manual (Clontech, 
Heidelberg, Germany). In case of co-transformation protocol it is possible to introduce 
the bait protein, ds cDNA and Sma I-linear pGADT7-Rec together into the yeast 
reporter strain, but the chances of all the three components been taken up by the same 
yeast cell may not be so good. In order to avoid this problem AH109 was sequentially 
transformed. First the yeast was transformed with the bait protein and then the bait 
containing AH109 were made competent under the appropriate selection pressure to 
retain bait protein in the competent cells and re-transformed with retina ds cDNA and 
Sma I-linear AD plasmid. The linear pGADT7-Rec was restored to its circular form by 
recombination with overlapping sequences at the 5’ and 3’ end of cDNA giving a 
complete GAL4 AD expression vector (Figure. 4.1). The division of the whole 
transformation procedure into two separate individual processes was done to maximise 
the efficiency and increase the probability of bait containing yeast competent cell 
receiving the AD fusion library plasmid. To validate the library transformation 
protocol, positive and negative control transformations were done simultaneously. 
Library transformants were grown on appropriate selection medium to check for 
transformation efficiency and number of library clones screened. In both cases the 
value obtained matched with the expected results thus verifying the whole 
transformation procedure. 
 To check for positive interacting clones transformants were selected through a 
eries of stringent media suitable for expression of reporter genes. In the first step 
ransformants were selected for His+ reporter gene expression along with tryptophan 
nd leucine which are markers for the DNA-BD and AD plasmids, respectively. The 
lones were made to grow for 4-6 days so as to provide enough time even for the weak 
nteracting clones to appear. All the clones (big or small) grown after library 
ransformation on TDO plates were restreaked to select for His+ reporter gene 
xpression once again and to eliminate in the process some of the weak clones. The 
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HIS3 reporter is the most sensitive, but also the least selective, generating large 
numbers of false positives. As mentioned earlier, since AH109 containing bait protein 
showed no background growth on SD/-Trp/-His medium hence 3-AT was not used to 
suppress HIS3 leaky expression. In the second round clones were streaked to select for 
Ade+ positives. To eliminate false positive clones grown in –His medium, clones were 
grown under both –Ade and –His selection pressure, since ADE2 reporter is most 
selective, eliminating almost all false positives. Although ADE2 reporter is too 
stringent, it provides a powerful secondary screen in combination with other reporter 
genes (MacDonald Paul N., 2001). Colonies lacking ability to survive -Ade selection 
turned pink and subsequently red. This phenotypic selection for adenine reporter gene 
expression, too, helped in reducing the selection of false positive clones. Apart from 
His+ and Ade+ selection for interacting protein, yeast strain AH109 also allows for 
third reporter gene assay i.e., lacZ coding for β-galactosidase enzyme. This reporter 
gene expression is based on phenotypic selection of blue or white colonies. X-gal, the 
substrate for β-galactosidase has the ability to turn colonies blue in case of positive 
expression or remained white indicating lack of β-galactosidase expressing positive 
clones. To check for lacZ gene, colonies were filter lifted from –Ade/-His plates and 
observed for appearance or lack of blue colour after incubation with X-gal. Thus, 
screening for all three reporter genes was done individually step by step to avoid 
selection of false positive clones. Repetition of filter lift assay was done to screen for 
the positive clones under most stringent conditions. For the transformation and 
screening procedure use of yeast strain AH109 was most effective, since it utilises not 
one but three reporter gene constructs which provide the opportunity to eliminate many 
false positives. In AH109 the three reporter constructs use different promoters (Table 
4.1) hence acting as an internal control, because many false positives result from a 
specific interaction with sequences within the promoter region (MacDonald Paul N., 
2001).  
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Table 4.1. Reporter gene constructs in yeast strains AH109 and Y187 (Matchmaker 
Library Construction and Screening Manual, Clontech, Heidelberg, Germany). The 
HIS3, ADE2 and MEL1/lacZ reporter genes in AH109 are under the control of three 
completely different heterologous GAL4-responsive UAS and promoter elements- 
GAL1, GAL2 and MEL1, respectively. Strain Y187 contains the lacZ reporter gene 
under control of the GAL1 UAS. 
 
AH109 Constructs 
GAL1 UAS GAL1 TATA HIS3 
 
GAL2 UAS GAL2 TATA ADE2 
 
MEL1 UAS MEL1 TATA lacZ 
 
MEL1 UAS MEL1 TATA MEL1 
 
Y187 Construct 
GAL1 UAS GAL1 TATA lacZ 
 
 
Clones positive for Ade+, His+ and lacZ+ needed to be identified and verified 
further. Since the interest was to identify only the AD/library clones for further 
processing, selection medium favouring growth of AD/library plasmid was used and 
AD/library plasmids were isolated from the positive clones. The yeast plasmid DNA 
isolated is not good for any downstream analysis because of heavy genomic DNA 
contamination, low copy number and low plasmid yield. So in order to obtain AD 
clones DNA in a pure form and large amount for any further analysis, in the next step 
E.coli was transformed with yeast plasmid DNA. As the quality of the yeast plasmid 
DNA isolated is not good, electrical transformation i.e., electroporation was done 
instead of chemical based transformation of bacteria, as electroporation has several 
fold higher transformation efficiency compared with chemical transformation. To 
check for the presence of similar size insert, the clones were digested with a restriction 
enzyme and subsequently sequenced to identify the fragment.  
Of the 65 AD positive clones, sequence of only 27 clones matched with known 
sequences in the databank both at nucleotide and protein level, while the rest of the 
clones gave ribosomal RNA, only vector sequence and some sequences not matching 
with anything known in the databank. It was important to verify the sequences not 
 115
only at the nucleotide level but also at the protein level since interaction in yeast 
occurs at the protein level and any sequence without meaningful protein makes no 
sense in pursuing further. From the 27 matched sequences some were present only one 
time while few were represented in duplicate or more. Before analysing the clones 
further, they were re-tested in yeast one more time for confirmation of interaction and 
further elimination of false positives by mating procedure.  
Yeast mating allowed target proteins expressed in two different haploid yeast 
strains of opposite mating type to come into contact, resulting in fusion of the two 
haploids to form a diploid yeast strain. It is possible to determine the interaction 
between the proteins by analysing the reporter gene expression in the diploid strain. To 
eliminate the scope for selection of false positives, each AD/library clone was mated 
with yeast strain expressing three different DNA-BD plasmids: empty pGBKT7, bait-
pGBKT7 and control pGBKT7 containing an unrelated fusion protein and selected for 
Ade+, His+ and lacZ+. True positives are those AD library clones exhibiting reporter 
gene expression only when AD plasmid is introduced by mating with yeast strain 
expressing plasmid encoding bait-pGBKT7 (MacDonald Paul N., 2001). After 
repeating the screening procedure similar to initial library transformation with 
different stringent growth media to check for reporter genes (Ade+ and His+) and blue 
colonies for positive lacZ expression only one clone gave positive for all the three 
reporter genes in the present study when mated with bait-pGBKT7 only and not with 
control plasmids.  
The clone 34/19 B identified as rat crystallin, α polypeptide A (Cryaa) mRNA. 
Sequence verification of the clone 34/19 B showed the presence of α-crystallin A 
coding sequence after the SMART III oligo sequence of pGADT7-Rec. The α-
crystallin A fragment starts with base pair 21 and found to be in-frame in the 
AD/library clone. On checking the list of 27 clones six matched with α-crystallin A 
mRNA, but surprisingly only one clone was positive for all three reporter genes after 
retesting of AD clones by mating. Sequence analysis of 6 α-crystallin A clones 
showed the presence of two patterns. In clone 34/19 B, 25/12 A and 30/5 A, SMART 
III oligo sequence was followed by α-crystallin A mRNA sequence, while in clone 3/9 
B, 16/1 B and 23/1 A, in-between SMART III oligo sequence and α-crystallin A 
mRNA sequence was present 45-60 bps of unknown sequence. However, the α-
crystallin A mRNA sequence was in-frame in all 6 clones but in none of the cases the 
clones were complete. The coding region of α-crystallin A (Accession No. 
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NM_012534) starts from base 13-534 corresponding to 522 bps and 174 amino acids. 
Two clones contained the start codon but ~ till bp 360, while two other clones 
corresponded to fragment size 15-363 bp, one clone was comparatively small from 63-
330 bp. The 6th clone i.e., 34/19 B was the longest from 13-955 bp including the 3’-
untranslated region of the gene.  
Reconfirming for the positive clone between the 6 α-crystallin A clones 
resulted again in only clone 34/19 B  positive for Ade+, His+ and lacZ+. From these 
experiments it is difficult to find a reason with regard to the difference in behaviour of 
α-crystallin A clones except that maybe 3’-region of the protein is more important 
than the initial N-terminal residues since five out of six clones finish at 360 bp or so. 
But this aspect of region specific interaction of α-crystallin A with C-tail of PAR-2 
needs further experimentation and analysis. 
Apart from the cytoplasmic tail PAR-2 also contains 3 cytoplasmic loops. 
Transmembrane signalling involving G-proteins is known to occur via the 3rd 
cytoplasmic loop of the PAR-1 receptor (Chen et al., 2001). Hence not only the C-tail 
but the intracellular loops are important components of receptor signalling mechanism. 
As done in earlier studies of similar type with PAR-1 (Mahajan et al., 2000; Pai et al., 
2001) in the present study too cytoplasmic loop 2 and 3 of rat PAR-2 were checked for 
interaction with α-crystallin A in yeast. The cytoplasmic loop 2 and 3 of rat PAR-2 are 
very small and consist of only 21 and 23 amino acids, respectively. Cloning of these 
two loops was done by a company (ATG: biosynthetics, Freiburg, Germany). For this 
first they synthesised the two loops as ds oligonucleotides and then cloned them into 
DNA-BD vector between the same restriction sites as the C-tail of PAR-2. The 
sequence of the cloned loops was confirmed before they were used for yeast mating 
with three AD clones of α-crystallin A. Mating results were negative for interaction 
between the cytoplasmic loops and α-crystallin A clones similar to what has been 
reported with regard to interaction studies concerning C-tail of PAR-1 in yeast 
(Mahajan et al., 2000; Pai et al., 2001). The AD clones by themselves failed to grow in 
SD/-Leu/-His plates indicating the lack of transcriptional activation by AD clones on 
their own. This set of experiment with cytoplasmic loops confirmed that the 
interaction observed between C-tail of PAR-2, the ‘bait’ and AD clone 34/19 B i.e., α-
crystallin A in yeast is specific and confined to C-tail of PAR-2 and not the 
cytoplasmic loops of the receptor. However, whether the interaction observed between 
C-tail of PAR-2 and α-crystallin A is a physiological one, occurs outside the yeast 
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system and has any meaning in terms of functional significance of the interaction 
needed to be studied and clarified with further sets of experiments. 
 
4.2.2 Checking for presence of α-crystallin A in different tissues, cell types and cell 
lines 
 
RT-PCR analysis using gene specific primers to check for the presence of α-
crystallin A in several tissues, cell types and cell lines available for this study 
presented a vivid picture of α-crystallin A mRNA expression. Retina, the source of 
AD fusion library for finding of PAR-2 interacting protein in the present study was 
positive for α-crystallin A mRNA expression. In fact intensity of the PCR band 
indicated abundant amounts of α-crystallin A mRNA in retina. Study involving non-
lenticular cells had found abundant amount of α-crystallin A in frog retinal cells, both 
in soluble form and associated with post-Golgi membranes of photoreceptors (Deretic 
et al., 1994). PCR signal for optic nerve was also intense compared with moderate 
amounts obtained in case of brain. To identify the cell types which express α-
crystallin A neuronal and glial primary cells as well as several cell lines were checked 
which gave quite a few surprising results. A glance across Table 3.6 shows that α-
crystallin A is not as ubiquitously expressed as the other isoform of α-crystallin i.e., α-
crystallin B. Of all, only hippocampal astrocytes and whole brain astrocytes express α-
crystallin A. The neuronal cell lines like RGC and N2A along with primary neuronal 
(mixed) culture also gave negative PCR results for expression of α-crystallin A. 
Expression of α-crystallin A  in retina but absence in neuronal retinal ganglion cell 
line (RGC) (Krishnamoorthy et al., 2001) suggests that α-crystallin A must be present 
in Müller cells of retina (astrocytic origin). An oligodendrocytic cell line, too, was 
negative for α-crystallin A mRNA. RT-PCR result in the present study shows clearly 
that α-crystallin A has a very selective distribution in brain cells compared to 
ubiquitously expressed α-crystallin B. Expression study to detect α-crystallin A in 
various non-lenticular tissues has found that this so-called lens-specific polypeptide is 
also present in brain, liver, lung, spleen, skin, small intestine and in a number of 
epithelial and fibroblast cell lines (Srinivasan et al., 1992). Immunocytochemical 
detection of α-crystallin A in various primary cell cultures confirmed the RT-PCR 
results in case of hippocampal astrocytes and whole brain astrocytes but not for 
hippocampal neurons. The primary cultures of hippocampal neurons used in this study 
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were mixed cultures containing neurons over astrocytic layer. α-crystallin A immuno-
staining was co-localised both with astrocyte marker and neuronal marker in the mixed 
neuronal cultures contrary to the results obtained with RT-PCR. This could be due to 
difference in levels of α-crystallin A expressed by astrocytes and neurons (RT-PCR 
using higher amount of starting material and more cycles was positive for 
hippocampal neurons).  
The presence of PAR-2 in different brain areas, including hippocampus 
(Striggow et al., 2001), retina (found in the present study) and cell types-neurons 
(D'Andrea et al., 1998) and astrocytes (Wang et al., 2002a) is known. The overlapping 
tissue and cell type distribution of both PAR-2 and α-crystallin A provides the first 
line of evidence outside yeast for the likelihood of their being interacting partners.  
 
4.2.3 Generation of PAR-2 and α-crystallin A fusion proteins 
   
Any interaction observed in yeast-two hybrid system is not 100% meaningful 
or confirmed till it is verified using in vitro methods with purified proteins in their 
initial characterisation since two-hybrid assay occasionally yields false positives. In 
this regard mammalian expression system was used in the present study to verify the 
protein interaction between PAR-2 and α-crystallin A. The mammalian expression 
system permits post-translational modification of eukaryotic proteins which allows a 
native protein to act in a biological environment, thus exhibiting its natural 
physiological functions. For detection purposes either full or partial PAR-2 and α-
crystallin A were cloned in several mammalian expression vectors with fluorescent 
and non-fluorescent tags as fusion proteins. As mentioned in Table 3.7, transfection in 
all cases was not successful. Different approaches were tried to get the transfection of 
pDsRed2N1 vector working but without success. Cell lines like RGC, RBL and 
NG108 too proved unsuccessful with DOTAP-based lipotransfection procedure (as 
described in Material and Methods). Up to 10 µg of DNA also failed to induce 
transfection in these cell lines. Successfully transfected cells were made stable under 
antibiotic selection pressure. This proved difficult in case of pCMV-HA fusion protein 
transfection since pCMV-HA vector has no Kan/Neo resistance site, hence requiring 
carrier DNA based transfection for stable expression of pCMV-HA fusion protein in 
cells.  
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Expression of fusion proteins cloned in vectors with fluorescent tag such as 
pEGFP was followed in cells by means of green fluorescence of the GFP tag. Colonies 
of cells originating from one cell cluster were selected for stable propagation as 
individual clones on the basis of high and even fluorescent cells. For vectors with non-
fluorescent tag the selection of clones required checking both at transcription and 
translation level. Like GFP clones, MycHis and HA fusion protein transfected cells 
were made stable and grown under appropriate selection pressure. Several clusters of 
cells each originating from a single cell were propagated as individual clones. The 
stable clones were checked for mRNA expression of fusion protein construct by RT-
PCR using the same primer pair as for generation of PCR product for cloning. On the 
protein level fusion constructs bigger than 10 kDa were detected by western blot 
analysis. Full crystallin-MycHis-HEK clones and crystallin Domain 2 clones could be 
verified in transfected cells for protein expression by western blot. Using the 
monoclonal antibody against myc antigen gave a positive band at the expected range 
between 20-25 kDa corresponding to full α-crystallin A protein (Srinivasan et al., 
1992). Small size of bait-HA fusion protein (~6.7 kDa) made its detection by western 
blot not possible. It is already known that detection of proteins smaller then 10 kDa is 
not easily feasible. Alternative strategies were used to detect the presence of bait-HA 
fusion protein in transfected cells since fusion construct could be detected at the 
transcription level. SDS-PAGE of whole cell lysate made using different protocols 
was stained using silver staining technique. The gel stained by this procedure showed 
the expression of bait-HA fusion protein in cell lysates (single and double transfected). 
Silver staining of SDS-PAGE is a more sensitive technique of detecting proteins bands 
compared to Coomassie Blue staining of the protein gels. Detection of bait-HA fusion 
construct at the protein level was checked by immuno-cytochemical staining of the 
transfected cells. Staining of transfected cells with antibodies against HA tag showed 
the presence of fusion protein in the transfected cells. Thus, by means of silver 
staining of protein gel and immunostaining it was possible to detect the presence of 
bait-HA fusion protein in transfected cells. Subcloning of C-tail PAR-2 in pEGFP-C2 
vector from pGBKT7 vector made possible the detection of C-tail PAR-2 as a GFP 
fusion construct by western blot due to bigger size of the fusion protein.  
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4.2.4 Cellular localisation of PAR-2 and α-crystallin A 
 
After checking the tissue and cell type where PAR-2 and α-crystallin A  are 
present  the next step was to identify the cellular localisation of the two proteins. For 
any protein-protein interaction to take place in a biological system it is necessary that 
both proteins should be either localised in the same compartment of the cell or in 
adjacent compartments where it is possible for them to be directly in contact with each 
other. For localisation study full PAR-2-pEGFP-N1 was transfected in two cell lines: 
HEK (epithelial) and N2A (neuronal). PAR-2-pEGFP-N1 fusion construct transfection 
in both HEK cells and in N2A cells resulted in membrane localisation of green 
fluorescent signal along with little cytoplasmic fluorescence. This pattern of PAR-2-
pEGFP-N1 construct localisation has also been described in transfected skin cells 
(keratinocytes) (Dery et al., 1999). α-crystallin A-pEGFP-N1 fusion protein was 
localised to cytosol of N2A cells excluding the nucleus. α-crystallin A has been 
reported to be a cytoplasmic protein (Deretic et al., 1994). Cytosolic localisation of α-
crystallin A in cells were further verified by immunostaining of α-crystallin A-
MycHis-HEK cells by anti-myc antibody. In α-crystallin A-MycHis-HEK cells also 
anti-myc antibody detected the presence of fusion protein in the cytosol excluding the 
nucleus. Cellular localisation of both proteins in adjacent cell compartments or even 
same cell compartment since C-terminal tail of PAR-2 has cytoplasmic localisation 
provide further evidence that the interaction between PAR-2 and α-crystallin A can 
occur in physiological environment. 
 
 
4.2.5 Co-immunoprecipitation  
 
Protein-protein interaction between C-tail of PAR-2 and α-crystallin A outside 
yeast was detected in mammalian expression system by co-immunoprecipitation of 
both proteins. HEK cells transfected with both fusion constructs could be precipitated 
in the presence of protein A with antibody against HA tag and detected with anti-myc 
antibody on western blot analysis. Negative results obtained with HEK-WT lysate and 
lack of binding to protein A in absence of anti-HA antibody by double transfected cell 
lysate verified the specificity of the interaction. This biochemical assay gave firm 
indication for existence of interaction between PAR-2 and α-crystallin A under 
physiological conditions.  
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4.2.6 Co-localisation of PAR-2 and α-crystallin A in Hippocampal astrocytes 
 
Although localisation studies using transfected cells showed the presence of 
PAR-2 and α-crystallin A  in adjacent compartments it was important to verify this in 
a system endogenously expressing both proteins. For this primary culture of rat 
hippocampal astrocytes were stained with specific antibodies against both proteins. 
Subcellular localisation of PAR-2 and α-crystallin A matched with what was observed 
in transfected cells and overlay of fluorescence for both proteins showed co-
localisation of PAR-2 and α-crystallin A in hippocampal astrocytes.  
The series of experiments done until now confirms PAR-2 and α-crystallin A 
interaction under native, physiological conditions. Hence we could prove by several 
lines of experimentation that there do exist protein-protein interaction between PAR-2 
and α-crystallin A in biological system. In the present study we have identified α-
crystallin A as a novel interacting partner for PAR-2. However, for any interaction 
taking place in nature there has to be a functional rationale behind its occurrence. 
Which means even PAR-2 and α-crystallin A interaction definitely has a functional 
significance which needs to be further explored and studied. This interaction might be 
a part of already existing signalling mechanisms or PAR-2 via α-crystallin A is 
involved in some novel functional aspect. 
 
4.2.7 α-crystallin A 
 
α-crystallins are major refractive proteins in vertebrate lens, composed of two 
highly homologous subunits αA and αB. The 20 kDa αA- and αB-crystallin proteins 
are approximtely 60% identical in amino acid sequence (Deretic et al., 1994; 
Kantorow and Piatigorsky, 1998). While α-crystallin B is a ubiquitous isoform and 
shares high homology in its carboxyl-terminal with small heat shock proteins (Ingolia 
and Craig, 1982), α-crystallin A was considered a lens-specific isoform (Overbeek et 
al., 1985). PCR analysis and Southern blot analysis established the presence of α-
crystallin A in several non-lenticular tissues such as retina, brain, lung, spleen, liver, 
epithelial and fibroblast cell lines (Srinivasan et al., 1992). Rat α-crystallin A has a 
522 bp long mRNA sequence and made up of 173 amino acid residues (Accession No. 
NM_012534). The coding region consists of two domains: N-terminal domain 
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represents alpha crystallin A chain, while C-terminal matches with Hsp20/ alpha 
crystallin family. α-crystallin exists both as soluble and membrane associated forms in 
retina (Deretic et al., 1994). Apart from maintaining lens transparency, α-crystallin in 
frog retinal cells is associated with subcellular fraction containing rhodopsin bearing 
post-Golgi membrane (chaperone activity) and helps in membrane transport in retina 
(Deretic et al., 1994). α-crystallin A can be phosphorylated in a cAMP-dependent and 
independent manner (Kantorow and Piatigorsky, 1998). This fact suggests that α-
crystallin A is not a passive structural entity of vertebrate lens but is under active 
metabolic control. It can bind to actin (Wang and Spector, 1996). Low expression of 
α-crystallin A in Royal college of Surgeons (RCS) rats indicates that α-crystallin A 
may have a significant role in the development of retinal dystrophy (Maeda et al., 
1999). α-crystallin A co-localises with actin cytoskeleton in the cell (Gopalakrishnan 
et al., 1993) and possibly induces expression of pro-inflammatory cytokines (Bhat and 
Sharma, 1999). α-crystallin A has also been shown to have anti-apoptotic activity 
(Andley et al., 2000).  
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5. Zusammenfassung 
 
  Die Degeneration oder das Überleben des Hirngewebes, nach einem Hirn-
Trauma oder Verletzung des Zentralen Nerven System (ZNS), hängen stark von der Art, 
Dauer und der Stärke der Verletzung ab. Eine der wichtige Substanz, die als Folge einer 
Verletzung des Zentralen Nervensystems nachgewiesen wurde, ist das Thrombin. Die 
Freisetzung bzw. Produktion von Thrombin im verletzten Gewebe geschieht entweder 
durch eine beeinträchtigte Blut-Hirn-Schranke oder es wird am Ort der Verletzung 
direkt durch Spaltung des endogenen Prothrombins produziert. So vermittelt Thrombin 
seine Wirkung durch Aktivierung der Protease aktivierten Rezeptoren (die so genannte 
PAR-Rezeptor-Familie). Zu dieser Rezeptor Familie gehören bislang PAR-1, PAR-2, 
PAR-3 und PAR-4. PAR-1, PAR-3 und PAR-4 gelten als Thrombin Rezeptoren, PAR-2 
wird durch Trypsin oder Mastzellen Tryptase aktiviert. 
  PARs gehören zu der Superfamilie der G-Protein gekoppelten Rezeptoren mit 
7 Transmembran-Domänen. Die Aktivierung dieser Rezeptoren wird von 
extrazellulären Proteasen vermittelt. PARs sind sowohl an der Degeneration als auch an 
der Reparatur des nach einer Verletzung geschädigten Gewebes beteiligt. 
  Teil 1: In der vorliegenden Arbeit wurde die mRNA-Expression aller vier 
PAR-Subtypen im Auge postnataler Ratten und in der Retina adulter Ratten mittels 
Reverse Transkription Polymerase Kettenreaktion (RT-PCR) gezeigt. Während die 
PAR-1-mRNA-Expression in den Augen der Neugeborenen eine 
entwicklungsabhängige Expression mit einer Abnahme der mRNA-Level von P1, P9 zu 
P16 aufweist, bleibt bei allen untersuchten Altersstadien das Niveau von PAR-2 
unverändert hoch und PAR-3 und PAR-4 weisen einen gleichbleibend niedrigen 
mRNA-Expressionsspiegel auf. In der Retina adulter Ratten zeigte die mRNA-
Expression der PAR-1 im Vergleich zu PAR-2 und PAR-3 ein höheres Niveau, während 
PAR-4-mRNA das geringste Expressions-Niveau aufwies. 
  Um die mögliche Rolle der PARs bei einem Trauma des ZNS zu untersuchen, 
wurde mittels semi-quantitaver RT-PCR die mRNA-Expression aller vier PAR- 
Subtypen in der Retina der adulten Rate nach einer Quetschung des optischen Nervs 
[optical nerve crush (ONC)], welche ein mildes Trauma des ZNS verursacht, analysiert. 
Die Expressionsstudie wurde zu verschiedenen Zeitpunkten nach der Applikation des 
milden Traumas, beginnend mit 6 Stunden bis zu 3 Wochen nach ONC, durchgeführt.  
Die mRNA-Expressions-Analyse zeigte bereits 6 Stunden nach der unilateralen 
ONC eine Hochregulation aller vier PARs in der Retina der behandelten Tiere, mit 
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Ausnahme von PAR-3, welches erst nach 12 stunden eine Hochregulation der mRNA 
zeigt. Die mRNA Niveaus der PAR-1, PAR-3 und PAR-4 erreichten drei Wochen 
nach ONC wieder den Wert der mRNAs in der Retina unbehandelter Tiere. Im 
Unterschied zu PAR-1, PAR-3 und PAR-4 blieb der mRNA-Expressionsspiegel von 
PAR-2 zu allen untersuchten Zeitpunkten höher als der entsprechende mRNA-level in 
der Retina der unbehandelten Tiere. 
Interessanterweise wurden vergleichbare Befunde auch in der Retina des 
kontralateralen, nicht verletzten Auges beobachtet. In früheren Studien wurde als 
Folge solcher ZNS-Läsionen an Stelle der Verletzung eine Zunahme der 
Thrombinfreisetzung, in der Retina eine Degeneration der Ganglienzellen sowie 
Apoptose und Aktivierung von PARs berichtet. Die anfängliche Hochregulation der 
PAR-mRNA-Expression als eine der Folgen des ONC (Modell eines milden Traumas) 
könnte als Effektor für den frühen Zelltod wirken. Die Abnahme des mRNA-
Expressions-Niveaus auf das Niveau der unbehandelten Tiere würde hingegen die 
Neuroprotektions-Rolle der PARs beschreiben. 
  Teil 2: Zur weiteren Charakterisierung der Veränderung der PAR-mRNA-
Expression nach einer ZNS- Verletzung wurde die Expression der PAR mRNAs nach 
einer verübergehenden fokalen Ischämie (transient focal ischemia), bei welcher der 
reduzierte Blutzufluss zu einer Kaskade pathophysiologischer Effekte, einschließlich 
Entzündung, Excitoxicität und Blutplättchenaktivierung an der Stelle der Verletzung 
führt, untersucht. Die fokale Ischämie wurde mittels Mikroinjektion von Endothelin in 
der Nähe der mittleren cerebralen Arterie  induziert. RT-PCR Analysen ergaben für 
PAR-1 eine signifikante und für PAR-2 eine geringfügige Abnahme der mRNA spiegel. 
PAR-3 wies anfänglich eine Zunahme, gefolgt von einer Abnahme der mRNA Niveaus 
auf, und PAR-4 zeigte die höchste Zunahme, das 2,5-fache, der mRNA- spiegel bereits 
12 Stunden nach der Ischämie. Auch bei diesem Paradigma stellen wir an der 
kontralateralen (unbehandelten) Seite eine Veränderung der mRNA-Expression der 
PARs in Form von Abnahme der mRNA Level von PAR-1, PAR-2 und PAR-3 fest. 
Eine Abnahme des PAR-4-mRNA spiegels wurde erst 7 Tage nach der Ischämie 
festgestellt. Die hier gezeigten  Befunde legen die Vermutung nahe, dass die Thrombin- 
Rezeptoren PAR-1, PAR-3, PAR-4 eine wichtige Rolle bei der Pathophysiologie des 
ZNS nach einem Trauma und auch bei der Ischämie spielen.  
  Teil 3: Um die intrazellulären Signalwege von PAR-2 näher verstehen zu 
können, charakterisierten wir in einem weiteren Abschnitt der vorliegenden Arbeit die 
 125
möglichen Interaktions-Proteine für PAR-2. Hierfür wurde die Methode des Yeast-
Two-Hybrid-Systems gewählt. Die Suche nach Interaktionspartnern wurde mit der 
Sequenz des C-Terminalen Bereichs von PAR-2 an einer selbst erzeugten  cDNA- 
Bibliothek  aus der Retina der Ratte durchgeführt. Die cDNA- Bibliothek suche ergab 
einen positiven Klon, der sowohl bei der folgenden Cotransformation mit der cDNA-
Bibliothek wie auch beim folgenden ‘Yeast Mating‘ eine Interaktion zeigte. Bei diesem 
Klon handelt es sich um α-Crystallin A. Um den Protein Interaktionsbereich genauer zu 
definieren, wurden die beiden zytoplasmatischen Schleifen des PAR-2 Rezeptors mit 
dem α-Crystallin A in Hefe durch ‘Yeast Mating‘ verifiziert. Diese ergab eine 
spezifische Interaktion nur mit dem C-terminalen Bereich des PAR-2 Rezeptors. Diese 
Interaktion wurde in Hefe und auch in Säugetier-Zellen verifiziert.  
  Die Expression des α-Crystallin A wurde mittels RT-PCR in verschiedenen 
Zell-Linen, wie auch Geweben untersucht. Die mRNA wurde in der Retina, dem 
optischen Nerv, Hirn und in Astrozyten aus dem Hippokampus in Primärkulturen 
spezifisch nachgewiesen. Die subzelluläre Lokalisation beider Proteine (PAR-2 und α-
Crystallin A) wurde mittels Transfektion von N2A und HEK-293 Zellen entweder mit 
α-Crystallin A- oder PAR-2- GFP Fusionsprotein untersucht. PAR-2 zeigte wie 
erwartet eine membranständige Lokalisation, während α-Crystallin A eine zytosolische 
Lokalisation aufwies. Die in der Hefe festgestellte Interaktion zwischen PAR-2 und α-
Crystallin A wurde dann mittels Coimmunopräzipitation und Immunozytochemie in 
Säugetierzellen verifiziert. Für Coimmunopräzipitation  nutzten wir cotransfizierte 
HEK-293 Zellen, welche beide Proteine (PAR und α-Crystallin A) mit verschiedenen 
Tags (Myc-His und HA)  überexpremierten. Die Immunopräzipitation erfolgte mit 
einem Antikörper gegen den Tag im PAR-2- Fusionsprotein (Hämagglutinin; HA). 
Dieser Komplex wurde mit dem Antikörper gegen den Tag im α-Crystallin A 
Fusionsprotein ebenfalls detektiert. Die Doppel-Immunocytochemischen 
Untersuchungen an hippokampalen Astrocyten in Primärkultur mit spezifischen 
Antikörpern gegen α-Crystallin A und PAR-2 bestätigten zum einen die Ergebnisse der 
subzellulären Lokalisation beider Proteine in den transfizierten Zellen und zum anderen 
zeigten diese Ergebnisse auch die schon in der Hefe beobachtete Interaktion in 
Säugetier-Zellen. Für das α-Crystallin A wurde eine co-Lokalisation mit 
Aktincytoskelett und eine mögliche Rolle bei der Freisetzung von proinflammatorischen 
Cytokinen  beschrieben. Eine weitere detaillierte Untersuchung dieser Interaktion kann 
die physiologische Bedentung dieser Interaktion klären.      
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  Zusammenfassung: Zeigen Wir in der vorliegenden Arbeit erstmalig: i) die 
mRNA-Expression von PAR-1-4 im sich entwickelnden Auge der neugeborenen Ratte 
und in der Retina der 12 Wochen alten Tiere; ii) die Veränderung der mRNA- 
Expression aller 4 PAR Subtypen bei zwei verschiedenen Paradigmen für ZNS-
Verletzung, nämlich Quetschung des optischen Nervs [optical nerve crush (ONC)] oder 
vorübergehende fokale Ischämie (transient focale ischemie); und iii) die molekulare 
Identifizierung eines Interaktions-Proteins für PAR-2 in der Retina der Ratte mittels 
Yeast-Two-Hybrid- Methode.  
  Die anfängliche Zunahme der mRNA-spiegel der PARs im verletzten 
Hirngewebe weist auf eine wichtige Funktion dieser Rezeptoren in der 
Pathophysiologie des zentralen Nervensystems hin. Das unterschiedliche 
Veränderungsmuster der mRNA- spiegel zu verschiedenen Zeitpunkten nach der ZNS-
Verletzung deutet auf eine differentielle mRNA Regulation dieser Gene hin. 
  Sowohl im ONC- Modell als auch in Modell der fokalen Ischämie konnte ein 
Effekt der unilateralen Läsion auf die kontralaterale Seite beobachtet werden. Wir 
konnten ebenfalls einen neuen Interaktionspartner für PAR-2, das α-Crystallin A, 
identifizieren. Eine Interaktion konnte durch verschiedene experimentelle Ansätze 
bestätigt werden. α-Crystallin A lokalisiert mit dem Aktincytoskelett in der Zelle und 
induziert möglicherweise die Expression proinflammatorischer Cytokine. Kenntnis über 
die physiologische Kontrolle der Interaktion zwischen PAR-2 und α- Crystallin A wird 
zur Aufklärung der funktionellen Rolle beider Proteine führen.      
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6. Abstract 
 
Degeneration or survival of cerebral tissue after brain injury depends on the 
source, intensity and duration of the insult. One serine protease that is closely 
associated with and produced in response to CNS injury is thrombin. Thrombin enters 
the injury cascade in brain either via a compromised blood-brain barrier or from 
endogenous prothrombin. Thrombin mediates its action through the protease-activated 
receptor family (subtypes PAR-1, -3 and -4), while PAR-2 is activated by trypsin or 
mast cell tryptase. PARs, belonging to the superfamily of G-protein coupled receptors 
with a 7-trans-membrane domain structure, are activated by proteolytic cleavage of 
their N-terminus. PARs are involved in tissue degeneration and repair upon injury.  
Part 1: In the present study, we have demonstrated for the first time the 
expression of all four subtypes of PARs in the post-natal eye and in retina of the adult 
rat by reverse transcription-polymerase chain reaction (RT-PCR). PAR-1 is 
developmentally regulated in the eye, with a decrease from P1, P9 to P16, while levels 
for PAR-2, PAR-3 and PAR-4 remain unchanged throughout. In the retina of the adult 
rat, PAR-1 is highly expressed, whereas PAR-2, PAR-3 are moderately expressed and 
PAR-4 is expressed at low levels. To elucidate possible roles of  PARs after trauma, 
we performed semi-quantitative RT-PCR analysis of expression of all 4 PAR subtypes 
after ONC. mRNA levels of all 4 PARs were upregulated as early as 6 h after 
unilateral ONC, except PAR-3, which showed a delayed upregulation. PAR-1, PAR-3 
and PAR-4 mRNA levels returned back almost to basal levels at 3 weeks post-crush, 
while PAR-2 mRNA level was still high by the end of 3 weeks after crush. As a result 
of unilateral lesion, PAR mRNA expression even in the contra-lateral, uninjured side 
was found to be affected to almost comparable levels as in the injured side. Previous 
studies have already shown increase in thrombin levels at the site of injury, retinal 
ganglion cell degeneration by necrosis and apoptosis and PAR activation as a 
consequence of nerve crush. PAR upregulation as a result of nerve crush in the mild 
trauma model could act as an effector of early cell death. Eventual return of receptor 
mRNA to basal levels is consistent with neuroprotection. 
Part 2: To further characterise PAR mRNA expression after CNS injury, we 
studied the model of transient focal ischemia. In the present study we examined the 
change in mRNA expression levels of PAR-1-4 as a result of transient focal ischemia 
in rat brain, induced by microinjection of endothelin near the middle cerebral artery. 
Using semi-quantitative RT-PCR analysis, PAR-1 was found to be significantly down-
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regulated, while PAR-2 mRNA levels decreased only moderately after the ischemic 
insult on the ipsilesional side. PAR-3 was transiently up-regulated, followed by 
downregulation, and PAR-4 mRNA levels showed the most striking (2.5 fold) increase 
at 12 h after ischemia in the injured side. In the contra-lateral hemisphere, mRNA 
expression was also affected. There, decreased mRNA levels were observed for PAR-
1, -2 and –3, while PAR-4 levels were reduced only after 7 days. Taken together, these 
data suggest the involvement of the thrombin receptors PAR-1, PAR-3 and PAR-4 in 
the pathophysiology of brain ischemia.  
Part 3: In order to gain more insight into PAR-2 signalling pathway and the 
proteins involved downstream of the receptor, we performed a yeast-two hybrid 
screening to fish out putative interacting partners for PAR-2 (rat). Screening for 
positive clones both after the initial library transformation (sequential) and 
subsequently by yeast mating resulted in identification of α-crystallin A as the 
interacting protein for PAR-2. Lack of interaction between cytoplasmic loop 2 and 3 
of PAR-2 and α-crystallin A by yeast mating confirmed the specificity of the 
interaction between C-tail of PAR-2 and α-crystallin A.  
RT-PCR analysis of several tissues and cell lines exhibited a selective 
expression of α-crystallin A in retina, optic nerve, brain and primary cultures of rat 
hippocampal astrocytes and whole brain astrocytes. However, presence of α-crystallin 
A at the protein level in primary cultures of hippocampal neurons indicated high 
expression  of α-crystallin A in hippocampal astrocytes compared with low levels in 
neurons.  
Subcellular localisation of α-crystallin A and PAR-2 as GFP fusion protein in 
N2A cells showed cytosolic expression for α-crystallin A, while PAR-2 was expressed 
on plasma membrane with little cytosolic fluorescence. HEK cells transfected with 
both bait and prey protein on precipitation with antibody against bait protein tag gave 
positive signal on detection with prey protein tag antibody. Co-immunoprecipitation of 
C-tail of PAR-2 and α-crystallin A verified the results from the yeast-two hybrid 
screening. Further, double labelling of hippocampal astrocyte primary cultures 
confirmed the subcellular localisation of both proteins observed in mammalian 
expression system, and the overlapping of staining pattern proved that an interaction 
between α-crystallin A and PAR-2 exist in native biological systems. The 
physiological control of this interaction will clarify the functional role of both, PAR-2 
and α-crystallin A signalling. 
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8. Abbreviations  
 
Ab   Antibody 
AD   Activation domain 
Ade   Adenine 
AP   Activating peptide 
AT   Adenine thymine 
3-AT   3-amino-1,2,4-triazole 
A.U   Arbitary units  
bp   Base pair 
cDNA   Complementary deoxyribonucleic acid 
CNS   Central nervous system 
cAMP   Cyclic adenosine monophosphate 
CAPS   3-(Cyclohexylamino)-1-propansulfonic acid 
Cl   Cytoplasmic loop 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DNA   Deoxyribonucleic acid 
dNTP   Deoxyribonucleoside triphosphate 
DNA-BD  Deoxyribonucleic acid binding domain 
DEPC    Diethyl pyrocarbonate 
DMSO   Dimethyl sulfoxide 
DMF   N,N-dimethylformamide  
ds   double stranded 
DMSO   Dimethyl sulfoxide 
DO   Dropout 
EGF   Epidermal growth factor 
e-MCAO  endothelin-Middle Cerebral Artery Occlusion 
EST   Expressed Sequence TAG  
ERK   Extracellular regulated kinase 
FCS   Fetal calf serum 
FTP   FCS-Triton-X100-PBS 
GAL   Galactose 
GC   Guanine cytosine 
GFAP   Glial fibrillary acidic protein 
GAPDH   Glyceraldehyde phosphate dehydrogenase  
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GFP   Green fluorescent protein 
GPCR   G-protein coupled receptor 
GDP   Guanosine diphosphate 
GTP   Guanosine triphosphate 
HA   Hemagglutinin 
HAT   Hypoxanthine aminopterine thymidine 
HBSS   Hank’s balanced salt solution 
Hsp   Heat shock protein 
hTRAP   Human thrombin receptor activating peptide 
HEK   Human embryonic kidney  
His   Histidine 
HW   Histidine-tryptophan 
H2O   Hydrogen dioxide 
H2O2   Hydrogen peroxide  
InsP3   Inositol 1,4,5-trisphosphate 
ICON   in vivo confocal neuroimaging technique  
JNK   c-jun related kinase 
Kana   Kanamycin 
KCM   KCl- CaCl2- MgCl2 
Leu   Leucine 
LB   Luria bertini  
LH   Leucine-Histidine 
LD-PCR  Long distance polymerase chain reaction 
LW   Leucine-tryptophan 
MMPs   Matrix Metalloproteinases 
MCA   Middle Cerebral Artery  
MAPK   Mitogen-activated protein kinase 
MCS   Multiple cloning site 
MES    (2-[N-Morpholino] ethanesulfonic acid) Hydrate 
mRNA   Messenger ribonucleic acid 
MOPS    N-Morpholino-3-propansulphonic acid 
MCS   Multiple cloning site  
ONC   Optic nerve crush 
OD   Optical density  
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OGD   Oxygen glucose deprivation 
p38 MAP  p38 mitogen activated protein 
PFA   Paraformaldehyde 
PNS   Peripheral nervous system 
PTX   Pertussis toxin 
PBS   Phosphate buffered saline 
PLC   Phospholipase C 
PAR   Protease-activated receptor 
PKC   Protein kinase C 
PCR   Polymerase Chain Reaction 
PVDF   Polyvinyliden difluorid  
QDO   Quadruplet dropout medium 
RGC   Retinal ganglion cells 
RT   Reverse Transcription 
SD   Synthetic dropout 
SDS-PAGE  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
ss   Single stranded 
TCM   Tris/HCl- CaCl2- MgCl2 
Trp   Trptophan 
TDO   Triple dropout medium 
TSR   Template Suppression Reagent  
TM   Transmembrane 
Tm   Melting temperature 
TRag   Thrombin receptor agonist 
TBE   Tris-boric acid-EDTA 
TE   Tris-EDTA 
UAS   Upstream activating sequence 
UV   Ultraviolet 
X-gal    5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
YPDA   Yeast-peptone-dextrose-adenine 
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